Through the patients' eyes: psychometric evaluation of the 64-item version of the Experienced Patient-Centeredness Questionnaire (EPAT-64)
Christalle E, Zeh S, Führes H, Hahlweg P, Zill J, Härter M, Bokemeyer C, Gallinat J, Gebhardt C, Magnussen C, Müller V, Schmalstieg-Bahr K, Strahl A, Kriston L, Scholl I
BMJ QUAL SAF. 2024 [Epub ahead of print].

Unveiling breast cancer metastasis through an advanced X-ray imaging approach
Conceição A, Müller V, Burandt E, Mohme M, Nielsen L, Liebi M, Haas S
SCI REP-UK. 2024;14(1):1448.

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren
Eichler H, Albisetti M, Halimeh S, Knöfler R, Königs C, Langer F, Miesbach W, Oldenburg J, Scholz U, Streif W, Klamroth R
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial
Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Mueller L, Wimberger P, Ruckhaeberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W
CLIN CHEM. 2024;70(1):307-318.

Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia
Herbst J, Vohl V, Krajina M, Leffers M, Kropidlowski J, Prieske K, Jaeger A, Oliveira-Ferrer L, Schmalfeldt B, Goy Y, Burandt E, Pantel K, Vollmert C, Sartori A, Woelber L, Effenberger K, Wikman H
CLIN CHEM. 2024;70(1):285-296.

Differences in patterns of sexual assault among female victims preceding and during the COVID-19 pandemic
Klasen C, Teltrop L, Belau M, Lohner L, Ondruschka B, Riecke K, Reuter S, Schmalfeldt B, Wilmes S, Witzel I
FORENSIC SCI MED PAT. 2024;20(2):595-602.

Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction
Marius W, Leticia O, Friedrich K, Stephan M, Louisa H, Tabea S, Elisa S, Pauline W, Yi D, Qi M, Barbara S, Carsten B, Walter F, Jasmin W, Franziska B
ONCOIMMUNOLOGY. 2024;13(1):2346359.

Study protocol of an exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA) - a randomized controlled trial
Maurer T, Belau M, Zyriax B, Welsch G, Jagemann B, Chang-Claude J, Daubmann A, Buchholz A, Glismann K, Moeller A, Sehouli J, Woopen H, Wimberger P, Harter P, Kaiser S, Maass N, Kiechle M, Engler T, Schmalfeldt B, Schulz H
BMC CANCER. 2024;24(1):.

Transcriptome-based identification of key actin-binding proteins associated with high metastatic potential in breast cancer
Müller C, Schmalfeldt B, Müller V, Schmalfeldt B, Windhorst S
FRONT MOL BIOSCI. 2024;11:1440276.

Personalised blood pressure management during major noncardiac surgery and postoperative neurocognitive disorders: a randomised trial
Nicklas J, Bergholz A, Däke F, Pham H, Rabe M, Schlichting H, Skrovanek S, Flick M, Kouz K, Fischer M, Olotu C, Izbicki J, Mann O, Fisch M, Schmalfeldt B, Frosch K, Renné T, Krause L, Zöllner C, Saugel B
BJA Open. 2024;11:100294.

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report about a Male Patient with Pectoral Implants
Riecke K, Steinhilper L, von Bülow C, Schwarz D, Burandt E, Striefler J, Müller V, Schmalfeldt B, Witzel I
BREAST CARE. 2024;19(1):73-76.

EANO guideline on molecular testing of meningiomas for targeted therapy selection
Sahm F, Bertero L, Brandner S, Capper D, Goldbrunner R, Jenkinson M, Kalamarides M, Lamszus K, Albert N, Mair M, Berghoff A, Mawrin C, Wirsching H, Maas S, Raleigh D, Reifenberger G, Schweizer L, Suwala A, Tabatabai G, Tabouret E, Short S, Wen P, Weller M, Le Rhun E, Wesseling P, van den Bent M, Preusser M
NEURO-ONCOLOGY. 2024 [Epub ahead of print].

HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis
Schneegans S, Löptien J, Mojzisch A, Loreth D, Kretz O, Raschdorf C, Hanssen A, Gocke A, Siebels B, Gunasekaran K, Ding Y, Oliveira-Ferrer L, Brylka L, Schinke T, Schlüter H, Paatero I, Voß H, Werner S, Pantel K, Wikman H
J EXP CLIN CANC RES. 2024;43(1):110.

Ovarian cancer cells regulate their mitochondrial content and high mitochondrial content is associated with a poor prognosis
Weigelt J, Petrosyan M, Oliveira-Ferrer L, Schmalfeldt B, Bartmann C, Dietl J, Stürken C, Schumacher U
BMC CANCER. 2024;24(1):43.

Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects
Wolters-Eisfeld G, Oliveira-Ferrer L
SEMIN IMMUNOPATHOL. 2024;46(6):1-20.

Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1
Bartkowiak K, Mossahebi Mohammadi P, Gärtner S, Kwiatkowski M, Andreas A, Geffken M, Peine S, Verpoort K, Scholz U, Deutsch T, Michel L, Schneeweiss A, Thewes V, Trumpp A, Müller V, Riethdorf S, Schlüter H, Pantel K
J PROTEOME RES. 2023;22(4):1213-1230.

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
Brauneck F, Schmalfeldt B, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J
FRONT IMMUNOL. 2023;14:1250258.

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
Chekerov R, Arndt T, Pietzner K, Canzler U, Wimberger P, Strauß H, Mahner S, Woelber L, de Gregorio N, Stocker G, von Abel E, Neunhoeffer T, Belau A, Mustea A, Yalinkaya I, Braicu E, Richter R, Sehouli J
J CANCER RES CLIN. 2023;149(10):7637-7649.

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
Decker T, Lüdtke-Heckenkamp K, Melnichuk L, Hirmas N, Lübbe K, Zahn M, Schmidt M, Denkert C, Lorenz R, Müller V, Zahm D, Mundhenke C, Bauer S, Thill M, Seropian P, Filmann N, Loibl S
BREAST. 2023;72:103575.

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, Decker T, Tesch H, Kümmel S, Uleer C, Wuerstlein R, Hoffmann O, Warm M, Marschner N, Schinköthe T, Kates R, Schumacher J, Otremba B, Zaiss M, Harbeck N, Schmidt M
TRIALS. 2023;24(1):338.

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Fasching P, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn H, Warm M, van Mackelenbergh M, Rabizadeh S, Schem C, Heinmöller E, Mueller V, Marmé F, Soon-Shiong P, Nekljudova V, Untch M, Loibl S
CLIN CANCER RES. 2023;29(13):2456-2465.

Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer
Fehm T, Welslau M, Müller V, Lüftner D, Schütz F, Fasching P, Janni W, Thomssen C, Witzel I, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux M, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Hartkopf A, Wöckel A, Kolberg H, Harbeck N, Stickeler E
GEBURTSH FRAUENHEILK. 2023;83(3):289-298.

'Case of the Month' from University Medical Center Hamburg-Eppendorf, Germany: Vulvar cancer after female-male gender reassignment
Finger A, Riechardt S, Dahlem R, Soave A, Rink M, Sauter G, Contreras H, Steinhilper L, Fisch M, Vetterlein M, Schuettfort V
BJU INT. 2023;131(6):685-688.

Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value
Franken A, Kraemer A, Sicking A, Watolla M, Rivandi M, Yang L, Warfsmann J, Polzer B, Friedl T, Meier-Stiegen F, Stoecklein N, Dayan D, Riethdorf S, Mueller V, Pantel K, Koch A, Hartkopf A, Krawczyk N, Ruckhaeberle E, Niederacher D, Fehm T, Neubauer H
BRIT J CANCER. 2023;128(9):1742-1752.

Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo
Genduso S, Freytag V, Schetler D, Kirchner L, Schiecke A, Maar H, Wicklein D, Gebauer F, Bröker K, Stürken C, Milde-Langosch K, Oliveira-Ferrer L, Ricklefs F, Ewald F, Wolters-Eisfeld G, Riecken K, Unrau L, Krause L, Bohnenberger H, Offermann A, Perner S, Sebens S, Lamszus K, Diehl L, Linder S, Jücker M, Schumacher U, Lange T
J HEMATOL ONCOL. 2023;16(1):.

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Uleer C, Grischke E, Aktas B, Schumacher C, Zu Eulenburg C, Kates R, Jóźwiak K, Graeser M, Wuerstlein R, Baehner R, Christgen M, Kreipe H, Harbeck N
ANN ONCOL. 2023;34(6):531-542.

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial
Gluz O, Nitz U, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, Hartkopf A, Potenberg J, Lüedtke-Heckenkamp K, Just M, Schem C, von Schumann R, Kolberg-Liedtke C, Eulenburg C, Schinköthe T, Graeser M, Wuerstlein R, Kates R, Kreipe H, Harbeck N
JAMA ONCOL. 2023;9(7):946-954.

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
Gonçalves J, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, Nekljudova V, Fasching P, Karn T, Marmé F, Müller V, Schem C, Sinn B, Stickeler E, van Mackelenbergh M, Schmitt W, Denkert C, Weichert W, Schwamborn K
INT J MOL SCI. 2023;24(3):2860.

Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial
Graeser M, Gluz O, Biehl C, Ulbrich-Gebauer D, Christgen M, Palatty J, Kuemmel S, Grischke E, Augustin D, Braun M, Potenberg J, Wuerstlein R, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer H, Pelz E, Zu Eulenburg C, Kates R, Ni H, Kolberg-Liedtke C, Feuerhake F, Kreipe H, Nitz U, Harbeck N
CLIN CANCER RES. 2023;29(4):805-814.

Major influencing factors on routine implementation of shared decision‑making in cancer care: qualitative process evaluation of a stepped‑wedge cluster randomized trial
Hahlweg P, Lindig A, Frerichs W, Zill J, Hanken H, Müller V, Peters M, Scholl I
BMC HEALTH SERV RES. 2023;23(1):840.

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
Harbeck N, Nitz U, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J, Aktas B, Forstbauer H, Grischke E, Scheffen I, Malter W, von Schumann R, Just M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe H, Gluz O
J CLIN ONCOL. 2023;41(22):3796-3804.

Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer
Hartkopf A, Fehm T, Welslau M, Müller V, Schütz F, Fasching P, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux M, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg H, Harbeck N, Stickeler E, Bartsch R, Schneeweiss A, Ettl J, Würstlein R, Krug D, Taran F, Lüftner D
GEBURTSH FRAUENHEILK. 2023;83(6):653-663.

EUSICA/COST IMMUNO-model workshop fostering collaboration to advance sinonasal cancer research: A meeting report
Hermsen M, Lechner M, Oliveira Ferrer L, Trama A, Eriksen P, Martinez-Balibrea E, von Buchwald C
ORAL ONCOL. 2023;146:106543.

Current Treatment Practices and Prognostic Factors in Early-Stage Ovarian Cancer-An Analysis of the NOGGO/JAGO
Heublein S, Baum J, Jaeger A, Grimm-Glang D, Olthoff J, Braicu E, Azzam Nieto O, Hassdenteufel K, Schmalfeldt B, Hanker L, Wallwiener M, Schneeweiss A, Sehouli J, Pietzner K
CANCERS. 2023;15(7):.

Return of individual genomic research results within the PRAEGNANT multicenter registry study
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L
BREAST CANCER RES TR. 2023;197(2):355-368.

Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis
Kempska J, Oliveira-Ferrer L, Grottke A, Qi M, Alawi M, Meyer F, Borgmann K, Hamester F, Eylmann K, Rossberg M, Smit D, Jücker M, Laakmann E, Witzel I, Schmalfeldt B, Müller V, Legler K
FRONT ONCOL. 2023;13:1129682.

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia
Kesic V, Carcopino X, Preti M, Vieira-Baptista P, Bevilacqua F, Bornstein J, Chargari C, Cruickshank M, Erzeneoglu E, Gallio N, Gultekin M, Heller D, Joura E, Kyrgiou M, Madić T, Planchamp F, Regauer S, Reich O, Esat Temiz B, Woelber L, Zodzika J, Stockdale C
INT J GYNECOL CANCER. 2023;33(4):446-461.

Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer Therapies
Kolberg H, Hartkopf A, Fehm T, Welslau M, Müller V, Schütz F, Fasching P, Janni W, Gyn Z, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux M, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Harbeck N, Stickeler E, Bartsch R, Schneeweiss A, Ettl J, Krug D, Taran F, Lüftner D, Würstlein R
GEBURTSH FRAUENHEILK. 2023;83(9):1117-1126.

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
Kurtz J, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier M, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz J, Largillier R, Heudel P, Heitz F
J CLIN ONCOL. 2023;41(30):4768-4778.

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E
JAMA ONCOL. 2023;9(2):197-205.

Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer
Lüftner D, Lux M, Fehm T, Welslau M, Müller V, Schütz F, Fasching P, Janni W, Thomssen C, Witzel I, Beierlein M, Belleville E, Untch M, Thill M, Ditsch N, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg H, Harbeck N, Stickeler E, Tesch H, Hartkopf A
GEBURTSH FRAUENHEILK. 2023;83(3):299-309.

Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer
Lux M, Hartkopf A, Fehm T, Welslau M, Müller V, Schütz F, Fasching P, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg H, Harbeck N, Bartsch R, Schneeweiss A, Ettl J, Würstlein R, Krug D, Taran F, Lüftner D, Stickeler E
GEBURTSH FRAUENHEILK. 2023;83(6):664-672.

Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry
Mandelkow T, Bady E, Lurati M, Raedler J, Müller J, Huang Z, Vettorazzi E, Lennartz M, Clauditz T, Lebok P, Steinhilper L, Woelber L, Sauter G, Berkes E, Bühler S, Paluchowski P, Heilenkötter U, Müller V, Schmalfeldt B, von der Assen A, Jacobsen F, Krech T, Krech R, Simon R, Bernreuther C, Steurer S, Burandt E, Blessin N
BIOMEDICINES. 2023;11(12):.

ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axis
Meškytė E, Pezzè L, Bartolomei L, Forcato M, Bocci I, Bertalot G, Barbareschi M, Oliveira-Ferrer L, Bisio A, Bicciato S, Baltriukienė D, Ciribilli Y
CELL DEATH DIS. 2023;14(4):263.

Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review
Müller V, Bartsch R, Lin N, Montemurro F, Pegram M, Tolaney S
CANCER TREAT REV. 2023;115:102527.

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare
Müller V, Fasching P, Nabieva N, Fehm T, Thill M, Schmidt M, Kühn T, Banys-Paluchowski M, Belleville E, Juhasz-Böss I, Untch M, Kolberg H, Harbeck N, Aktas B, Stickeler E, Kreuzeder J, Hartkopf A, Janni W, Ditsch N
GEBURTSH FRAUENHEILK. 2023;83(6):673-685.

European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023
Oonk M, Planchamp F, Baldwin P, Mahner S, Mirza M, Fischerová D, Creutzberg C, Guillot E, Garganese G, Lax S, Redondo A, Sturdza A, Taylor A, Ulrikh E, Vandecaveye V, van der Zee A, Wölber L, Zach D, Zannoni G, Zapardiel I
INT J GYNECOL CANCER. 2023;33(7):1023-1043.

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023
Park-Simon T, Müller V, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Huober J, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Mundhenke C, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Wuerstlein R, Janni W, Thill M
BREAST CARE. 2023;18(4):288-304.

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz J, Canzler U, Sehouli J, Heubner M, Hartkopf A, Baumann K, Hasenburg A, Hanker L, Belau A, Schmalfeldt B, Denschlag D, Park-Simon T, Selle F, Jackisch C, Burges A, Lück H, Emons G, Meier W, Gropp-Meier M, Schröder W, de Gregorio N, Hilpert F, Harter P
J CLIN ONCOL. 2023;41(4):893-902.

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione S, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum I, Ray-Coquard I
JCO PRECIS ONCOL. 2023;7(7):e2200258.

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
Reimer F, Bryan S, Legler K, Karn T, Eppenberger-Castori S, Matschke J, Pereira-Veiga T, Wikman H, Witzel I, Müller V, Schmalfeldt B, Milde-Langosch K, Schumacher U, Stürken C, Oliveira-Ferrer L
CANCER CELL INT. 2023;23(1):47.

Impact of Introducing a PACU24 Concept on the Perioperative Outcome of Patients with Advanced Ovarian Cancer Treated with Cytoreductive Surgery
Reuter S, Schmalfeldt B, Haas S, Zapf A, Cevirme S, Prieske K, Wölber L, Müller V, Zöllner C, Jaeger A
GEBURTSH FRAUENHEILK. 2023;83(8):1022-1030.

Impact of introducing a PACU24 concept on the perioperative outcome of patients with advanced ovarian cancer treated with cytoreductive surgery
Reuter S, Zapf A, Cevirme S, Wölber L, Muller V, Haas S, Zöllner C, Schmalfeldt B, Jaeger A
INT J GYNECOL CANCER. 2023;33(Suppl 3):.

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
Riecke K, Müller V, Neunhöffer T, Park-Simon T, Weide R, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Wuerstlein R, Denkert C, Decker T, Fehm T, Nekljudova V, Rey J, Loibl S, Laakmann E, Witzel I
ESMO OPEN. 2023;8(3):101213.

Evaluation of a short instrument for measuring health-related quality of life in oncological patients in routine care (HELP-6): an observational study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kroger N, Muller V, Krüll A, Schulz H, Bleich C
FRONT PSYCHOL. 2023;14:1158449.

A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany
van der Ven J, Linz V, Anic K, Schmidt M, Loewe A, Krajnak S, Schmidt M, Kommoss S, Schmalfeldt B, Sehouli J, Hasenburg A, Battista M
ARCH GYNECOL OBSTET. 2023;308(2):527-534.

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer
Volk A, Legler K, Hamester F, Kuerti S, Eylmann K, Rossberg M, Schmalfeldt B, Oliveira-Ferrer L
J CANCER RES CLIN. 2023;149(17):15957-15967.

High Homogeneity of Mesothelin Expression in Primary and Metastatic Ovarian Cancer
Weidemann S, Gorbokon N, Lennartz M, Hube-Magg C, Fraune C, Bernreuther C, Clauditz T, Jacobsen F, Jansen K, Schmalfeldt B, Wölber L, Paluchowski P, Berkes E, Heilenkötter U, Sauter G, Uhlig R, Wilczak W, Steurer S, Simon R, Krech T, Marx A, Burandt E, Lebok P
APPL IMMUNOHISTO M M. 2023;31(2):77-83.

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Williams T, Schneeweiss A, Jackisch C, Shen C, Weber K, Fasching P, Denkert C, Furlanetto J, Heinmöller E, Schmatloch S, Karn T, Szeto C, van Mackelenbergh M, Nekljudova V, Stickeler E, Soon-Shiong P, Schem C, Mairinger T, Müller V, Marme F, Untch M, Loibl S
CLIN CANCER RES. 2023;29(17):3384-3394.

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group
Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, Mahner S, de Gregorio N, Hanker L, Heitz F, Marmé F, Woelber L, Holtmann L, Elser G, Harter P
INT J GYNECOL CANCER. 2023;33(7):1083-1089.

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
Yamamoto Y, Yamashiro H, Schneeweiss A, Müller V, Gluz O, Klare P, Aktas B, Magdolna D, Büdi L, Pikó B, Mangel L, Toi M, Morita S, Ohno S
BREAST CANCER-TOKYO. 2023;30(1):88-100.

Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer
Arnold S, Kortland J, Maltseva D, Nersisyan S, Samatov T, Lezius S, Tonevitsky A, Milde-Langosch K, Wicklein D, Schumacher U, Stürken C
J CANCER RES CLIN. 2022;148(6):1525-1542.

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022
Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, Fallenberg E, Friedrich M, Kümmel S, Müller V, Janni W, Albert U, Bauerfeind I, Blohmer J, Budach W, Dall P, Fasching P, Fehm T, Gluz O, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Loibl S, Lüftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Gerber B
GEBURTSH FRAUENHEILK. 2022;82(10):1031-1043.

Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer
Bartkowiak K, Heidrich I, Kwiatkowski M, Banys-Paluchowski M, Andreas A, Wurlitzer M, Geffken M, Voß H, Zeller T, Blankenberg S, Peine S, Joosse S, Müller V, Schlüter H, Oliveira-Ferrer L, Pantel K
CLIN CHEM. 2022;68(2):344-353.

T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer
Burandt E, Blessin N, Rolschewski A, Lutz F, Mandelkow T, Yang C, Bady E, Reiswich V, Simon R, Sauter G, Mahner S, Gregorio N, Klapdor R, Kalder M, Braicu E, Fürst S, Klar M, Strauß H, Prieske K, Wölber L
CANCERS. 2022;14(17):.

Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma
Christgen M, Kandt L, Antonopoulos W, Bartels S, Van Bockstal M, Bredt M, Brito M, Christgen H, Colpaert C, Cserni B, Cserni G, Daemmrich M, Danebrock R, Dedeurwaerdere F, van Deurzen C, Erber R, Fathke C, Feist H, Fiche M, Gonzalez C, Ter Hoeve N, Kooreman L, Krech T, Kristiansen G, Kulka J, Laenger F, Lafos M, Lehmann U, Martin-Martinez M, Mueller S, Pelz E, Raap M, Ravarino A, Reineke-Plaass T, Schaumann N, Schelfhout A, De Schepper M, Schlue J, Van de Vijver K, Waelput W, Wellmann A, Graeser M, Gluz O, Kuemmel S, Nitz U, Harbeck N, Desmedt C, Floris G, Derksen P, van Diest P, Vincent-Salomon A, Kreipe H
J PATHOL CLIN RES. 2022;8(2):191-205.

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E
ANN ONCOL. 2022;33(3):321-329.

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
Ding Y, Schmalfeldt B, Vettorazzi E, Legler K, Milde-Langosch K, Woelber L, Jaeger A, Prieske K, Mueller V, Schmalfeldt B, Kuerti S
PLOS ONE. 2022;17(6):.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
Ditsch N, Wöcke A, Untch M, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Lüftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M
BREAST CARE. 2022;17(4):403-420.

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT
Engler T, Fasching P, Lüftner D, Hartkopf A, Müller V, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Wallwiener M, Beckmann M, Hein A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Untch M, Taran F, Enzinger H, Krabisch P, Welslau M, Maasberg M, Hempel D, Lux M, Michel L, Janni W, Wallwiener D, Brucker S, Fehm T, Schneeweiss A
GEBURTSH FRAUENHEILK. 2022;82(10):1055-1067.

The History and Future of Basic and Translational Cell-Free DNA Research at a Glance
Gahan P, Schwarzenbach H, Anker P
DIAGNOSTICS. 2022;12(5):.

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong A, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek S, Eisen A, Elsafy F, Fein L, Fielding A, Ford J, Friedman S, Gelmon K, Gianni L, Gnant M, Hollingsworth S, Im S, Jager A, Jóhannsson Ó, Lakhani S, Janni W, Linderholm B, Liu T, Loman N, Korde L, Loibl S, Lucas P, Marmé F, Martinez de Dueñas E, McConnell R, Phillips K, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer C, Španić T, Stickeler E, Toi M, Traina T, Viale G, Zoppoli G, Park Y, Yerushalmi R, Yang H, Pang D, Jung K, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke G, Sun Q, Parton M, Colleoni M, Schmidt M, Brufsky A, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt A
ANN ONCOL. 2022;33(12):1250-1268.

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian M, Gebauer D, Kates R, Paré L, Grischke E, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Wuerstlein R, Graeser M, Pelz E, Jóźwiak K, Zu Eulenburg C, Kreipe H, Harbeck N
CLIN CANCER RES. 2022;28(22):4995-5003.

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer
Grote I, Bartels S, Christgen H, Radner M, Gronewold M, Kandt L, Raap M, Lehmann U, Gluz O, Graeser M, Kuemmel S, Nitz U, Harbeck N, Kreipe H, Christgen M
MODERN PATHOL. 2022;35(12):1804-1811.

Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer
Hamester F, Stürken C, Legler K, Eylmann K, Möller K, Roßberg M, Gorzelanny C, Bauer A, Windhorst S, Schmalfeldt B, Laakmann E, Müller V, Witzel I, Oliveira-Ferrer L
CELLS-BASEL. 2022;11(20):.

Insights into the Steps of Breast Cancer-Brain Metastases Development: Tumor Cell Interactions with the Blood-Brain Barrier
Hamester F, Stürken C, Saygi C, Qi M, Legler K, Gorzelanny C, Robador J, Schmalfeldt B, Laakmann E, Müller V, Witzel I, Oliveira-Ferrer L
INT J MOL SCI. 2022;23(3):.

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Harter P, Mouret-Reynier M, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup T, Floquet A, El-Balat A, Scambia G, Guerra Alia E, Fabbro M, Schmalfeldt B, Hardy-Bessard A, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I
GYNECOL ONCOL. 2022;164(2):254-264.

A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial
Hillemanns P, Denecke A, Woelber L, Böhmer G, Jentschke M, Schjetne K, Bruins Slot K, Fredriksen A
CLIN CANCER RES. 2022;28(22):4885-4892.

MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Huebner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Jückstock J, Nabieva N, Schneeweiss A, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Rack B
CANCERS. 2022;14(7):.

Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
Jaeger A, Prieske K, Mathey S, Fischer I, Vettorazzi E, Kuerti S, Reuter S, Dieckmann J, Schmalfeldt B, Woelber L
ARCH GYNECOL OBSTET. 2022;305(1):233-240.

Frequency of Injuries to Women after Sexual Offense - Relevance of a Gynecology Examination
Klasen C, Meyer L, Anders S, Lohner L, Ondruschka B, Pinnschmidt H, Püschel K, Schmalfeldt B, Seifert D, Wilmes S, Witzel I
GEBURTSH FRAUENHEILK. 2022;82(4):420-426.

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
Kolberg-Liedtke C, Feuerhake F, Garke M, Christgen M, Kates R, Grischke E, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Graeser M, Nitz U, Kreipe H, Gluz O, Harbeck N
BREAST CANCER RES. 2022;24(1):.

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference
Kolberg-Liedtke C, Lüftner D, Brucker S, Budach W, Denkert C, Fasching P, Haidinger R, Harbeck N, Huober J, Jackisch C, Janni W, Krug D, Kühn T, Loibl S, Müller V, Schneeweiss A, Thomssen C, Untch M, Thill M
BREAST CARE. 2022;17(3):336-345.

NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer
Konrad S, Schwamborn K, Krüger A, Honert K, Schmitt M, Hellmann D, Schmalfeldt B, Meindl A, Kiechle M, Quante A, Brambs C, Grill S, Ramser J
BIOMARK MED. 2022;16(14):1029-1041.

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
Laakmann E, Witzel I, Neunhöffer T, Park-Simon T, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm D, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V
ESMO OPEN. 2022;7(3):.

6q deletion is frequent but unrelated to patient prognosis in breast cancer
Lebok P, Bönte H, Kluth M, Möller-Koop C, Witzel I, Wölber L, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Burandt E
BREAST CANCER-TOKYO. 2022;29(2):216-223.

Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients
Leffers M, Herbst J, Kropidlowski J, Prieske K, Bohnen A, Peine S, Jaeger A, Prieske K, Goy Y, Schmalfeldt B, Pantel K, Wölber L, Effenberger K, Wikman H
CANCERS. 2022;14(16):.

EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Leichsenring J, Vladimirova V, Solbach C, Karn T, Ataseven B, Sinn B, Barinoff J, Müller V, Blohmer J, Schem C, Engels K, Marmé F, Fisseler-Eckhoff A, Fasching P, Stickeler E, van Mackelenbergh M, Denkert C, Stenzinger A, Loibl S, Gröschel S
BMC CANCER. 2022;22(1):1040.

Vaginal injuries after consensual sexual intercourse - a survey among office-based gynecologists in Hamburg, Germany
Lohner L, Nigbur L, Klasen C, Witzel I, Garland J, Ondruschka B, Anders S
FORENSIC SCI MED PAT. 2022;18(3):352-358.

ABC6 Consensus: Assessment by a Group of German Experts
Lüftner D, Fasching P, Haidinger R, Harbeck N, Jackisch C, Müller V, Schumacher-Wulf E, Thomssen C, Untch M, Würstlein R
BREAST CARE. 2022;17(1):90-100.

Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer
Lüftner D, Schütz F, Stickeler E, Fasching P, Janni W, Kolberg-Liedtke C, Kolberg H, Thomssen C, Müller V, Fehm T, Belleville E, Bader S, Untch M, Welslau M, Thill M, Tesch H, Ditsch N, Lux M, Wöckel A, Aktas B, Schneeweiss A, Würstlein R, Hartkopf A
GEBURTSH FRAUENHEILK. 2022;82(2):215-225.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Makker V, Colombo N, Casado Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Smith A, Keefe S, Bird S, Dutta L, Orlowski R, Lorusso D
NEW ENGL J MED. 2022;386(5):437-448.

Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study)
Maurer T, Belau M, von Grundherr J, Schlemmer Z, Patra S, Becher H, Schulz K, Zyriax B, Schmalfeldt B, Chang-Claude J
BMJ OPEN. 2022;12(2):.

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry
Müller V, Hein A, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Beckmann M, Schneeweiss A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Meyer J, Wurmthaler L, Kurbacher C, Wuerstlein R, Untch M, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Fehm T, Michel L
EUR J CANCER. 2022;172:13-21.

Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer
Müller V, Welslau M, Lüftner D, Schütz F, Stickeler E, Fasching P, Janni W, Thomssen C, Witzel I, Fehm T, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux M, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf A, Kolberg H, Wöckel A
GEBURTSH FRAUENHEILK. 2022;82(6):590-600.

Liquid Biopsy-basierte Überwachung der BRCA1-Promoter Hypermethylierung als Therapieresistenz Marker in Brust- und Eierstockkrebs
Netkova-Heintzen M, Wankner M, Joosse S
GYN Praktische Gynäkologie. 2022;27(6):494-500.

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
Ningsi R, Elazezy M, Stegat L, Laakmann E, Peine S, Riethdorf S, Müller V, Pantel K, Joosse S
CANCERS. 2022;14(11):.

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke E, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer H, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe H, Harbeck N
LANCET ONCOL. 2022;23(5):625-635.

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer
Nitz U, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke E, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer H, Malter W, Hauptmann M, Kates R, Gräser M, Würstlein R, Shak S, Baehner F, Kreipe H, Harbeck N
J CLIN ONCOL. 2022;40(23):2557-2567.

Ovarian Cancer-Cell Pericellular Hyaluronan Deposition Negatively Impacts Prognosis of Ovarian Cancer Patients
Oliveira-Ferrer L, Schmalfeldt B, Dietl J, Bartmann C, Schumacher U, Stürken C
BIOMEDICINES. 2022;10(11):.

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions
Preti M, Joura E, Vieira-Baptista P, Van Beurden M, Bevilacqua F, Bleeker M, Bornstein J, Carcopino X, Chargari C, Cruickshank M, Erzeneoglu B, Gallio N, Heller D, Kesic V, Reich O, Stockdale C, Esat Temiz B, Woelber L, Planchamp F, Zodzika J, Querleu D, Gultekin M
INT J GYNECOL CANCER. 2022;32(7):830-845.

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-invasive Vulvar Lesions
Preti M, Joura E, Vieira-Baptista P, Van Beurden M, Bevilacqua F, Bleeker M, Bornstein J, Carcopino X, Chargari C, Cruickshank M, Erzeneoglu B, Gallio N, Heller D, Kesic V, Reich O, Stockdale C, Temiz B, Woelber L, Planchamp F, Zodzika J, Querleu D, Gultekin M
J LOW GENIT TRACT DI. 2022;26(3):229-244.

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
Razis E, Escudero M, Palmieri C, Mueller V, Bartsch R, Rossi G, Gampenrieder S, Kolberg H, Zdenkowski N, Pavic M, Connolly R, Rosset L, Arcuri J, Tesch H, Vallejos C, Retamales J, Musolino A, Del Mastro L, Christodoulou C, Aebi S, Paluch-Shimon S, Gupta S, Ohno S, Macpherson I, Ekholm M, Zaman K, Vidal M, Chakiba C, Fumagalli D, Thulin A, Witzel I, Kotecki N, Gil-Gil M, Linderholm B
ESMO OPEN. 2022;7(3):.

The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer
Reuter S, Woelber L, Trepte C, Perez D, Zapf A, Cevirme S, Mueller V, Schmalfeldt B, Jaeger A
ARCH GYNECOL OBSTET. 2022;306(1):199-207.

Zytoreduktive Chirurgie und hypertherme intraperitoneale Chemoperfusion beim Ovarialkarzinom
Schmalfeldt B
CHIRURGIE. 2022;93(12):1144-1151.

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
Schmidt M, Lübbe K, Decker T, Thill M, Bauer L, Müller V, Link T, Furlanetto J, Reinisch M, Mundhenke C, Hoffmann O, Zahn M, Müller L, Denkert C, van Mackelenbergh M, Fasching P, Burchardi N, Nekljudova V, Loibl S
ESMO OPEN. 2022;7(6):.

Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT
Tahir E, Azar M, Shihada S, Seiffert K, Goy Y, Beitzen-Heineke A, Molwitz I, Muellerleile K, Stehning C, Schön G, Adam G, Petersen C, Müller V, Lund G
EUR RADIOL. 2022;32(3):1853-1865.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022
Thill M, Lüftner D, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N
BREAST CARE. 2022;17(4):421-429.

Update Breast Cancer 2021 Part 4 - Prevention and Early Stages
Thomssen C, Fehm T, Stickeler E, Fasching P, Janni W, Kolberg-Liedtke C, Kolberg H, Lüftner D, Müller V, Schütz F, Belleville E, Bader S, Untch M, Welslau M, Thill M, Hartkopf A, Tesch H, Ditsch N, Lux M, Wöckel A, Aktas B, Schneeweiss A, Würstlein R
GEBURTSH FRAUENHEILK. 2022;82(2):206-214.

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial
Trapp E, Fasching P, Fehm T, Schneeweiss A, Mueller V, Harbeck N, Lorenz R, Schumacher C, Heinrich G, Schochter F, de Gregorio A, Tzschaschel M, Rack B, Janni W, Friedl T
CANCERS. 2022;14(16):.

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial
Tripathy D, Tolaney S, Seidman A, Anders C, Ibrahim N, Rugo H, Twelves C, Diéras V, Müller V, Du Y, Currie S, Hoch U, Tagliaferri M, Hannah A, Cortés J
JAMA ONCOL. 2022;8(7):1047-1052.

Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care - a Randomized Pilot Study
Ullrich A, Wilde S, Müller V, Sinn M, Gebhardt C, Velthaus J, Gerlach C, Bokemeyer C, Oechsle K
ONCOL RES TREAT. 2022;45(3):118-129.

Advanced Breast Cancer: AGO Recommendations 2022 - Focus on ABC6 Consensus
Untch M, Fasching P, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, Schumacher-Wulf E, Würstlein R, Thomssen C
GEBURTSH FRAUENHEILK. 2022;82(10):1044-1054.

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza M, Brasiuniene B, Madry R, Brenton J, Ausems M, Büttner R, Lambrechts D
ANN ONCOL. 2022;33(3):276-287.

Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients with Ovarian Cancer
Weber-Lassalle K, Ernst C, Reuss A, Möllenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, Park-Simon T, Hanker L, Prieske K, Schmidt S, Weber-Lassalle N, Pohl-Rescigno E, Kommoss S, Marmé F, Heitz F, Stingl J, Schmutzler R, Harter P, Hahnen E
JNCI-J NATL CANCER I. 2022;114(4):565-570.

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
Weimer P, Wellbrock J, Sturmheit T, Ferrer L, Ding Y, Menzel S, Witt M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Brauneck F
CELLS-BASEL. 2022;11(6):.

Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer
Welslau M, Müller V, Lüftner D, Schütz F, Stickeler E, Fasching P, Janni W, Thomssen C, Witzel I, Fehm T, Belleville E, Bader S, Seitz K, Untch M, Thill M, Tesch H, Ditsch N, Lux M, Aktas B, Banys-Paluchowski M, Schneeweiss A, Harbeck N, Würstlein R, Hartkopf A, Wöckel A, Seliger B, Massa C, Kolberg H
GEBURTSH FRAUENHEILK. 2022;82(6):580-589.

Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Wimberger P, Gerber M, Pfisterer J, Erdmann K, Füssel S, Link T, du Bois A, Kommoss S, Heitz F, Sehouli J, Kimmig R, de Gregorio N, Schmalfeldt B, Park-Simon T, Baumann K, Hilpert F, Grube M, Schröder W, Burges A, Belau A, Hanker L, Kuhlmann J
CLIN CANCER RES. 2022;28(21):4660-4668.

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Woelber L, Hampl M, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, Heublein S, Gass P, Rohner A, Canzler U, Becker S, Bommert M, Bauerschlag D, Denecke A, Hanker L, Runnebaumn I, Forner D, Schochter F, Klar M, Schwab R, Koepke M, Kalder M, Hantschmann P, Ratiu D, Denschlag D, Schroeder W, Tuschy B, Baumann K, Mustea A, Soergel P, Bronger H, Bauerschmitz G, Kosse J, Koch M, Ignatov A, Sehouli J, Dannecker C, Mahner S, Jaeger A
CANCERS. 2022;14(2):.

Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study
Woelber L, Prieske K, Eulenburg C, Corradini S, Petersen C, Bommert M, Blankenstein T, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Beckmann M, Mustea A, Mahner S, Jaeger A
GYNECOL ONCOL. 2022;164(1):68-75.

Interdisziplinäre Expertenzusammenarbeit in der Senologie intensiviert: Verbesserung der Versorgung durch kontinuierlicheWartung–das „Living-Guideline-Konzept “der onkologischen S3-Leitlinie Mammakarzinom
Albert U, Janni W, Muller V, Wöckel A
Senologie. 2021;18:113–114.

ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing
Asperger H, Cieslik J, Alberter B, Köstler C, Polzer B, Müller V, Pantel K, Riethdorf S, Koch A, Hartkopf A, Wiesmüller L, Janni W, Schochter F, Franken A, Niederacher D, Fehm T, Neubauer H
TRANSL ONCOL. 2021;14(8):101132.

Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells
Bartkowiak K, Heidrich I, Kwiatkowski M, Gorges T, Andreas A, Geffken M, Verpoort K, Müller V, Schlüter H, Pantel K
CANCERS. 2021;13(3):.

Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis
Baum J, Braicu E, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri M, Vanderstichele A, Benedetti Panici P, Mueller M, Ruscito I, Woopen H, Sehouli J
INT J GYNECOL CANCER. 2021;31(5):713-720.

Therapiealgorithmen für das Mammakarzinom
Blohmer J, Schneeweiss A, Bauerfeind I, Fehm T, Muller V, Thomssen C, Witzel I, Wöckel A, Janni W
ONKOLOGE. 2021;27:1165–1174 .

Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design
Blomen C, Pott A, Volk A, Budäus L, Witzel I
SCI REP-UK. 2021;11(1):20178.

Physiotherapy and combined cognitive-behavioural therapy for patients with chronic pelvic pain syndrome: results of a non-randomised controlled feasibility trial
Brünahl C, Klotz S, Dybowski C, Albrecht R, Höink J, Fisch M, Ketels G, Löwe B
BMJ OPEN. 2021;11(12):.

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
Bryan S, Witzel I, Borgmann K, Oliveira-Ferrer L
CANCERS. 2021;13(16):.

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Coleman R, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv S, Chen M, Harris J, Smith M, Nicacio L, Teng M, Laenen A, Rangwala R, Manso L, Mirza M, Monk B, Vergote I
LANCET ONCOL. 2021;22(5):609-619.

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Colombo N, Dubot C, Lorusso D, Caceres M, Hasegawa K, Shapira-Frommer R, Tewari K, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe S, Monk B
NEW ENGL J MED. 2021;385(20):1856-1867.

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆
Denkert C, Untch M, Benz S, Schneeweiss A, Weber K, Schmatloch S, Jackisch C, Sinn H, Golovato J, Karn T, Marmé F, Link T, Budczies J, Nekljudova V, Schmitt W, Stickeler E, Müller V, Jank P, Parulkar R, Heinmöller E, Sanborn J, Schem C, Sinn B, Soon-Shiong P, van Mackelenbergh M, Fasching P, Rabizadeh S, Loibl S
ANN ONCOL. 2021;32(4):500-511.

Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer
Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B, Stürken C, Oliveira-Ferrer L
MOL ONCOL. 2021;15(12):3578-3595.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Thill M
BREAST CARE. 2021;16(3):214-227.

Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers
Ditsch N, Stickeler E, Behrens A, Belleville E, Fasching P, Fehm T, Hartkopf A, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg H, Lüftner D, Lux M, Müller V, Schneeweiss A, Schütz F, Schulmeyer C, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler L, Würstlein R, Thill M, Aktas B
GEBURTSH FRAUENHEILK. 2021;81(5):539-548.

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse S
MOL ONCOL. 2021;15(12):3615-3625.

Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer
Elazezy M, Schwentesius S, Stegat L, Wikman H, Werner S, Mansour W, Failla A, Peine S, Müller V, Thiery J, Ebrahimi Warkiani M, Pantel K, Joosse S
CANCERS. 2021;13(15):.

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer - Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching P, Yadav S, Hu C, Wunderle M, Häberle L, Hart S, Rübner M, Polley E, Lee K, Gnanaolivu R, Hadji P, Hübner H, Tesch H, Ettl J, Overkamp F, Lux M, Ekici A, Volz B, Uhrig S, Lüftner D, Wallwiener M, Müller V, Belleville E, Untch M, Kolberg H, Beckmann M, Reis A, Hartmann A, Janni W, Wimberger P, Taran F, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Hartkopf A, Couch F
J CLIN ONCOL. 2021;39(15):1619-1630.

Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel
Fehm T, Stickeler E, Fasching P, Janni W, Kolberg-Liedtke C, Kolberg H, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf A
GEBURTSH FRAUENHEILK. 2021;81(6):654-665.

Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Friedl T, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Jückstock J, Schneeweiss A, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Rack B
JAMA ONCOL. 2021;7(8):1149-1157.

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Friedrich M, Kühn T, Janni W, Müller V, Banys-Pachulowski M, Kolberg-Liedtke C, Jackisch C, Krug D, Albert U, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe H, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Möbus V, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Thill M, Ditsch N
GEBURTSH FRAUENHEILK. 2021;81(10):1112-1120.

Therapie der Axilla im Rahmen der primären Operation
Friedrich M, Kühn T, Janni W, Muller V, Fasching P, Banys-Paluchowski M, Ditsch N
GYN Praktische Gynäkologie. 2021.

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials
Furlanetto J, Marmé F, Seiler S, Thode C, Untch M, Schmatloch S, Schneeweiss A, Bassy M, Fasching P, Strik D, Stickeler E, Schem C, Karn T, Grischke E, Denkert C, van Mackelenbergh M, Müller V, Nekljudova V, Loibl S
EUR J CANCER. 2021;152:193-203.

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
Graeser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, Jozwiak K, Christgen M, Kuemmel S, Grischke E, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe H, Harbeck N
J IMMUNOTHER CANCER. 2021;9(5):.

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
Graeser M, Harbeck N, Gluz O, Würstlein R, Zu Eulenburg C, Schumacher C, Grischke E, Forstbauer H, Dimpfl M, Braun M, Christgen M, Kreipe H, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Kümmel S, Nitz U
BREAST. 2021;59:58-66.

Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials
Graeser M, Schrading S, Gluz O, Strobel K, Herzog C, Umutlu L, Frydrychowicz A, Rjosk-Dendorfer D, Würstlein R, Culemann R, Eulenburg C, Adams J, Nitzsche H, Prange A, Kümmel S, Grischke E, Forstbauer H, Braun M, Potenberg J, von Schumann R, Aktas B, Kolberg-Liedtke C, Harbeck N, Kuhl C, Nitz U
BREAST CANCER RES. 2021;23(1):.

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials: Combined analysis from the WSG ADAPT subtrials
Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, Schumacher C, Grischke E, Forstbauer H, Braun M, Christgen M, Adams J, Nitzsche H, Just M, Fischer H, Aktas B, Potenberg J, von Schumann R, Kolberg-Liedtke C, Harbeck N, Kuhl C, Nitz U
INT J CANCER. 2021;148(10):2614-2627.

Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany
Grimm D, Mathes S, Woelber L, Van Aken C, Schmalfeldt B, Mueller V, Kiechle M, Brambs C, Paepke D
ARCH GYNECOL OBSTET. 2021;303(5):1315-1330.

Gynecologists' attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany
Grimm D, Voiss P, Paepke D, Dietmaier J, Cramer H, Kümmel S, Beckmann M, Woelber L, Schmalfeldt B, Freitag U, Kalder M, Wallwiener M, Theuser A, Hack C
ARCH GYNECOL OBSTET. 2021;303(4):967-980.

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke E, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H
CANCER MED-US. 2021;10(23):8581-8594.

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status
Hein A, Hartkopf A, Emons J, Lux M, Volz B, Taran F, Overkamp F, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wurmthaler L, Wallwiener M, Müller V, Beckmann M, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Kolberg H
EUR J CANCER. 2021;155:1-12.

CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients
Heinze K, Rengsberger M, Gajda M, Jansen L, Osmers L, Oliveira-Ferrer L, Schmalfeldt B, Dürst M, Häfner N, Runnebaum I
CLIN EPIGENETICS. 2021;13(1):15.

Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance
Hoyer H, Mehlhorn G, Scheungraber C, Hagemann I, Hirchenhain C, Woelber L, Stolte C, Hampl M, Scherbring S, Denecke A, Bartels J, Ebert A, Meneder S, Petzold A, Heller T, Heidtke K, Schwarz E, Stübs F, Schütze S, Stange E, Jaeger A, Martignoni F, Dellmann A, Rody A, Hillemanns P, Fehm T, Petry K, Böhmer G, Schmalfeldt B, Wimberger P, Beckmann M, Runnebaum I, Dürst M
CANCERS. 2021;13(13):.

Perimenopause and Postmenopause - Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020)
Inwald E, Albring C, Baum E, Beckermann M, Bühling K, Emons G, Gudermann T, Hadji P, Imthurn B, Kiesel L, Klemperer D, Klose P, König K, Krüger S, Langhorst J, Leitzmann M, Ludolph A, Lüftner D, Müller D, Neulen J, Nothacker M, Petri E, Prautzsch H, Regitz-Zagrosek V, Schaudig K, Schütz F, Schwenkhagen A, Strowitzki T, Stute P, Taute B, Tempfer C, Arnim C, Wildt L, Windler E, Ortmann O
GEBURTSH FRAUENHEILK. 2021;81(6):612-636.

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, Marmé F, Sinn H, van Mackelenbergh M, Sinn B, Zahm D, Ingold-Heppner B, Schem C, Stickeler E, Fasching P, Nekljudova V, Taube E, Heppner F, Müller V, Denkert C, Loibl S
PLOS ONE. 2021;16(9):.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study
Joura E, Ulied A, Vandermeulen C, Rua Figueroa M, Seppä I, Hernandez Aguado J, Ahonen A, Reich O, Virta M, Perino A, Peris Tuser M, Peters K, Origoni M, Raspagliesi F, Tjalma W, Tummers P, Woelber L, Nieminen P, van Damme P, Sehouli J, Fiol Ruiz G, Brucker S, Fehm T, Cheon K, Rawat S, Luxembourg A, Wittke F
VACCINE. 2021;39(20):2800-2809.

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Müller V, Taube E, Fasching P, Schmitt W, Marmé F, Stickeler E, Sinn B, Jank P, Schem C, Klauschen F, van Mackelenbergh M, Denkert C, Loibl S, Capper D
CLIN EPIGENETICS. 2021;13(1):.

High mitochondrial content is associated with breast cancer aggressiveness
Lebok P, Schütt K, Kluth M, Witzel I, Wölber L, Paluchowski P, Terracciano L, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Von Leffern I, Krech T, Krech R, Jacobsen F, Burandt E
MOL CLIN ONCOL. 2021;15(4):.

CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse S, Lamszus K, Westphal M, Müller V, Glatzel M, Matschke J, Gebhardt C, Schneider S, Belczacka I, Volkmer B, Greinert R, Yaspo M, Harter P, Pantel K, Wikman H
INT J MOL SCI. 2021;22(13):.

Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer
Lüftner D, Hartkopf A, Lux M, Overkamp F, Tesch H, Titzmann A, Pöschke P, Wallwiener M, Müller V, Beckmann M, Belleville E, Janni W, Fehm T, Kolberg H, Ettl J, Wallwiener D, Schneeweiss A, Brucker S, Fasching P
BREAST CARE. 2021;16(2):108-114.

Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients
Lux M, Schneeweiss A, Hartkopf A, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching P, Kolberg H, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer C, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N
GEBURTSH FRAUENHEILK. 2021;81(4):469-480.

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot J, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T
ANN ONCOL. 2021;32(10):1245-1255.

Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis
Moreno-Layseca P, Jäntti N, Godbole R, Sommer C, Jacquemet G, Al-Akhrass H, Conway J, Kronqvist P, Kallionpää R, Oliveira-Ferrer L, Cervero P, Linder S, Aepfelbacher M, Zauber H, Rae J, Parton R, Disanza A, Scita G, Mayor S, Selbach M, Veltel S, Ivaska J
NAT CELL BIOL. 2021;23(10):1073-1084.

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Muñoz-Mateu M, Arkenau H, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K
EUR J CANCER. 2021;153:223-233.

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T
ESMO OPEN. 2021;6(6):.

Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020
Muller V, Dieras V, Cardoso F, Cameron D, Cortes J
BREAST CARE. 2021;16(1):89–93.

First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study
Müller V, Ruhnke M, Hoffmann O, Grafe A, Tomé O, Fett W, Bruch H, Sommer-Joos A, Schneeweiss A
BREAST. 2021;60:70-77.

Asbestos Exposure and Ovarian Cancer - a Gynaecological Occupational Disease. Background, Mandatory Notification, Practical Approach
Nowak D, Schmalfeldt B, Tannapfel A, Mahner S
GEBURTSH FRAUENHEILK. 2021;81(5):555-561.

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer-A Study of the OVCAD Consortium
Obermayr E, Braicu E, Polterauer S, Loverix L, Concin N, Woelber L, Mahner S, Sehouli J, Van Gorp T, Vergote I, Zeillinger R, Aust S
CANCERS. 2021;13(23):.

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium
Obermayr E, Reiner A, Brandt B, Braicu E, Reinthaller A, Loverix L, Concin N, Woelber L, Mahner S, Sehouli J, Vergote I, Zeillinger R
CANCERS. 2021;13(11):.

Transcriptome Analysis in Vulvar Squamous Cell Cancer
Prieske K, Alawi M, Jaeger A, Wankner M, Eylmann K, Reuter S, Lebok P, Burandt E, Blessin N, Schmalfeldt B, Prieske K, Joosse S, Woelber L
CANCERS. 2021;13(24):.

Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study
Prieske K, Woelber L, Muallem M, Eulenburg C, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Ignatov A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Beckmann M, Mustea A, Meier W, Harter P, Wimberger P, Sehouli J, Mahner S
GYNECOL ONCOL. 2021;161(2):442-448.

MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer
Rico S, Schmalfeldt B, Müller V, Wölber L, Witzel I, Paluchowski P, von Leffern I, Heilenkötter U, Jacobsen F, Bernreuther C, Clauditz T, Simon R, Steurer S, Burandt E, Marx A, Krech T
PATHOL RES PRACT. 2021;224:.

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores
Riecke K, Müller V, Weide R, Schmidt M, Park-Simon T, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Laakmann E, Thill M, A Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I
CANCERS. 2021;13(4):.

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Kurbacher C, Klein E, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker S
BREAST. 2021;55:138-139.

AGO Algorithms for the Treatment of Breast Cancer: Update 2021
Schneeweiss A, Fasching P, Fehm T, Gerber B, Jackisch C, Loibl S, Schmidt M, Stickeler E, Wöckel A, Janni W, Müller V
GEBURTSH FRAUENHEILK. 2021;81(10):1101-1111.

Evaluation of a program for routine implementation of shared decision-making in cancer care: results of a stepped wedge cluster randomized trial
Scholl I, Hahlweg P, Lindig A, Frerichs W, Zill J, Cords H, Bokemeyer C, Coym A, Schmalfeldt B, Smeets R, Vollkommer T, Witzel I, Härter M, Kriston L
IMPLEMENT SCI. 2021;16(1):.

Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial
Schouten P, Richters L, Vis D, Kommoss S, van Dijk E, Ernst C, Kluin R, Marmé F, Lips E, Schmidt S, Scheerman E, Prieske K, van Deurzen C, Burges A, Ewing-Graham P, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof P, Wessels L, Hahnen E, Harter P, Linn S, Schmutzler R
CLIN CANCER RES. 2021;27(23):6559-6569.

Exosomes in Immune Regulation
Schwarzenbach H, Gahan P
NON-CODING RNA. 2021;7(1):.

The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study
Seiffert K, Thoene K, Eulenburg C, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I
BREAST. 2021;55:98-104.

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Sinn B, Loibl S, Hanusch C, Zahm D, Sinn H, Untch M, Weber K, Karn T, Becker C, Marmé F, Schmitt W, Müller V, Schem C, Treue D, Stickeler E, Klauschen F, Burchardi N, Furlanetto J, van Mackelenbergh M, Fasching P, Schneeweiss A, Denkert C
CLIN CANCER RES. 2021;27(9):2584-2591.

Update Breast Cancer 2021 Part 1 - Prevention and Early Stages
Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching P, Fehm T, Hartkopf A, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg H, Lüftner D, Lux M, Müller V, Schneeweiss A, Schütz F, Schulmeyer C, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler L, Würstlein R, Thill M
GEBURTSH FRAUENHEILK. 2021;81(5):526-538.

A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer
Strati A, Zavridou M, Kallergi G, Politaki E, Kuske A, Gorges T, Riethdorf S, Joosse S, Koch C, Bohnen A, Mueller V, Koutsodontis G, Kontopodis E, Poulakaki N, Psyrri A, Mavroudis D, Georgoulias V, Pantel K, Lianidou E
CLIN CHEM. 2021;67(10):1395-1405.

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
Stürken C, Möbus V, Milde-Langosch K, Schmatloch S, Fasching P, Rüschoff J, Stickeler E, Henke R, Denkert C, Hanker L, Schem C, Vladimirova V, Karn T, Nekljudova V, Köhne C, Marmé F, Schumacher U, Loibl S, Müller V
BMC CANCER. 2021;21(1):920.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
Thill M, Friedrich M, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N
BREAST CARE. 2021;16(3):228-235.

Behandlung von Patientinnen mit frühem Mammakarzinom: Evidenz, Kontroversen, Konsens–Meinungsbild deutscher Expert* innen zur 17. Internationalen St.-Gallen-Konsensuskonferenz.
Untch M, Fasching P, Brucker S, Budach W, Denkert C, Haidinger R, Huober J, Jackisch C, Janni W, Kolberg-Liedtke C, Krug D, Kühn T, Loibl S, Lüftner D, Muller V, Schneeweiss A, Thill M, Harbeck N, Thomssen C
Senologie. 2021;18(2):163-181.

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
Untch M, Fasching P, Brucker S, Budach W, Denkert C, Haidinger R, Huober J, Jackisch C, Janni W, Kolberg-Liedtke C, Krug D, Kühn T, Loibl S, Lüftner D, Müller V, Schneeweiss A, Thill M, Harbeck N, Thomssen C
GEBURTSH FRAUENHEILK. 2021;81(6):637-653.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Winer E, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J
LANCET ONCOL. 2021;22(4):499-511.

Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study
Woelber L, Bommert M, Harter P, Prieske K, Zu Eulenburg C, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Beckmann M, Mustea A, Meier W, Mahner S, Jaeger A
ANN SURG ONCOL. 2021;28(11):6696-6704.

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC)
Woelber L, Mathey S, Prieske K, Kuerti S, Hillen C, Burandt E, Coym A, Mueller V, Schmalfeldt B, Jaeger A
ONCOL RES. 2021;28(6):645-659.

p53 and p16 expression profiles in vulvar cancer - a translational analysis by the AGO-CaRE- study group
Woelber L, Prieske K, Eulenburg C, Oliveira-Ferrer L, DE Gregorio N, Klapdor R, Kalder M, Braicu I, Fuerst S, Klar M, Straub H, Beckmann M, Meier W, Ignatov A, Mustea A, Jueckstock J, Schmidt G, Bauernschlag D, Hellriegel M, Canzler U, Petry K, Kommoss S, Hantschmann P, Heubner M, Mahner S, Burandt E
AM J OBSTET GYNECOL. 2021;224(6):595.e1-595.e11.

Tubulin Tyrosine Ligase Like 4 (TTLL4) overexpression in breast cancer cells is associated with brain metastasis and alters exosome biogenesis
Arnold J, Schattschneider J, Blechner C, Krisp C, Schlüter H, Schweizer M, Nalaskowski M, Oliveira-Ferrer L, Windhorst S
J EXP CLIN CANC RES. 2020;39(1):205.

Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients
Banys-Paluchowski M, Milde-Langosch K, Fehm T, Witzel I, Oliveira-Ferrer L, Schmalfeldt B, Müller V
BREAST CANCER RES TR. 2020;179(2):403-414.

ASCO 2020
Bartsch R, Dieras V, Cortes J, Müller V, Ruhstaller T
BREAST CARE. 2020;15(4):433-436.

Should empiric therapies be used for male factor infertility?
Buhling K, Chan P, Kathrins M, Showell M, Vij S, Sigman M
FERTIL STERIL. 2020;113(6):1121-1130.

Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group
Canzler U, Lück H, Neuser P, Sehouli J, Burges A, Harter P, Schmalfeldt B, Aminossadati B, Mahner S, Kommoss S, Wimberger P, Pfisterer J, de Gregorio N, Hasenburg A, Gropp-Meier M, El-Balat A, Jackisch C, du Bois A, Meier W, Wagner U
ARCH GYNECOL OBSTET. 2020;301(5):1267-1274.

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
de Gregorio A, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, de Gregorio N, Deniz M, Fink V, Bekes I, Andergassen U, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Janni W
BREAST CANCER RES. 2020;22(1):111.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020
Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, Müller V, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fallenberg E, Fasching P, Fehm T, Gerber B, Gluz O, Hanf V, Harbeck N, Heil J, Huober J, Kreipe H, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Moebus V, Mundhenke C, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Solbach C, Solomayer E, Stickeler E, Thomssen C, Witzel I, Wöckel A, Thill M
BREAST CARE. 2020;15(3):294-309.

HER2-positives und metastasiertes Mammakarzinom: Standards und neue Entwicklungen
Fehm T, Müller V
ONKOLOGE. 2020;26(6):518-523.

Iron core coil designs for MPI
Förger F, Graeser M, Knopp T
Int J Magn Part Imag. 2020;6(2):.

Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients
Franken A, Honisch E, Reinhardt F, Meier-Stiegen F, Yang L, Jaschinski S, Esposito I, Alberter B, Polzer B, Huebner H, Fasching P, Pancholi S, Martin L, Ruckhaeberle E, Schochter F, Tzschaschel M, Hartkopf A, Mueller V, Niederacher D, Fehm T, Neubauer H
J MOL DIAGN. 2020;22(1):111-121.

High homogeneity of MMR deficiency in ovarian cancer
Fraune C, Rosebrock J, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Büscheck F, Höflmayer D, Schmalfeldt B, Müller V, Wölber L, Witzel I, Paluchowski P, Wilke C, Heilenkötter U, von Leffern I, Clauditz T, Wilczak W, Sauter G, Steurer S, Burandt E
GYNECOL ONCOL. 2020;156(3):669-675.

Psychosocial Distress in Women With Breast Cancer and Their Partners and Its Impact on Supportive Care Needs in Partners
Goerling U, Bergelt C, Müller V, Mehnert-Theuerkauf A
FRONT PSYCHOL. 2020;11:564079.

Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol
Görlach M, Schrage T, Bokemeyer C, Kröger N, Müller V, Petersen C, Betz C, Krüll A, Schulz H, Bleich C
HEALTH QUAL LIFE OUT. 2020;18(1):3.

Organ specific mouse head coil for improved image quality in magnetic particle imaging
Graeser M, Liebing T, Szwargulski P, Förger F, Thieben F, Ludewig P, Knopp T
Int J Magn Part Imag. 2020;6(2):.

Receive path calibration to exchange system matrix data of different receivers
Graeser M, Szwargulski P, von Gladiss A, Förger F, Thieben F, Ludewig P, Knopp T
Int J Magn Part Imag. 2020;6(2):.

Course of cervical intraepithelial neoplasia diagnosed during pregnancy
Grimm D, Lang I, Prieske K, Jaeger A, Müller V, Kuerti S, Burandt E, Lezius S, Schmalfeldt B, Woelber L
ARCH GYNECOL OBSTET. 2020;301(6):1503-1512.

Klinische Endpunkte in Real-World-Register-Studien: PRAEGNANT-Netzwerk für Patientinnen mit fortgeschrittenem Mammakarzinom
Hartkopf A, Emons J, Lux M, Taran F, Overkamp F, Tesch H, Titzmann A, Pöschke P, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Janni W, Fehm T, Kolberg H, Ettl J, Wallwiener D, Schneeweiss A, Brucker S, Fasching P
ONKOLOGE. 2020;26(6):530-541.

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Huebner H, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J
BMC CANCER. 2020;20(1):1091.

Update Breast Cancer 2020 Part 3 - Early Breast Cancer
Huober J, Schneeweiss A, Hartkopf A, Müller V, Lux M, Janni W, Ettl J, Belleville E, Thill M, Fasching P, Kolberg H, Schulmeyer C, Welslau M, Overkamp F, Tesch H, Fehm T, Lüftner D, Schütz F, Wöckel A
GEBURTSH FRAUENHEILK. 2020;80(11):1105-1114.

Cerebral metastasis in recurrent squamous cell carcinoma of the vulva: case report and review of the literature
Jaeger A, Biermann M, Prieske K, Grimm D, Grottke A, Salamon J, Petersen C, Mueller V, Schmalfeldt B, Woelber L
ARCH GYNECOL OBSTET. 2020;301(2):327-332.

Differentialdiagnose vulvärer Pruritus: nicht immer Pilze...
Jaeger A, Wölber L
Frauenheilkunde up2date. 2020;2020(04):.

Neues zu VIN und Vulvakarzinom
Jaeger A, Wölber L
Onkologie heute. 2020;2020(05):18-24.

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, Sinn H, van Mackelenbergh M, Sinn B, Zahm D, Ingold-Heppner B, Schem C, Stickeler E, Fasching P, Nekljudova V, Taube E, Heppner F, Müller V, Denkert C, Loibl S
PLOS ONE. 2020;15(8):e0238021.

BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis
Kalachand R, Stordal B, Madden S, Chandler B, Cunningham J, Goode E, Ruscito I, Braicu E, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills G, Lu K, Carey M, Timms K, Kupryjanczyk J, Rzepecka I, Podgorska A, McAlpine J, Swisher E, Bernards S, O'Riain C, O'Toole S, O'Leary J, Bowtell D, Thomas D, Prieske K, Joosse S, Woelber L, Chaudhry P, Häfner N, Runnebaum I, Hennessy B
JNCI-J NATL CANCER I. 2020;112(12):1190-1203.

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Karn T, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, Higgs B, Jank P, Sinn H, Huober J, Becker C, Blohmer J, Marmé F, Schmitt W, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P, Jackisch C, Untch M, Schneeweiss A, Loibl S
ANN ONCOL. 2020;31(9):1216-1222.

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S
CLIN CANCER RES. 2020;26(8):1896-1904.

IL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans
Kempski J, Giannou A, Riecken K, Zhao L, Steglich B, Lücke J, Garcia-Perez L, Karstens K, Wöstemeier A, Nawrocki M, Pelczar P, Witkowski M, Nilsson S, Konczalla L, Shiri A, Kempska J, Wahib R, Brockmann L, Huber P, Gnirck A, Turner J, Zazara D, Arck P, Stein A, Simon R, Daubmann A, Meiners J, Perez D, Strowig T, Koni P, Kruglov A, Sauter G, Izbicki J, Guse A, Roesch T, Lohse A, Flavell R, Gagliani N, Huber S
GASTROENTEROLOGY. 2020;159(4):1417-1430.e3.

Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study
Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst S, Strauss H, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeld B, Mahner S
INT J GYNECOL CANCER. 2020;30(7):920-926.

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Koch C, Kuske A, Joosse S, Yigit G, Sflomos G, Thaler S, Smit D, Werner S, Borgmann K, Gärtner S, Mossahebi Mohammadi P, Battista L, Cayrefourcq L, Altmüller J, Salinas-Riester G, Raithatha K, Zibat A, Goy Y, Ott L, Bartkowiak K, Tan T, Zhou Q, Speicher M, Müller V, Gorges T, Jücker M, Thiery J, Brisken C, Riethdorf S, Alix-Panabières C, Pantel K
EMBO MOL MED. 2020;12(9):.

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
Laakmann E, Emons J, Taran F, Janni W, Uhrig S, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann M, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching P, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Lux M, Hartkopf A
GEBURTSH FRAUENHEILK. 2020;80(11):e289.

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon T, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V
CANCERS. 2020;12(10):.

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Lin N, Borges V, Anders C, Murthy R, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard P, Oliveira M, Mueller V, Zelnak A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer E
J CLIN ONCOL. 2020;38(23):2610-2619.

Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
Lüftner D, Schneeweiss A, Hartkopf A, Müller V, Wöckel A, Janni W, Ettl J, Belleville E, Schütz F, Thill M, Huober J, Fasching P, Kolberg H, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm T, Lux M
GEBURTSH FRAUENHEILK. 2020;80(4):391-398.

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Weber K, Seliger B
J IMMUNOTHER CANCER. 2020;8(2):.

An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial
Maurer T, von Grundherr J, Patra S, Jäger A, Becher H, Schmalfeld B, Zyriax B, Chang-Claude J
INT J GYNECOL CANCER. 2020;30(4):541-545.

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Michel L, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Huebner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Fehm T
CANCERS. 2020;12(10):.

UTROSCT – Eine seltene, potenziell maligne Differenzialdiagnose der Uterustumoren
Müller M, Berkes E, Fraune C, Sauer M
ROFO-FORTSCHR RONTG. 2020.

ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium
Münsterberg J, Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Hamester F, Robador J, Bauer A, Werner Schneider S, Wrage M, Lamszus K, Matschke J, Vashist Y, Uzunoglu G, Steurer S, Horst A, Oliveira-Ferrer L, Glatzel M, Schinke T, Corbeil D, Pantel K, Maire C, Wikman H
NEURO-ONCOLOGY. 2020;22(7):955-966.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Lin N, Borges V, Abramson V, Anders C, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar S, Müller V, Braga S, Duhoux F, Greil R, Cameron D, Carey L, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels M, Walker L, Feng W, Winer E
NEW ENGL J MED. 2020;382(7):597-609.

Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial
Nicklas J, Diener O, Leistenschneider M, Sellhorn C, Schön G, Winkler M, Daum G, Schwedhelm E, Schröder J, Fisch M, Schmalfeldt B, Izbicki J, Bauer M, Coldewey S, Reuter D, Saugel B
BRIT J ANAESTH. 2020;125(2):122-132.

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
Oliveira-Ferrer L, Milde-Langosch K, Eylmann K, Rossberg M, Müller V, Schmalfeldt B, Witzel I, Wellbrock J, Fiedler W
INT J MOL SCI. 2020;21(2):.

Oncological care organisation during COVID-19 outbreak
Onesti C, Rugo H, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz S, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels J, Conte P, Awada A, Jerusalem G
ESMO OPEN. 2020;5(4):.

Design of a magnetostimulation head coil with rutherford cable winding
Ozaslan A, Cagil A, Graeser M, Knopp T, Saritas E
Int J Magn Part Imag. 2020;6(2):.

Open-label placebos for menopausal hot flushes: a randomized controlled trial
Pan Y, Meister R, Löwe B, Kaptchuk T, Buhling K, Nestoriuc Y
SCI REP-UK. 2020;10(1):20090.

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Pfisterer J, Shannon C, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean A, Hein A, Zeimet A, Hanker L, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy T, Park-Simon T, Mouret-Reynier M, Costan C, Meier W, Reinthaller A, Goh J, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz J
LANCET ONCOL. 2020;21(5):699-709.

Perceived relatedness, death acceptance, and demoralization in patients with cancer
Philipp R, Mehnert A, Müller V, Reck M, Vehling S
SUPPORT CARE CANCER. 2020;28(6):2693-2700.

Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial
Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching P, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler R, Schneeweiss A, Hahnen E
JAMA ONCOL. 2020;6(5):744-748.

Genomic characterization of vulvar squamous cell carcinoma
Prieske K, Alawi M, Oliveira-Ferrer L, Jaeger A, Eylmann K, Burandt E, Schmalfeldt B, Joosse S, Woelber L
GYNECOL ONCOL. 2020;158(3):547-554.

Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
Riecke K, Witzel I
BREAST CARE. 2020;15(6):579-585.

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial
Rüger A, Schneeweiss A, Seiler S, Tesch H, van Mackelenbergh M, Marmé F, Lübbe K, Sinn B, Karn T, Stickeler E, Müller V, Schem C, Denkert C, Fasching P, Nekljudova V, Garfias-Macedo T, Hasenfuß G, Haverkamp W, Loibl S, von Haehling S
J AM HEART ASSOC. 2020;9(23):e018143.

Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J
NEW ENGL J MED. 2020;382(9):810-821.

Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer
Schneeweiss A, Bauerfeind I, Fehm T, Janni W, Thomssen C, Witzel I, Wöckel A, Müller V
BREAST CARE. 2020;15(6):608-618.

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Schneeweiss A, Ettl J, Lüftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Kurbacher C, Klein E, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker S
BREAST. 2020;54:88-95.

Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies
Schneeweiss A, Hartkopf A, Müller V, Wöckel A, Lux M, Janni W, Ettl J, Belleville E, Huober J, Thill M, Fasching P, Kolberg H, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm T, Lüftner D, Schütz F
GEBURTSH FRAUENHEILK. 2020;80(3):277-287.

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Schochter F, Werner K, Köstler C, Faul A, Tzschaschel M, Alberter B, Müller V, Neubauer H, Fehm T, Friedl T, Polzer B, Janni W, Rack B, Wiesmüller L
CANCERS. 2020;12(4):.

Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kröger N, Mueller V, Petersen C, Krüll A, Schulz H, Bleich C
JMIR RES PROTOC. 2020;9(7):e17854.

Optimizing expectations about endocrine treatment for breast cancer: Results of the randomized controlled psy-breast trial
Shedden-Mora M, Pan Y, Heisig S, von Blanckenburg P, Rief W, Witzel I, Albert U, Nestoriuc Y
Clinical Psychology in Europe. 2020;2(1):.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Swain S, Miles D, Kim S, Im Y, Im S, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes M, Cortés J
LANCET ONCOL. 2020;21(4):519-530.

Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer
Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching P, Kolberg H, Schulmeyer C, Welslau M, Overkamp F, Fehm T, Lux M, Schneeweiss A, Lüftner D, Janni W
GEBURTSH FRAUENHEILK. 2020;80(11):1115-1122.

Gradient power reducing using pulsed selection-field sequences
Thieben F, Boberg M, Szwargulski P, Graeser M, Knopp T
Int J Magn Part Imag. 2020;6(2):.

International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts
Thomssen C, Lüftner D, Untch M, Haidinger R, Würstlein R, Harbeck N, Augustin D, Briest S, Ettl J, Fasching P, Förster F, Kurbacher C, Lück H, Marschner N, Müller L, Müller V, Perlova-Griff L, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K
BREAST CARE. 2020;15(1):82-95.

ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results
Untch M, Würstlein R, Lüftner D, Haidinger R, Fasching P, Augustin D, Briest S, Ettl J, Förster F, Kurbacher C, Lück H, Marschner N, Müller L, Müller V, Radke I, Ruckhäberle E, Scheffen I, Schumacher-Wulf E, Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K, Thomssen C, Harbeck N
GEBURTSH FRAUENHEILK. 2020;80(6):588-600.

The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1
Well L, Jaeger A, Kehrer-Sawatzki H, Farschtschi S, Avanesov M, Sauer M, de Sousa M, Bannas P, Derlin T, Adam G, Mautner V, Salamon J
PLOS ONE. 2020;15(4):e0232031.

Immunoglobulin G Subclass-Specific Glycosylation Changes in Primary Epithelial Ovarian Cancer
Wieczorek M, Braicu E, Oliveira-Ferrer L, Sehouli J, Blanchard V
FRONT IMMUNOL. 2020;11:654.

Hereditäres Mamma- und Ovarialkarzinom. Prophylaktische Operation: Für wen und wann?
Witzel I
Gynäkologische Praxis. 2020;2020(46, Heft 3):.

Male Breast Cancer Patients: Lack of Evidence
Witzel I
BREAST CARE. 2020;15(1):3-4.

Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019
Witzel I, Lambertini M, Balic M, Wuerstlein R, Müller V
BREAST CARE. 2020;15(2):192-196.

Brain Metastasis in Breast Cancer Patients-Need for Improvement
Witzel I, Oliveira-Ferrer L, Müller V
CANCERS. 2020;12(11):.

Therapieoptionen beim hormonrezeptorpositiven, HER-2-negativen metastasierten Mammakarzinom
Wöckel A, Bauerfeind I, Fehm T, Janni W, Muller V, Thill M, Thomssen C, Untch M, Witzel I, Andreas S
GYNAKOLOGE. 2020;53(11):780-783.

Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Woelber L, Bommert M, Prieske K, Fischer I, Zu Eulenburg C, Vettorazzi E, Harter P, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Beckmann M, Mustea A, Meier W, Wimberger P, Hanker L, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Mahner S, Schmalfeldt B, Jaeger A
GEBURTSH FRAUENHEILK. 2020;80(12):1221-1228.

New treatment standards for vulvar cancer 2020
Woelber L, Jaeger A, Prieske K
CURR OPIN OBSTET GYN. 2020;32(1):9-14.

Vulvar pruritus-Causes, Diagnosis and Therapeutic Approach
Woelber L, Prieske K, Mendling W, Schmalfeldt B, Tietz H, Jaeger A
DTSCH ARZTEBL INT. 2020;116(8):126-133.

In Reply
Wölber L
DTSCH ARZTEBL INT. 2020;117(37):613.

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

HUM MUTAT. 2019;40(9):1557-1578.

Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study

GYNECOL ONCOL. 2019;154(3):571-576.

Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential
Arkadius P, Tzschaschel M, Schochter F, Friedl T, Rack B, Hartkopf A, Fasching P, Schneeweiss A, Volkmar M, Jens H, Wolfgang J, Tanja F
CURR OPIN OBSTET GYN. 2019;31(1):76-81.

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, Marmé F, Nekljudova V, Schem C, Stickeler E, Willumsen N, Karsdal M, Untch M, Müller V
CANCERS. 2019;11(8):.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Banys-Paluchowski M, Witzel I, Aktas B, Fasching P, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer E, Fehm T, Müller V
SCI REP-UK. 2019;9(1):2318.

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)
Bischoff J, Barinoff J, Mundhenke C, Bauerschlag D, Costa S, Herr D, Lübbe K, Marmé F, Maass N, von Minckwitz G, Grischke E, Müller V, Schmidt M, Gerber B, Kümmel S, Schumacher C, Krabisch P, Seiler S, Thill M, Nekljudova V, Loibl S
ANTI-CANCER DRUG. 2019;30(4):394-401.

Influence of oral vitamin and mineral supplementation on male infertility: a meta-analysis and systematic review
Buhling K, Schumacher A, Eulenburg C, Laakmann E
REPROD BIOMED ONLINE. 2019;39(2):269-279.

Impact of Micronutrient Status during Pregnancy on Early Nutrition Programming
Cetin I, Bühling K, Demir C, Kortam A, Prescott S, Yamashiro Y, Yarmolinskaya M, Koletzko B
ANN NUTR METAB. 2019;74(4):269-278.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
Denkert C, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Mehta K, Blohmer J, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Viale G
BREAST CANCER RES TR. 2019;176(3):557-568.

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
Fasching P, Hartkopf A, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran F, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm T, Schneeweiss A, Untch M, Pott D, Lux M, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann M, Brucker S, Kolberg H
BREAST CANCER RES TR. 2019;173(2):319-328.

How do women and health care professionals view hormonal long-acting reversible contraception?: Results from an international survey
Faustmann T, Crocker J, Moeller C, Engler Y, Caetano C, Buhling K
EUR J CONTRACEP REPR. 2019;24(6):422-429.

Superficially invasive stage IA vulvar squamous cell carcinoma-therapy and prognosis
Grimm D, Prieske K, Mathey S, Kuerti S, Burandt E, Schmalfeldt B, Woelber L
INT J GYNECOL CANCER. 2019;29(3):466-473.

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
Guan J, Darb-Esfahani S, Richter R, Taube E, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu E
J CANCER RES CLIN. 2019;145(4):1063-1073.

Adaptation and qualitative evaluation of encounter decision aids in breast cancer care
Hahlweg P, Witzel I, Muller V, Elwyn G, Durand M, Scholl I
ARCH GYNECOL OBSTET. 2019;299(4):1141-1149.

Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation: impact of N-glycosylation on tumour cell aggregation
Hamester F, Legler K, Wichert B, Kelle N, Eylmann K, Rossberg M, Ding Y, Kürti S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L
BRIT J CANCER. 2019;121(11):944-953.

Culturally competent healthcare - A scoping review of strategies implemented in healthcare organizations and a model of culturally competent healthcare provision
Handtke O, Schilgen B, Mösko M
PLOS ONE. 2019;14(7):e0219971.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim J, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum I, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A
NEW ENGL J MED. 2019;380(9):822-832.

Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
Hartkopf A, Müller V, Wöckel A, Lux M, Janni W, Ettl J, Belleville E, Schütz F, Fasching P, Kolberg H, Welslau M, Overkamp F, Taran F, Brucker S, Wallwiener M, Tesch H, Fehm T, Schneeweiss A, Lüftner D
GEBURTSH FRAUENHEILK. 2019;79(12):1309-1319.

Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
Hartkopf A, Müller V, Wöckel A, Lux M, Janni W, Nabieva N, Taran F, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching P, Fehm T, Kolberg H, Overkamp F, Schneeweiss A, Tesch H
GEBURTSH FRAUENHEILK. 2019;79(3):256-267.

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon T, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler R, Harter P
J MED GENET. 2019;56(9):574-580.

Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
Janni W, Schneeweiss A, Müller V, Wöckel A, Lux M, Hartkopf A, Nabieva N, Taran F, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching P, Fehm T, Kolberg H, Ettl J
GEBURTSH FRAUENHEILK. 2019;79(3):268-280.

A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer
Kind S, Jaretzke A, Büscheck F, Möller K, Dum D, Höflmayer D, Hinsch A, Weidemann S, Fraune C, Möller-Koop C, Hube-Magg C, Simon R, Wilczak W, Lebok P, Witzel I, Müller V, Schmalfeldt B, Paluchowski P, Wilke C, Heilenkötter U, von Leffern I, Krech T, Krech R, von der Assen A, Bawahab A, Burandt E
MOL CARCINOGEN. 2019;58(12):2306-2315.

Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study
Klapdor R, Wölber L, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N, Hillemanns P, Fürst S, Mahner S
GYNECOL ONCOL. 2019;154(3):565-570.

Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
Kolberg H, Schneeweiss A, Fehm T, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M, Janni W, Hartkopf A, Taran F, Wallwiener M, Overkamp F, Tesch H, Ettl J, Lüftner D, Müller V, Schütz F, Fasching P, Brucker S
GEBURTSH FRAUENHEILK. 2019;79(5):470-482.

Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells
Kurze A, Buhs S, Eggert D, Oliveira-Ferrer L, Müller V, Niendorf A, Wagener C, Nollau P
CELL COMMUN SIGNAL. 2019;17(1):107.

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
Laakmann E, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Zahm D, Blohmer J, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Loibl S
BREAST CANCER RES. 2019;21(1):60.

Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer
Lebok P, von Hassel A, Meiners J, Hube-Magg C, Simon R, Höflmayer D, Hinsch A, Dum D, Fraune C, Göbel C, Möller K, Sauter G, Jacobsen F, Büscheck F, Prien K, Krech T, Krech R, von der Assen A, Wölber L, Witzel I, Schmalfeldt B, Geist S, Paluchoswski P, Wilke C, Heilenkötter U, Terracciano L, Müller V, Wilczak W, Burandt E
AGING-US. 2019;11(18):7796-7804.

A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns
Loessner D, Rockstroh A, Shokoohmand A, Holzapfel B, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements J, Hutmacher D
BIOMATERIALS. 2019;190-191:63-75.

Sexual activity and quality of life in patients after treatment for breast and ovarian cancer
Mayer S, Iborra S, Grimm D, Steinsiek L, Mahner S, Bossart M, Woelber L, Voss P, Gitsch G, Hasenburg A
ARCH GYNECOL OBSTET. 2019;299(1):191-201.

Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study
Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne C, Solbach C, Ingold Heppner B, Steiger K, Müller V, Fasching P, Karn T, van Mackelenbergh M, Marmé F, Schmitt W, Schem C, Stickeler E, Loibl S, Denkert C
EUR J CANCER. 2019;114:76-88.

Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
Pan Y, Meister R, Löwe B, Winkelmann A, Kaptchuk T, Bühling K, Nestoriuc Y
TRIALS. 2019;20(1):508.

Characterizing death acceptance among patients with cancer
Philipp R, Mehnert A, Lo C, Muller V, Reck M, Vehling S
PSYCHO-ONCOLOGY. 2019;28(4):854-862.

Skeletal-versus soft-tissue-based cephalometric analyses: is the correlation reproducible?
Ploder O, Köhnke R, Winsauer H, Götz C, Bissinger O, Haller B, Kolk A
ACTA ODONTOL SCAND. 2019;77(2):135-141.

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study
Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, Hasenburg A, Sehouli J, Fürst S, Strauß H, Baumann K, Thiel F, Mustea A, Harter P, Wimberger P, Kölbl H, Reinthaller A, Woelber L, Mahner S
GYNECOL ONCOL. 2019;153(2):286-291.

Clonality of circulating tumor cells in breast cancer brain metastasis patients
Riebensahm C, Joosse S, Mohme M, Hanssen A, Matschke J, Goy Y, Witzel I, Lamszus K, Kropidlowski J, Petersen C, Kolb-Kokocinski A, Sauer S, Borgmann K, Glatzel M, Müller V, Westphal M, Riethdorf S, Pantel K, Wikman H
BREAST CANCER RES. 2019;21(1):101.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?
Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker L, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum I, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J
ARCH GYNECOL OBSTET. 2019;299(1):1-5.

Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)
Schnürch H, Ackermann S, Alt-Radtke C, Angleitner L, Barinoff J, Beckmann M, Böing C, Dannecker C, Fehm T, Gaase R, Gass P, Gebhardt M, Gieseking F, Günthert A, Hack C, Hantschmann P, Horn L, Koch M, Letsch A, Mallmann P, Mangold B, Marnitz S, Mehlhorn G, Paradies K, Reinhardt M, Tholen R, Torsten U, Weikel W, Wölber L, Hampl M
GEBURTSH FRAUENHEILK. 2019;79(10):1060-1078.

Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
Schütz F, Fasching P, Welslau M, Hartkopf A, Wöckel A, Lux M, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg H, Overkamp F, Taran F, Brucker S, Wallwiener M, Tesch H, Fehm T, Schneeweiss A, Müller V
GEBURTSH FRAUENHEILK. 2019;79(10):1079-1089.

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Stamm H, Oliveira-Ferrer L, Grossjohann E, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W, Wellbrock J
ONCOIMMUNOLOGY. 2019;8(12):e1674605.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
Thill M, Jackisch C, Janni W, Müller V, Albert U, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching P, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux M, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N
BREAST CARE. 2019;14(4):247-255.

Diagnosis and Therapy Before Assisted Reproductive Treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 1, Basic Assessment of the Woman
Toth B, Baston-Büst D, Behre H, Bielfeld A, Bohlmann M, Bühling K, Dittrich R, Goeckenjan M, Hancke K, Kliesch S, Köhn F, Krüssel J, Kuon R, Liebenthron J, Nawroth F, Nordhoff V, Pinggera G, Rogenhofer N, Rudnik-Schöneborn S, Schuppe H, Schüring A, Seifert-Klauss V, Strowitzki T, Tüttelmann F, Vomstein K, Wildt L, Wischmann T, Wunder D, Zschocke J
GEBURTSH FRAUENHEILK. 2019;79(12):1278-1292.

Diagnosis and Treatment Before Assisted Reproductive Treatments. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Register Number 015-085, February 2019) - Part 2, Hemostaseology, Andrology, Genetics and History of Malignant Disease
Toth B, Baston-Büst D, Behre H, Bielfeld A, Bohlmann M, Bühling K, Dittrich R, Goeckenjan M, Hancke K, Kliesch S, Köhn F, Krüssel J, Kuon R, Liebenthron J, Nawroth F, Nordhoff V, Pinggera G, Rogenhofer N, Rudnik-Schöneborn S, Schuppe H, Schüring A, Seifert-Klauss V, Strowitzki T, Tüttelmann F, Vomstein K, Wildt L, Wischmann T, Wunder D, Zschocke J
GEBURTSH FRAUENHEILK. 2019;79(12):1293-1308.

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch J, Friedl T, Fasching P, Haeberle L, Fehm T, Schneeweiss A, Beckmann M, Pantel K, Mueller V, Rack B, Scholz C
JNCI-J NATL CANCER I. 2019;111(4):380-387.

Impact of taste and smell training on taste disorders during chemotherapy – TASTE trial
von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J
CANCER MANAG RES. 2019;11:4493—4504.

Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
Welslau M, Hartkopf A, Müller V, Wöckel A, Lux M, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching P, Kolberg H, Nabieva N, Overkamp F, Taran F, Brucker S, Wallwiener M, Tesch H, Schneeweiss A, Fehm T
GEBURTSH FRAUENHEILK. 2019;79(10):1090-1099.

Hormonersatztherapie und vaskuläres Risiko: Kommentar zur Version 2.0 der AWMF-S3-Leitlinie „Peri- und Postmenopause – Diagnostik und Interventionen“ 2019
Windler E, Baum E, Bühling K, Taute B, Stute P, Ortmann O
GYNAKOL ENDOKRINOL. 2019;2020(18):10-13.

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Witzel I, Loibl S, Wirtz R, Fasching P, Denkert C, Weber K, Lück H, Huober J, Karn T, Mackelenbergh M, Marmé F, Schem C, Stickeler E, Untch M, Müller V
BRIT J CANCER. 2019;121(12):1009-1015.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching P, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer E, Witzel I, Müller V
BMC CANCER. 2018;18(1):541.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Banys-Paluchowski M, Fehm T, Witzel I, Aktas B, Fasching P, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer E, Müller V
GEBURTSH FRAUENHEILK. 2018;78(11):1151.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer
Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching P, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer E, Fehm T, Müller V
BREAST CANCER RES TR. 2018;172(1):93-104.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-Analysis: A Meta-analysis
Bidard F, Michiels S, Riethdorf S, Mueller V, Esserman L, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz J, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua M, Hall C, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran F, Cappelletti M, Ignatiadis M, Proudhon C, Wolf D, Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker S, Weber K, Reyal F, Amara D, Karhade M, Mathiesen R, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Pantel K
JNCI-J NATL CANCER I. 2018;110(6):560-567.

Versorgung mit Mikronährstoffen bei Kinderwunsch, in der Schwangerschaft und in der Stillzeit
Bühling K
Gynakol Geburtsmed Gynakol Endokrinol . 2018;14(1):36-58.

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Fasching P, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa S, Blohmer J, Fehm T, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Muller V, Nekljudova V, Weber K, Rack B, Rubner M, von Minckwitz G, Couch F
J CLIN ONCOL. 2018;36(22):2281-2287.

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians
Gass P, Untch M, Müller V, Möbus V, Thomssen C, Häberle L, Erber R, Hein A, Jud S, Lux M, Hack C, Hartmann A, Kolberg H, Ettl J, Lüftner D, Jackisch C, Beckmann M, Janni W, Schneeweiss A, Fasching P, Nabieva N
GEBURTSH FRAUENHEILK. 2018;78(7):707-714.

Comparison of PapilloCheck and Linear Array to Detect and Differentiate Human Papillomaviruses in Cervical and Tonsillar Smears from Females with Cervical Intraepithelial Lesions
Grimm D, Woelber L, Prieske K, Schmalfeldt B, Kürti S, Busch C, Teudt I, Brummer O, Mueller V, Meyer T
EUR J MICROBIOL IMMU. 2018;8(4):107-111.

ABC4 Consensus: Assessment by a German Group of Experts
Harbeck N, Lüftner D, Marschner N, Untch M, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Wuerstlein R, Thomssen C
BREAST CARE. 2018;13(1):48-58.

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Hartkopf A, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Schneeweiss A
BREAST. 2018;37:42-51.

Fulminante thromboembolische Komplikationen bei benignem Ovarialtumor
Hillen C, Weinrich J, Dieckmann J, Schmalfeldt B
Frauenarzt. 2018;59(2):110-112.

Soziale Ungleichheit bei der Inanspruchnahme onkologischer Versorgungsangebote
Hofreuter-Gätgens K, Klein J, Fisch M, Graefen M, Schlotfeldt T, Witzel I, von dem Knesebeck O
GESUNDHEITSWESEN. 2018;80(2):94-100.

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
Kümmel S, Jackisch C, Müller V, Schneeweiss A, Klawitter S, Lux M
CANCER MANAG RES. 2018;10:5423-5431.

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer
Legler K, Rosprim R, Karius T, Eylmann K, Rossberg M, Wirtz R, Müller V, Witzel I, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L
BRIT J CANCER. 2018;118(6):847-856.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018
Liedtke C, Jackisch C, Thill M, Thomssen C, Müller V, Janni W
BREAST CARE. 2018;13(3):196-208.

Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner B, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C
CLIN CANCER RES. 2018;24(14):3358-3365.

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Lux M, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Brucker S
CANCERS. 2018;11(1):10.

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
Möbus V, Jackisch C, Lück H, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum I, Hinke A, Konecny G, Untch M, Kurbacher C
ANN ONCOL. 2018;29(1):178-185.

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Müller V, Clemens M, Jassem J, Al-Sakaff N, Auclair P, Nüesch E, Holloway D, Shing M, Bang Y
BMC CANCER. 2018;18(1):295.

Zerebrale Metastasierung beim Mammakarzinom
Muller V, Laakmann E, Grottke A, Riecke K, Witzel I
Senologie. 2018;15(04):213-218.

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
Müller V, Nabieva N, Häberle L, Taran F, Hartkopf A, Volz B, Overkamp F, Brandl A, Kolberg H, Hadji P, Tesch H, Ettl J, Lux M, Lüftner D, Belleville E, Fasching P, Janni W, Beckmann M, Wimberger P, Hielscher C, Fehm T, Brucker S, Wallwiener D, Schneeweiss A, Wallwiener M
BREAST. 2018;37:154-160.

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H
SCI REP-UK. 2018;8:12974.

Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients
Oliveira-Ferrer L, Goswami R, Galatenko V, Ding Y, Eylmann K, Legler K, Kürti S, Schmalfeldt B, Milde-Langosch K
DIS MARKERS. 2018;2018:6714287.

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
Pan C, Stevic I, Müller V, Ni Q, Ferrer L, Pantel K, Schwarzenbach H
MOL ONCOL. 2018;12(11):1935-1948.

The Predictive Significance of Metastasis-Associated in Colon Cancer-1 (MACC1) in Primary Breast Cancer
Prguda-Mujic J, Milde-Langosch K, Mueller V, Suljagic M, Coric J, Ler D
ANN CLIN LAB SCI. 2018;48(2):191-196.

Participation of elderly gynecological cancer patients in clinical trials
Prieske K, Trillsch F, Oskay-Özcelik G, Chekerov R, Bleich C, Oliveira-Ferrer L, Grimm D, Kuerti S, Mueller V, Suling A, Schmalfeldt B, Sehouli J, Mahner S, Woelber L
ARCH GYNECOL OBSTET. 2018;298(4):797-804.

Herausforderungen in der Therapie der Patientin mit Vulvakarzinom
Prieske K, Wölber L
2018.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer
Schiewek J, Schumacher U, Lange T, Joosse S, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S
J CANCER RES CLIN. 2018;144(11):2195-2205.

Die gesundheitliche Situation von Pflegekräften mit Migrationshintergrund: ein systematisches Review
Schilgen B, Nienhaus A, Handtke O, Schulz H, Mösko M
2018. RiRe - Risiken und Ressourcen in Gesundheitsdienst und Wohlfahrtspflege. Nienhaus A (Hrsg.). 1. Aufl. Landsberg am Lech: ecomed Medizin, 341-378.

Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention
Schneeweiss A, Lux M, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Wallwiener D, Brucker S, Schütz F, Fasching P, Fehm T
GEBURTSH FRAUENHEILK. 2018;78(3):246-259.

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann M, Fasching P, Janni W, Friedl T
ONCOL RES TREAT. 2018;41(3):93-98.

Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial
Scholl I, Hahlweg P, Lindig A, Bokemeyer C, Coym A, Hanken H, Müller V, Smeets R, Witzel I, Kriston L, Härter M
IMPLEMENT SCI. 2018;13(1):51.

Tumormetastasierung: Molekularbiologische Forschung Wenn Krebs in Zukunft erfolgreich behandelt werden soll, dann müssen wir die Prozesse der Metastasierung genau verstehen, um daraus neue therapeutische Ansätze zu entwickeln
Schumacher U, Stürken C, Schmalfeldt B
Hamb Ärztebl. 2018;72(11):12-15.

Zielgerichtete Therapie des Mammakarzinoms
Seiffert K, Schmalfeldt B, Müller V
Senologie. 2018;15(03):160-165.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Stevic I, Müller V, Weber K, Fasching P, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H
BMC MED. 2018;16(1):179.

Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers
Taran F, Schneeweiss A, Lux M, Janni W, Hartkopf A, Nabieva N, Overkamp F, Kolberg H, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Wallwiener D, Brucker S, Fasching P, Fehm T, Schütz F
GEBURTSH FRAUENHEILK. 2018;78(3):237-245.

No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas
Trillsch F, Eichhorn P, Oliveira-Ferrer L, Kuempfel T, Burges A, Mahner S, Havla J
J NEUROL. 2018;265(2):431-432.

4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017: ABC4 Consensus: Assessment by a Panel of German Experts
Untch M, Würstlein R, Marschner N, Lüftner D, Augustin D, Briest S, Ettl J, Haidinger R, Müller L, Müller V, Ruckhäberle E, Harbeck N, Thomssen C
GEBURTSH FRAUENHEILK. 2018;78(5):469-480.

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
van Mackelenbergh M, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching P, Blohmer J, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber K, Loibl S
BREAST CANCER RES TR. 2018;167(1):59-71.

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
Villegas S, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner B, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S
BREAST CANCER RES TR. 2018;168(1):179-187.

Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial
Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S, Marmé F, Weber-Lassalle N, Prieske K, Dietrich D, Borde J, Pohl-Rescigno E, Reuss A, Ataseven B, Engel C, Stingl J, Schmutzler R, Hahnen E
HUM MUTAT. 2018;39(12):2040-2046.

Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer
Wichert B, Milde-Langosch K, Galatenko V, Schmalfeldt B, Oliveira-Ferrer L
GLYCOBIOLOGY. 2018;28(11):898-903.

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry
Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon T, Schmidt M, Fasching P, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S, Müller V
EUR J CANCER. 2018;102:1-9.

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P, Jírů-Hillmann S, Albert U, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe H, Knoefel W, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn H, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Lux M, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S
GEBURTSH FRAUENHEILK. 2018;78(11):1056-1088.

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P, Albert U, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Kreipe H, Knoefel W, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn H, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Lux M, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Krockenberger M
GEBURTSH FRAUENHEILK. 2018;78(10):927-948.

Correlation of Isotope Count With Sentinel Node Positivity in Vulvar Cancer
Wölber L, Joosse S, Grimm D, Mathey S, Mahner S, Burandt E, Klutmann S, Schmalfeldt B, Prieske K
INT J GYNECOL CANCER. 2018;28(7):1403-1409.

ABC4-Konsensus: Bewertung durch eine deutsche Expertengruppe: 4. Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom (ABC4), Lissabon, 04. 11. 2017
Würstlein R, Harbeck N, Thomssen C, Lüftner D, Augustin D, Briest S, Ettl J, Haidinger R, Müller H, Muller V, Ruckhäberle E, Marschner N, Untch M
Frauenarzt. 2018;59(7):528-535.

Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients
Avril S, Dincer Y, Malinowsky K, Wolff C, Gündisch S, Hapfelmeier A, Boxberg M, Bronger H, Becker K, Schmalfeldt B
ONCOTARGET. 2017;8(58):97851-97861.

Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells
Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin R, Smirnov D, Li W, Geffken M, Pantel K, Joosse S
ONCOTARGET. 2017;8(34):56066-56080.

The Value of Antiangiogenics in Breast Cancer Therapy
Banys-Paluchowski M, Fehm T, Muller V
2017. Tumor Angiogenesis. Marmé D (Hrsg.). 1. Aufl. Springer, 1-13.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients
Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V
ANTICANCER RES. 2017;37(6):3117-3128.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V
SCI REP-UK. 2017;7(1):Art. 17307.

Sarcopenia in Advanced Serous Ovarian Cancer
Bronger H, Hederich P, Hapfelmeier A, Metz S, Noël P, Kiechle M, Schmalfeldt B
INT J GYNECOL CANCER. 2017;27(2):223-232.

Mental disorders in patients with chronic pelvic pain syndrome (CPPS)
Brünahl C, Dybowski C, Albrecht R, Riegel B, Höink J, Fisch M, Löwe B
J PSYCHOSOM RES. 2017;98:19-26.

The role of transvaginal ultrasonography for detecting ovarian cancer in an asymptomatic screening population: a systematic review
Buhling K, Lezon S, Eulenburg C, Schmalfeldt B
ARCH GYNECOL OBSTET. 2017;295(5):1259-1268.

Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial
Chekerov R, Harter P, Fuxius S, Hanker L, Woelber L, Müller L, Klare P, Abenhardt W, Nedkova Y, Yalcinkaya I, Heinrich G, Sommer H, Mahner S, Wimberger P, Koensgen-Mustea D, Richter R, Oskay-Oezcelik G, Sehouli J
Gynecologic oncology research and practice. 2017;4:6.

Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
de Gregorio A, Friedl T, Huober J, Scholz C, de Gregorio N, Rack B, Trapp E, Alunni-Fabbroni M, Riethdorf S, Muller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Jaeger B, Hartkopf A, Taran F, Fasching P, Janni W, Fehm T
JCO PRECIS ONCOL. 2017;2017(1):1-12.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung K, Azim H, Al-Sakaff N, Lauer S, Shing M, Pivot X
EUR J CANCER. 2017;82:237-246.

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
Gligorov J, Curigliano G, Müller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X
BREAST. 2017;34:89-95.

Antibody persistence and evidence of immune memory at 5 years following administration of the 9-valent HPV vaccine
Guevara A, Cabello R, Woelber L, Moreira E, Joura E, Reich O, Shields C, Ellison M, Joshi A, Luxembourg A
VACCINE. 2017;35(37):5050-5057.

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler R
JAMA ONCOL. 2017;3(10):1378-1385.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon T, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker S, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R
PLOS ONE. 2017;12(10):e0186043.

Strong fascin expression promotes metastasis independent of its F-actin bundling activity
Heinz L, Muhs S, Schiewek J, Grüb S, Nalaskowski M, Lin Y, Wikman H, Oliveira-Ferrer L, Lange T, Wellbrock J, Konietzny A, Mikhaylova M, Windhorst S
ONCOTARGET. 2017;8(66):110077-110091.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression
Hohensee I, Chuang H, Grottke A, Werner S, Schulte A, Horn S, Lamszus K, Bartkowiak K, Witzel I, Westphal M, Matschke J, Glatzel M, Jücker M, Pukrop T, Pantel K, Wikman H
ONCOTARGET. 2017;8(4):6155-6168.

Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience
Jendrian S, Steffens K, Schmalfeldt B, Laakmann E, Bergelt C, Witzel I
BREAST CANCER RES TR. 2017;163(3):517-526.

Selectin-independent adhesion during ovarian cancer metastasis
Khaustova N, Maltseva D, Oliveira-Ferrer L, Stürken C, Milde-Langosch K, Makarova J, Rodin S, Schumacher U, Tonevitsky A
BIOCHIMIE. 2017;142:197-206.

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study
Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst S, Strauß H, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S
ANN SURG ONCOL. 2017;24(5):1314-1321.

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
Kuerti S, Oliveira-Ferrer L, Milde-Langosch K, Schmalfeldt B, Legler K, Woelber L, Prieske K, Mahner S, Trillsch F
ONCOTARGET. 2017;8(26):43218-43227.

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review
Laakmann E, Müller V, Schmidt M, Witzel I
BREAST CARE. 2017;12(3):168-171.

Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer
Laakmann E, Witzel I, Müller V
BREAST CARE. 2017;12(3):165-167.

PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells
Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K
J PATHOL CLIN RES. 2017;3(2):123-138.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017
Liedtke C, Thill M, Jackisch C, Thomssen C, Müller V, Janni W
BREAST CARE. 2017;12(3):172-183.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
Ludwig H, Weisel K, Petrucci M, Leleu X, Cafro A, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M
LEUKEMIA. 2017;31(4):997-1000.

Update Breast Cancer 2017 - Implementation of Novel Therapies
Lux M, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Ettl J, Huober J, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Fasching P
GEBURTSH FRAUENHEILK. 2017;77(12):1281-1290.

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report
Minlikeeva A, Freudenheim J, Cannioto R, Eng K, Szender J, Mayor P, Etter J, Cramer D, Diergaarde B, Doherty J, Dörk T, Edwards R, deFazio A, Friel G, Goodman M, Hillemanns P, Høgdall E, Jensen A, Jordan S, Karlan B, Kjær S, Klapdor R, Matsuo K, Mizuno M, Nagle C, Odunsi K, Paddock L, Rossing M, Schildkraut J, Schmalfeldt B, Segal B, Starbuck K, Terry K, Webb P, Zsiros E, Ness R, Modugno F, Bandera E, Chang-Claude J, Moysich K
BRIT J CANCER. 2017;117(7):1063-1069.

German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients
Möbus V, von Minckwitz G, Jackisch C, Lück H, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C
ANN ONCOL. 2017;28(8):1803-1810.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases
Mohme M, Riethdorf S, Dreimann M, Werner S, Maire C, Joosse S, Bludau F, Mueller V, Neves R, Stoecklein N, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker S
SCI REP-UK. 2017;7(1):7196.

San Antonio 2016: Progress on the Long Way to Individualized Treatment of Breast Cancer
Müller V, Gluz O, Pierga J, Thill M, Rack B, Witzel I
BREAST CARE. 2017;12(1):54-58.

Role of protein glycosylation in cancer metastasis
Oliveira-Ferrer L, Legler K, Milde-Langosch K
SEMIN CANCER BIOL. 2017;44:141-152.

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer
Oonk M, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F, Mahner S, Mahantshetty U, Mirza M, Petersen C, Querleu D, Regauer S, Rob L, Rouzier R, Ulrikh E, van der Velden J, Vergote I, Woelber L, van der Zee A
INT J GYNECOL CANCER. 2017;27(4):832-837.

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
Pivot X, Verma S, Fallowfield L, Müller V, Lichinitser M, Jenkins V, Sánchez Muñoz A, Machackova Z, Osborne S, Gligorov J
EUR J CANCER. 2017;86:82-90.

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
Polasik A, Tzschaschel M, Schochter F, de Gregorio A, Friedl T, Rack B, Hartkopf A, Fasching P, Schneeweiss A, Müller V, Huober J, Janni W, Fehm T
GEBURTSH FRAUENHEILK. 2017;77(12):1291-1298.

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
Prieske K, Prieske S, Joosse S, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L
ONCOTARGET. 2017;8(47):83063-83074.

Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial
Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Schem C, von Minckwitz G, Untch M, Pantel K
CLIN CANCER RES. 2017;23(18):5384-5393.

News from ASCO 2017
Schmidt M, Fehm T, Liedtke C, Müller V
BREAST CARE. 2017;12(4):266-268.

Zielgerichtete Therapie des Mammakarzinoms
Seiffert K, Schmalfeldt B, Müller V
DEUT MED WOCHENSCHR. 2017;142(22):1669-1675.

No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival
Sucheston-Campbell L, Cannioto R, Clay A, Etter J, Eng K, Liu S, Battaglia S, Hu Q, Szender J, Minlikeeva A, Joseph J, Mayor P, Abrams S, Segal B, Wallace P, Soh K, Zsiros E, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Bjørge L, Bruegl A, Campbell I, Campbell S, Chenevix-Trench G, Cramer D, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty J, du Bois A, Eccles D, Engelholm S, Fasching P, Gayther S, Gentry-Maharaj A, Glasspool R, Goodman M, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Hogdall C, Høgdall E, Huzarski T, Jensen A, Johnatty S, Jung A, Karlan B, Klapdor R, Kluz T, Konopka B, Krüger Kjær S, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine D, Lundvall L, McGuire V, McNeish I, Menon U, Modugno F, Ness R, Orsulic S, Paul J, Pearce C, Pejovic T, Pharoah P, Ramus S, Rothstein J, Rossing M, Rübner M, Schildkraut J, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry K, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh C, Webb P, Wentzensen N, Whittemore A, Wu A, Ziogas A, Odunsi K, Chang-Claude J, Goode E, Moysich K
CANCER EPIDEM BIOMAR. 2017;26(3):420-424.

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017
Thill M, Liedtke C, Solomayer E, Müller V, Janni W, Schmidt M
BREAST CARE. 2017;12(3):184-191.

Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Trapp E, Steidl J, Rack B, Kupka M, Andergassen U, Jückstock J, Kurt A, Vilsmaier T, de Gregorio A, de Gregorio N, Tzschaschel M, Lato C, Polasik A, Tesch H, Schneeweiss A, Beckmann M, Fasching P, Janni W, Müller V
BREAST. 2017;35:130-135.

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker S, Dall P, Denkert C, Fasching P, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C
GEBURTSH FRAUENHEILK. 2017;77(6):633-644.

Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry
Wallwiener M, Heindl F, Brucker S, Taran F, Hartkopf A, Overkamp F, Kolberg H, Hadji P, Tesch H, Ettl J, Lux M, Rauh C, Blum S, Nabieva N, Brodkorb T, Faschingbauer C, Langemann H, Schulmeyer C, Volz B, Rübner M, Lüftner D, Müller V, Belleville E, Janni W, Fehm T, Wallwiener D, Ganslandt T, Beckmann M, Schneeweiss A, Fasching P, Gass P
GEBURTSH FRAUENHEILK. 2017;77(8):870-878.

Role of HYAL1 expression in primary breast cancer in the formation of brain metastases
Witzel I, Marx A, Müller V, Wikman H, Matschke J, Schumacher U, Stürken C, Prehm P, Laakmann E, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L
BREAST CANCER RES TR. 2017;162(3):427-438.

HER2-positive Mammakarzinome
Witzel I, Muller V
2017. Colloqium Senologie 2017/2018. Untch M, Harbeck N, Thomssen C (Hrsg.). 1. Aufl. Lukon Verlagsgesellschaft mbH München, 213-236.

Oral Human Papillomavirus in Women With High-Grade Cervical Intraepithelial Neoplasia
Woelber L, Breuer J, Meyer T, Vettorazzi E, Prieske K, Bohlmann I, Busch C, Teudt I, Brummer O, Mueller V, Schmalfeldt B, Grimm D
J LOW GENIT TRACT DI. 2017;21(3):177-183.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S
NAT COMMUN. 2017;8(1):269.

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M
BMC CANCER. 2016;16:522.

Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas
Bednarz-Knoll N, Efstathiou A, Gotzhein F, Wikman H, Mueller V, Kang Y, Pantel K
CLIN CHEM. 2016;62(2):378-386.

A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age
Borgatta L, Bühling K, Rybowski S, Roth K, Rosen K
EUR J CONTRACEP REPR. 2016;21(5):372-9.

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M, Avril S
BRIT J CANCER. 2016;115(5):553-63.

Cyclin D1 gene amplification is highly homogeneous in breast cancer
Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Wilczak W
BREAST CANCER-TOKYO. 2016;23(1):111-9.

Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium
Cannioto R, LaMonte M, Kelemen L, Risch H, Eng K, Minlikeeva A, Hong C, Szender J, Sucheston-Campbell L, Joseph J, Berchuck A, Chang-Claude J, Cramer D, DeFazio A, Diergaarde B, Dörk T, Doherty J, Edwards R, Fridley B, Friel G, Goode E, Goodman M, Hillemanns P, Hogdall E, Hosono S, Kelley J, Kjaer S, Klapdor R, Matsuo K, Odunsi K, Nagle C, Olsen C, Paddock L, Pearce C, Pike M, Rossing M, Schmalfeldt B, Segal B, Szamreta E, Thompson P, Tseng C, Vierkant R, Schildkraut J, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Ness R, Jensen A, Webb P, Terry K, Bandera E, Moysich K
BRIT J CANCER. 2016;115(1):95-101.

Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
Cannioto R, LaMonte M, Risch H, Hong C, Sucheston-Campbell L, Eng K, Brian Szender J, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva A, Zirpoli G, Bandera E, Berchuck A, Cramer D, Doherty J, Edwards R, Fridley B, Goode E, Goodman M, Hogdall E, Hosono S, Jensen A, Jordan S, Kjaer S, Matsuo K, Ness R, Olsen C, Olson S, Leigh Pearce C, Pike M, Anne Rossing M, Szamreta E, Thompson P, Tseng C, Vierkant R, Webb P, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Schildkraut J, Terry K, Kelemen L, Moysich K
CANCER EPIDEM BIOMAR. 2016;25(7):1114-24.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48]
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;146:135.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer
Claussen C, Rausch A, Lezius S, Amirkhosravi A, Davila M, Francis J, Hisada Y, Mackman N, Bokemeyer C, Schmalfeldt B, Mahner S, Langer F
THROMB RES. 2016;141:39-48.

Corrigendum to "Borderline tumours of the ovary A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914]
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss H, Hellriegel M, Wimberger P, Keyver-Paik M, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S
EUR J CANCER. 2016;65:192-193.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon T, Mahner S, Schröder W, Lück H, Heubner M, Hanker L, Thiel F, Hilpert F
GYNECOL ONCOL. 2016;140(3):450-6.

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer
Gasch C, Oldopp T, Mauermann O, Gorges T, Andreas A, Coith C, Müller V, Fehm T, Janni W, Pantel K, Riethdorf S
MOL ONCOL. 2016;10(8):1330-43.

A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents
Gemzell-Danielsson K, Buhling K, Dermout S, Lukkari-Lax E, Montegriffo E, Apter D
CONTRACEPTION. 2016;93(6):507-12.

In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines
Ghadban T, Jessen A, Reeh M, Dibbern J, Mahner S, Mueller V, Wellner U, Güngör C, Izbicki J, Vashist Y
INT J MOL MED. 2016;38(4):1296-302.

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells
Gorges T, Kuske A, Röck K, Mauermann O, Müller V, Peine S, Verpoort K, Novosadova V, Kubista M, Riethdorf S, Pantel K
CLIN CHEM. 2016;62(11):1504-1515.

Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients
Hein A, Gass P, Walter C, Taran F, Hartkopf A, Overkamp F, Kolberg H, Hadji P, Tesch H, Ettl J, Wuerstlein R, Lounsbury D, Lux M, Lüftner D, Wallwiener M, Müller V, Belleville E, Janni W, Fehm T, Wallwiener D, Ganslandt T, Ruebner M, Beckmann M, Schneeweiss A, Fasching P, Brucker S
BREAST CANCER RES TR. 2016;158(1):59-65.

What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy
Heisig S, Shedden-Mora M, von Blanckenburg P, Rief W, Witzel I, Albert U, Nestoriuc Y
PSYCHO-ONCOLOGY. 2016;25(12):1485-1492.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

Einfluss der Familienanamnese auf das Brustkrebsrisiko postmenopausaler Brustkrebspatientinnen – Ergebnisse aus der MARIE-Studie
Krauß K, zu Eulenburg C, Thoene K, Rudolph A, Chang-Claude J, Witzel I
Senologie. 2016 [Epub ahead of print];13(02):.

Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain
Laakmann E, Riecke K, Goy Y, Kersten J, Krüll A, Müller V, Petersen C, Witzel I
J CANCER RES CLIN. 2016;142(1):325-32.

Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry
Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, Hesse T, Würschmidt F, Fehm T, Möbus V, von Minckwitz G, Loibl S, Park-Simon T, Mueller V
INT J MOL SCI. 2016;17(10):E1615.

Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer
Lebok P, Huber J, Burandt E, Lebeau A, Marx A, Terracciano L, Heilenkötter U, Jänicke F, Müller V, Paluchowski P, Geist S, Wilke C, Simon R, Sauter G, Quaas A
MOL MED REP. 2016;14(2):1443-50.

High levels of class III β-tubulin expression are associated with aggressive tumor features in breast cancer
Lebok P, Öztürk E, Heilenkötter U, Jaenicke F, Müller V, Paluchowski P, Geist S, Wilke C, Burandt E, Lebeau A, Wilczak W, Krech T, Simon R, Sauter G, Quaas A
ONCOL LETT. 2016;11(3):1987-1994.

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer
Lebok P, Roming M, Kluth M, Koop C, Ozden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Burandt E
ONCOTARGET. 2016;7(49):81322-81331.

Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer
Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H
ADV EXP MED BIOL. 2016;924:3-8.

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H
ONCOTARGET. 2016;7(13):16923-35.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study
Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong D, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu E
TUMOR BIOL. 2016;37(3):3009-16.

Patterns of distant metastases in vulvar cancer
Prieske K, Haeringer N, Grimm D, Trillsch F, Eulenburg C, Burandt E, Schmalfeldt B, Mahner S, Mueller V, Woelber L
GYNECOL ONCOL. 2016;142(3):427-34.

Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015
Schnürch H, Ackermann S, Alt C, Barinoff J, Böing C, Dannecker C, Gieseking F, Günthert A, Hantschmann P, Horn L, Kürzl R, Mallmann P, Marnitz S, Mehlhorn G, Hack C, Koch M, Torsten U, Weikel W, Wölber L, Hampl M
GEBURTSH FRAUENHEILK. 2016;76(10):1035-1049.

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Schramm A, Friedl T, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni-Fabbroni M, Müller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Hartkopf A, Taran F, Wallwiener D, Janni W, Fehm T
ARCH GYNECOL OBSTET. 2016;293(2):271-81.

RHAMM splice variants confer radiosensitivity in human breast cancer cell lines
Schütze A, Vogeley C, Gorges T, Twarock S, Butschan J, Babayan A, Klein D, Knauer S, Metzen E, Müller V, Jendrossek V, Pantel K, Milde-Langosch K, Fischer J, Röck K
ONCOTARGET. 2016;7(16):21428-40.

Dimensionality, Stability, and Validity of the Beck Hopelessness Scale in Cancer Patients Receiving Curative and Palliative Treatment
Spangenberg L, Zenger M, Garcia-Torres F, Mueller V, Reck M, Mehnert A, Vehling S
J PAIN SYMPTOM MANAG. 2016;51(3):615-22.

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
Trillsch F, Kuerti S, zu Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S
BRIT J CANCER. 2016;114(2):213-220.

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study
Werwitzke S, Geisen U, Nowak-Göttl U, Eichler H, Stephan B, Scholz U, Holstein K, Klamroth R, Knöbl P, Huth-Kühne A, Bomke B, Tiede A
J THROMB HAEMOST. 2016;14(5):940-7.

The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
Witzel I, Müller V
BREAST CARE. 2016;11(3):165-6.

Breast cancer brain metastases:biology and new clinical perspectives
Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H
BREAST CANCER RES. 2016;18(1):8.

The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node
Woelber L, Eulenburg C, Grimm D, Trillsch F, Bohlmann I, Burandt E, Dieckmann J, Klutmann S, Schmalfeldt B, Mahner S, Prieske K
ANN SURG ONCOL. 2016;23(8):2508-14.

Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study
Woelber L, Griebel L, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S
EUR J CANCER. 2016;69:180-188.

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates R, Cowens W, Hornberger J, Pelz E, Harbeck N
CURR MED RES OPIN. 2016;32(7):1217-24.

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
zu Eulenburg C, Suling A, Neuser P, Reuss A, Canzler U, Fehm T, Luyten A, Hellriegel M, Woelber L, Mahner S
PLOS ONE. 2016;11(11):e0165705.

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Bachmann H, Meier W, du Bois A, Kimmig R, Kuhlmann J, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P
BRIT J CLIN PHARMACO. 2015;80(5):1139-48.

Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response
Bartkowiak K, Kwiatkowski M, Buck F, Gorges T, Nilse L, Assmann V, Andreas A, Müller V, Wikman H, Riethdorf S, Schlüter H, Pantel K
CANCER RES. 2015;75(24):5367-77.

The effect of estrogen synthesis inhibition on hippocampal memory
Bayer J, Rune G, Schultz H, Tobia M, Mebes I, Katzler O, Sommer-Blöchl T
PSYCHONEUROENDOCRINO. 2015;56:213-225.

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression
Bednarz-Knoll N, Nastały P, Żaczek A, Stoupiec M, Riethdorf S, Wikman-Kocher H, Müller V, Skokowski J, Szade J, Sejda A, Wełnicka-Jaśkiewicz M, Pantel K
ONCOTARGET. 2015;6(29):26789-803.

A Versatile Microarray Platform for Capturing Rare Cells
Brinkmann F, Hirtz M, Haller A, Gorges T, Vellekoop M, Riethdorf S, Müller V, Pantel K, Fuchs H
SCI REP-UK. 2015;5:Art. 15342.

Der Schwangerschaftsratgeber
Bühling K
2015. Der Schwangerschaftsratgeber. Hamburg: akademos Wissenschaftsverlag GmbH, 1-74.

Mikronährstoffe in der Therapie männlicher Infertilität
Bühling K, Laakmann E
Gynakol Geburtsmed Gynakol Endokrinol . 2015;11(1):4-19.

Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study
Farthmann J, Hasenburg A, Weil M, Fotopoulou C, Ewald-Riegler N, du Bois O, Trillsch F, Mahner S, Strauss H, Wimberger P, Reuss A, du Bois A
SUPPORT CARE CANCER. 2015;23(1):117-23.

Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
Fasching P, Brucker S, Fehm T, Overkamp F, Janni W, Wallwiener M, Hadji P, Belleville E, Häberle L, Taran F, Lüftner D, Lux M, Ettl J, Müller V, Tesch H, Wallwiener D, Schneeweiss A
GEBURTSH FRAUENHEILK. 2015;75(1):41-50.

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study
Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A
INT J GYNECOL CANCER. 2015;25(7):1248-52.

Podoplanin increases migration and angiogenesis in malignant glioma
Grau S, Trillsch F, Tonn J, Goldbrunner R, Noessner E, Nelson P, von Luettichau I
AM J CLIN PATHOL. 2015;8(7):8663-70.

Sexual Activity and Function in Patients With Gynecological Malignancies After Completed Treatment
Grimm D, Hasenburg A, zu Eulenburg C, Steinsiek L, Mayer S, Eltrop S, Prieske K, Trillsch F, Mahner S, Woelber L
INT J GYNECOL CANCER. 2015;25(6):1134-41.

Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions
Grimm D, zu Eulenburg C, Brummer O, Schliedermann A, Trillsch F, Prieske K, Gieseking F, Selka E, Mahner S, Woelber L
SUPPORT CARE CANCER. 2015;24(1):419-428.

Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer
Győrffy B, Karn T, Sztupinszki Z, Weltz B, Müller V, Pusztai L
INT J CANCER. 2015;136(9):2091-8.

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
Heil J, Kümmel S, Schaefgen B, Paepke S, Thomssen C, Rauch G, Ataseven B, Große R, Dreesmann V, Kühn T, Loibl S, Blohmer J, von Minckwitz G
BRIT J CANCER. 2015;113(11):1565-1570.

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Kunz G, Beckmann M, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Fasching P
INT J CANCER. 2015;137(12):2981-8.

Tumour exosome integrins determine organotropic metastasis
Hoshino A, Costa-Silva B, Shen T, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies A, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss J, Dumont-Cole V, Kramer K, Wexler L, Narendran A, Schwartz G, Healey J, Sandstrom P, Jørgen Labori K, Kure E, Grandgenett P, Hollingsworth M, de Sousa M, Kaur S, Jain M, Mallya K, Batra S, Jarnagin W, Brady M, Fodstad O, Muller V, Pantel K, Minn A, Bissell M, Garcia B, Kang Y, Rajasekhar V, Ghajar C, Matei I, Peinado H, Bromberg J, Lyden D
NATURE. 2015;527(7578):329-35.

Fetal gender specific expression of tandem-repeat galectins in placental tissue from normally progressed human pregnancies and intrauterine growth restriction (IUGR)
Hutter S, Knabl J, Andergassen U, Mayr D, Hofmann S, Kuhn C, Mahner S, Arck P, Jeschke U
PLACENTA. 2015;36(12):1352-61.

Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers
Jackisch C, Müller V, Dall P, Neumeister R, Park-Simon T, Ruf-Dördelmann A, Seiler S, Tesch H, Ataseven B
GEBURTSH FRAUENHEILK. 2015;75(6):566-573.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura E, Giuliano A, Iversen O, Bouchard C, Mao C, Mehlsen J, Moreira E, Ngan Y, Petersen L, Lazcano-Ponce E, Pitisuttithum P, Restrepo J, Stuart G, Woelber L, Yang Y, Cuzick J, Garland S, Huh W, Kjaer S, Bautista O, Chan I, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A
NEW ENGL J MED. 2015;372(8):711-23.

Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers
Khan S, Karn T, Symmans W, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C
BREAST CANCER RES TR. 2015;149(3):789-97.

Partial PTEN deletion is linked to poor prognosis in breast cancer
Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, Taskin B, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E
BMC CANCER. 2015;15(1):963.

8p deletion is strongly linked to poor prognosis in breast cancer
Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E
CANCER BIOL THER. 2015;16(7):1080-7.

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
Lindner J, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner B, Gerber B, Gade S, Darb-Esfahani S, Sinn B, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G
ANN ONCOL. 2015;26(1):95-100.

Utility and Reproducibility of the International Federation for Cervical Pathology and Colposcopy Classification of Transformation Zones in Daily Practice: A Multicenter Study of the German Colposcopy Network
Luyten A, Buttmann-Schweiger N, Hagemann I, Scherbring S, Boehmer G, Gieseking F, Woelber L, Glasenapp F, Hampl M, Kuehler-Obbarius C, van den Bergh M, Petry K
J LOW GENIT TRACT DI. 2015;19(3):185-8.

Utility of EFC quality indicators for colposcopy in daily practice: results from an independent, prospective multicenter trial
Luyten A, Hagemann I, Scherbring S, Boehmer G, Gieseking F, Woelber L, Glasenapp F, Hampl M, Kuehler-Obbarius C, van den Bergh M, Leeson S, Redman C, Petry K
EUR J OBSTET GYN R B. 2015;191:43-7.

Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study
Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Thiel F, Mustea A, Meier W, du Bois A, Griebel L, Woelber L
JNCI-J NATL CANCER I. 2015;107(3):.

Systemic treatment of vulvar cancer
Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Müller V, Jänicke F, Woelber L
EXPERT REV ANTICANC. 2015;15(6):629-37.

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
Mahner S, Woelber L, Müller V, Witzel I, Prieske K, Grimm D, von Amsberg G, Trillsch F
FRONT ONCOL. 2015;5:211.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
Meng X, Joosse S, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H
BRIT J CANCER. 2015;113(9):1358-1366.

Relevance of βGal-βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients
Milde-Langosch K, Schütze D, Oliveira-Ferrer L, Wikman-Kocher H, Müller V, Lebok P, Pantel K, Schröder C, Witzel I, Schumacher U
BREAST CANCER RES TR. 2015;151(3):515-28.

Systemische Therapie: Her2-positive Mammakarzinome
Muller V
2015. Colloqium Senologie 2015/2016. Untch M, Harbeck N, Thomssen C, Costa S (Hrsg.). 1. Aufl. München: Agilium Verlag und Gesundheitsakademie GmbH, .

Zirkulierende Tumorzellen im Blut. Optionen zur Therapieoptimierung beim Mammakarzinom
Müller V, Rack B, Trapp E, Schramm A, Meier-Stiegen F, Janni W, Fehm T
Gynäkologische Praxis. 2015;39:605-14.

Disseminierte und zirkulierende Tumorzellen, zirkulierende DNA und RNA im Blut - Biomarker beim Mammakarzinom?
Muller V, Riethdorf S, Pantel K
2015. Tumorbiologie und Diagnostik des primären Mammakarzinoms. Vetter M, Kantelhardt E (Hrsg.). 1. Aufl. Bremen: Uni-Med, 84-91.

Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer
Oliveira-Ferrer L, Heßling A, Trillsch F, Mahner S, Milde-Langosch K
TUMOR BIOL. 2015;36(11):9023-30.

Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties
Oliveira-Ferrer L, Kürschner M, Labitzky V, Wicklein D, Müller V, Lüers G, Schumacher U, Milde-Langosch K, Schröder C
J CANCER RES CLIN. 2015;141(10):1715-26.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Oza A, Cibula D, Benzaquen A, Poole C, Mathijssen R, Sonke G, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe E, Dougherty B, Barrett J, Friedlander M
LANCET ONCOL. 2015;16(1):87-97.

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study
Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik M, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss H, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A
BRIT J CANCER. 2015;112(4):660-6.

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer
Ueo H, Sugimachi K, Gorges T, Bartkowiak K, Yokobori T, Müller V, Shinden Y, Ueda M, Ueo H, Mori M, Kuwano H, Maehara Y, Ohno S, Pantel K, Mimori K
BRIT J CANCER. 2015;112(9):1519-26.

Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function.
von Bülow C, Oliveira Ferrer L, Löning T, Trillsch F, Mahner S, Milde-Langosch K
MOL CLIN ONCOL. 2015;3(5):1067-1072.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid induced 2
Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood A, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen S, Klefstrom J, Wilmanns M, Müller V, Pantel K, Wikman-Kocher H
CANCER DISCOV. 2015;5(5):506-19.

Targeted Therapies in Breast Cancer: New Approaches and Old Challenges
Witzel I, Müller V
BREAST CARE. 2015;10(3):157-8.

A Systematic Model Specification Procedure for an Illness-Death Model without Recovery
zu Eulenburg C, Mahner S, Woelber L, Wegscheider K
PLOS ONE. 2015;10(4):Art. e0123489.

Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?
Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B
BREAST CARE. 2014;9(1):16-21.

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong D, Zeillinger R, Pils D
MOL CANCER. 2014;13:67.

A first-in-human study of PDC31 (prostaglandin F2α receptor inhibitor) in primary dysmenorrhea
Böttcher B, Laterza R, Wildt L, Seufert R, Buhling K, Singer C, Hill W, Griffin P, Jilma B, Schulz M, Smith R
HUM REPROD. 2014;29(11):2465-2473.

Psychosomatische Aspekte des chronischen Unterbauchschmerzsyndroms: Psychometrische Ergebnisse der Pilotphase einer interdisziplinären Sprechstunde
Brünahl C, Riegel B, Höink J, Kutup A, Eichelberg E, Löwe B
SCHMERZ. 2014;28(3):311-318.

Bedeutung von Mikronährstoffen bei Kinderwunsch, in Schwangerschaft und Stillzeit
Bühling K
Hebamme. 2014;27(1):12-22.

Sexuelle Probleme während und nach der Schwangerschaft
Bühling K
GYNAKOLOGE. 2014;47:86-88.

The use of complementary and alternative medicine by women transitioning through menopause in Germany: results of a survey of women aged 45-60 years
Buhling K, Daniels B, von Studnitz F, zu Eulenburg C, Mueck A
COMPLEMENT THER MED. 2014;22(1):94-98.

Understanding the barriers and myths limiting the use of intrauterine contraception in nulliparous women: results of a survey of European/Canadian healthcare providers
Buhling K, Hauck B, Dermout S, Ardaens K, Marions L
EUR J OBSTET GYN R B. 2014;183:146-154.

Contraceptive counselling and self-prescription of contraceptives of German gynaecologists: results of a nationwide survey
Buhling K, Klovekorn L, Daniels B, Studnitz F, zu Eulenburg C, Mueck A
EUR J CONTRACEP REPR. 2014;19(6):448-456.

The effect of micronutrient supplements on male fertility
Buhling K, Laakmann E
CURR OPIN OBSTET GYN. 2014;26(3):199-209.

Worldwide use of intrauterine contraception
Buhling K, Zite N, Lotke P, Black K
CONTRACEPTION. 2014;89(3):162-173.

Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients
Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P
ONCOL REP. 2014;32(6):2628-34.

Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice
Burandt E, Schreiber M, Stein A, Minner S, Clauditz T, Bokemeyer C, Jänicke F, Fisch M, Izbicki J, Knecht R, Sauter G, Stahl P
GENE CHROMOSOME CANC. 2014;53(3):228-39.

Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri
Choschzick M, Woelber L, Gieseking F, Oosterwijk E, Tennstedt P
HISTOPATHOLOGY. 2014;64(4):600-2.

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor
Doberstein K, Milde-Langosch K, Bretz N, Schirmer U, Harari A, Witzel I, Ben-Arie A, Hubalek M, Müller-Holzner E, Reinold S, Zeimet A, Altevogt P, Fogel M
BMC CANCER. 2014;14:958.

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman-Kocher H, Pantel K, Schwarzenbach H
ONCOTARGET. 2014;5(20):9650-63.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice
Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M
CELL SIGNAL. 2014;26(5):1021-9.

Clinical management of epithelial ovarian cancer during pregnancy
Grimm D, Woelber L, Trillsch F, Keller-v. Amsberg G, Mahner S
EUR J CANCER. 2014;50(5):963-971.

Prävention von Nozebo-Effekten in der endokrinen Therapie
Heisig S, Shedden Mora M, von Blanckenburg P, Schuricht F, Witzel I, Rief W, Albert U, Nestoriuc Y
Frauenarzt. 2014;55(10):1002-1007.

Subcutaneous Administration of Monoclonal Antibodies in Oncology
Jackisch C, Müller V, Maintz C, Hell S, Ataseven B
GEBURTSH FRAUENHEILK. 2014;74(4):343-349.

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
Joosse S, Müller V, Steinbach B, Pantel K, Schwarzenbach H
BRIT J CANCER. 2014;111(5):909-17.

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer
Karn T, Rody A, Müller V, Schmidt M, Becker S, Holtrich U, Pusztai L
Genomics Data. 2014;2(12/2014):354-356.

Quality of life as a primary endpoint in ovarian cancer trials
Mahner S, Burges A
LANCET ONCOL. 2014;15(4):363-364.

Surgery or topical therapy for vulval intraepithelial neoplasia
Mahner S, Wölber L
LANCET ONCOL. 2014;15(12):1287-1288.

Prognostic relevance of glycosylation-associated genes in breast cancer
Milde-Langosch K, Karn T, Schmidt M, Zu Eulenburg C, Oliveira Ferrer L, Wirtz R, Schumacher U, Witzel I, Schütze D, Müller V
BREAST CANCER RES TR. 2014;145(2):295-305.

Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study
Müller V, Fuxius S, Steffens C, Lerchenmüller C, Luhn B, Vehling-Kaiser U, Hurst U, Hahn L, Soeling U, Wohlfarth T, Zaiss M
ONCOL RES TREAT. 2014;37(12):748-755.

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching P, Mau C, Pantel K, Schwarzenbach H
BREAST CANCER RES TR. 2014;147(1):61-8.

Augenärztliche Kontrolle vor Tamoxifengabe
Müller V, Keserü M
Gynäkologische Praxis. 2014;38(1):50.

c-FOS suppresses ovarian cancer progression by changing adhesion
Oliveira Ferrer L, Rößler K, Haustein V, Schröder C, Wicklein D, Maltseva D, Khaustova N, Samatov T, Tonevitsky A, Mahner S, Jänicke F, Schumacher U, Milde-Langosch K
BRIT J CANCER. 2014;110(3):753-63.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L
ANN ONCOL. 2014;25(10):1979-1987.

Knochen als Rückzugsort für "dormant cells"
Rack B, Müller V, Fehm T, Pestka A, Kasemir-Baur S, Friese K, Janni W
GYNAKOLOGE. 2014.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu E
EUR J CANCER. 2014;50(12):2090-2098.

OPG and PgR show similar cohort-specific effects as prognostic factors in ER positive breast cancer
Sänger N, Ruckhäberle E, Bianchini G, Heinrich T, Milde-Langosch K, Müller V, Rody A, Solomayer E, Fehm T, Holtrich U, Becker S, Karn T
MOL ONCOL. 2014;8(7):1196-207.

Sources of meaning in cancer patients - influences on global meaning, anxiety and depression in a longitudinal study
Scheffold K, Mehnert A, Müller V, Koch-Gromus U, Härter M, Vehling S
EUR J CANCER CARE. 2014;23(4):472-480.

Aktuelles zur Therapie des Ovarialkarzinoms
Schmalfeldt B
2014. Tumorzentrum München Jahrbuch 2014. . München: Agileum Verlag und Gesundheitsakademie GmbH, .

Manual Maligne Ovarialtumoren.: Empfehlungen zu Diagnostik, Therapie und Nachsorge.
Schmalfeldt B
2014.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study
Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss H, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik M, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A
ANN ONCOL. 2014;25(7):1320-1327.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J, Hauschild M, Fehm T, Nekljudova V, Gerber B
ANN ONCOL. 2014;25(12):2363-2372.

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients
Wikman-Kocher H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, Huhtala H, Terracciano L, Kallioniemi A, Sauter G, Müller V, Witzel I, Lamszus K, Kemming D, Pantel K
ONCOTARGET. 2014;5(10):3076-3087.

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V
ONCOTARGETS THER. 2014;7:2205-2213.

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry
Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, Jänicke F
BMC CANCER. 2014;14:806.

Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients
Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse S
PLOS ONE. 2013;8(9):e75038.

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium
Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu E, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong D
BMC CANCER. 2013;13:422.

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
Bidard F, Fehm T, Ignatiadis M, Smerage J, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes D, Piccart M, Pierga J
CANCER METAST REV. 2013;32(1-2):179-188.

Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study
Braicu E, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong D, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J
GYNECOL ONCOL. 2013;128(2):245-51.

Attitude of German women towards hormone therapy: results of a lay survey.
Bühling K, Daniels B, von Studnitz F, zu Eulenburg C, Mueck A
GYNECOL ENDOCRINOL. 2013;29(5):460-464.

The effect of micronutrient supplements on female fertility.
Bühling K, Grajecki D
CURR OPIN OBSTET GYN. 2013;25(3):173-180.

Anti-mullerian hormone: usefulness in clinical practice
Buhling K, Stute P, Ziller V
EUR J ENDOCRINOL. 2013;2013:791386.

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.
Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A
BREAST CANCER RES TR. 2013;137(3):745-753.

Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
Chekerov R, Braicu I, Castillo-Tong D, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J
INT J GYNECOL CANCER. 2013;23(2):268-75.

HER2 amplification in squamous cell carcinomas of the vulva
Choschzick M, Hess S, Grob T, Burandt E, Wölber L, Simon R, Sauter G
HISTOPATHOLOGY. 2013;62(6):965-7.

Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era
Creutzberg C, Kitchener H, Birrer M, Landoni F, Lu K, Powell M, Aghajanian C, Edmondson R, Goodfellow P, Quinn M, Salvesen H, Thomas G
INT J GYNECOL CANCER. 2013;23(8):1528-34.

Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells.
Dippel V, Milde-Langosch K, Wicklein D, Schumacher U, Altevogt P, Oliveira-Ferrer L, Jänicke F, Schröder C
J CANCER RES CLIN. 2013;139(1):107-121.

Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab
Dohrmann T, Kutup A, Mahner S, Müller V, Jänicke F, Izbicki J, Vashist Y
J CLIN ONCOL. 2013;31(12):e208-10.

Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss H, Hellriegel M, Wimberger P, Keyver-Paik M, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S
EUR J CANCER. 2013;49(8):1905-14.

The prognostic significance of Jun transcription factors in ovarian cancer
Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Jänicke F, Milde-Langosch K
J CANCER RES CLIN. 2013;139(10):1673-80.

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Eiermann W, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, Witzel I, Eidtmann H, Bachinger A, Hell S, Blohmer J
ANN ONCOL. 2013;24(3):618-624.

Zirkulierende Tumorzellen in der Diagnose und Therapie des Mammakarzinoms
Fehm T, Hartkopf A, Janni W, Solomayer E, Rack B, Müller V
BREAST CARE. 2013;8:375-377.

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy S, Maggioni A, Trope C, Sehouli J
ANN SURG ONCOL. 2013;20(4):1348-1354.

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Harbeck N, Beckmann M, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G, Untch M, Jackisch C
BREAST CARE. 2013;8(1):49-55.

AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013
Harbeck N, Scharl A, Thomssen C, Müller V
BREAST CARE. 2013;8(3):181-5.

Surgical intervention in relapsed ovarian cancer is beneficial: pro
Harter P, Heitz F, Mahner S, Hilpert F, du Bois A
ANN ONCOL. 2013;24 Suppl 10:x33-34.

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer
Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, Sehouli J, du Bois A, Wagner U
GEBURTSH FRAUENHEILK. 2013;73(3):221-223.

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer
Henningsen M, zu Eulenburg C, Kolarova T, Qi J, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu V, Venkatesan N, Rong H, Dandekar S, Udar N, Jänicke F, Los G, Slamon D, Konecny G
MOL CANCER THER. 2013;12(6):1002-15.

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong D, Zeillinger R, Zeimet A, Vergote I
GYNECOL ONCOL. 2013;131(1):15-20.

Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases
Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Müller V, Pantel K, Wikman H
AM J PATHOL. 2013;183(1):83-95.

Towards individualised treatment in ovarian cancer
Mahner S, Pfisterer J
LANCET ONCOL. 2013;14(2):101-2.

Adjuvant therapy in node-positive vulvar cancer
Mahner S, Trillsch F, Kock L, Rohsbach D, Petersen C, Krüll A, Harter P, Jänicke F, Woelber L
EXPERT REV ANTICANC. 2013;13(7):839-44.

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
Mahner S, zu Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A
EUR J CANCER. 2013;49(1):142-149.

Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer
Mathey S, Graeser M, Zu Eulenburg C, Woelber L, Trillsch F, Jänicke F, Müller V, Milde-Langosch K, Mahner S
ONCOLOGY-BASEL. 2013;85(2):69-77.

Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium
Melmer A, Fineder L, Lamina C, Kollerits B, Dieplinger B, Braicu I, Sehouli J, Cadron I, Vergote I, Mahner S, Zeimet A, Castillo-Tong D, Ebenbichler C, Zeillinger R, Dieplinger H
GYNECOL ONCOL. 2013;128(1):38-43.

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz R
BREAST CANCER RES TR. 2013;137(1):57-67.

Variation in cell signaling protein expression may introduce sampling bias in primary epithelial ovarian cancer
Mittermeyer G, Malinowsky K, Beese C, Höfler H, Schmalfeldt B, Becker K, Avril S
PLOS ONE. 2013;8(10):e77825.

HER2-positive Mammakarzinome
Müller V
2013. Colloqium Senologie 2013. Untch M, Harbeck N, Thomssen C, Costa S (Hrsg.). 1. Aufl. München: Agilium Verlag und Gesundheitsakademie GmbH, 115-132.

Impressions from the san antonio breast cancer symposium december 2012
Müller V, Fehm T, Kümmel S, Liedtke C, Rack B, Steger G
BREAST CARE. 2013;8(1):77-83.

Neoadjuvante Therapie des Mammakarzinoms
Müller V, Harbeck N
2013. Aktuelle Empfehlungen zur Prävention, Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome. Scharl A (Hrsg.). 6. Aufl. München: W. Zuckschwerdt Verlag, 151-165.

Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium
Obermayr E, Castillo-Tong D, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R
GYNECOL ONCOL. 2013;128(1):15-21.

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway
Oliveira Ferrer L, Wellbrock J, Bartsch U, Penas E, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G
MOL CANCER. 2013;12(1):144.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Pestalozzi B, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez R, Müller V, Dodwell D, Gelber R, Piccart-Gebhart M, Cameron D
LANCET ONCOL. 2013;14(3):244-8.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium
Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R
BMC CANCER. 2013;13:178.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L
LANCET ONCOL. 2013;14(10):962-70.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann K, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway R, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken J, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi C, Berek J, Pfisterer J
J CLIN ONCOL. 2013;31(12):1554-61.

AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013
Scharl A, Thomssen C, Harbeck N, Müller V
BREAST CARE. 2013;8(3):174-80.

Aktuelles zur Diagnostik und Primärtherapie des Ovarialkarzinoms
Schmalfeldt B
2013. Tumorzentrum München Jahrbuch 2013. Schwendt J, Nüssler V (Hrsg.). München: Agileum Verlag und Gesundheitsakademie GmbH, .

Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients
Schröder C, Milde-Langosch K, Gebauer F, Schmid K, Müller V, Wirtz R, Meyer-Schwesinger C, Schluter H, Sauter G, Schumacher U
J CANCER RES CLIN. 2013;139:1745-1755.

Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer
Schütze D, Milde-Langosch K, Witzel I, Rody A, Karn T, Schmidt M, Choschzick M, Jänicke F, Müller V
J CANCER RES CLIN. 2013;139(5):747-54.

Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe
Tjalma W, Fiander A, Reich O, Powell N, Nowakowski A, Kirschner B, Koiss R, O'Leary J, Joura E, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza S, Jenkins D, Holl K, , Wölber L
INT J CANCER. 2013;132(4):854-67.

Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT)
Trillsch F, Ruetzel J, Herwig U, Doerste U, Woelber L, Grimm D, Choschzick M, Jänicke F, Mahner S
J OVARIAN RES. 2013;6(1):48.

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
Trillsch F, Woelber L, zu Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong D, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J
J OVARIAN RES. 2013;6(1):42.

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones K, Bujard H, Olek A, Olek K, Gellhaus K, Braicu I, Könsgen D, Fryer C, Ravot E, Hellwag A, Westerfeld N, Gruss O, Meissner M, Hasan M, Weber M, Hoffmüller U, Zimmermann S, Loddenkemper C, Mahner S, Babel N, Berns E, Adams R, Zeilinger R, Baron U, Vergote I, Maughan T, Marme F, Dickhaus T, Sehouli J, Olek S
EPIGENETICS-US. 2013;8(11):1226-35.

High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells
Volkmann J, Reuning U, Rudelius M, Häfner N, Schuster T, Becker V Ros A, Weimer J, Hilpert F, Kiechle M, Dürst M, Arnold N, Schmalfeldt B, Meindl A, Ramser J
INT J CANCER. 2013;132(12):2820-32.

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Kreienberg R, Müller V, Lück H, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S
J CLIN ONCOL. 2013;31(28):3531-9.

Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
von Minckwitz G, Schmitt W, Loibl S, Müller B, Blohmer J, Sinn B, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching P, Karn T, Müller V, Jackisch C, Denkert C
CLIN CANCER RES. 2013;19(16):4521-31.

The value of complementary and alternative medicine in the treatment of climacteric symptoms: results of a survey among German gynecologists
von Studnitz F, zu Eulenburg C, Mueck A, Buhling K
COMPLEMENT THER MED. 2013;21(5):492-5.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013
Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier B, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C
GEBURTSH FRAUENHEILK. 2013;73(9):874-889.

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M, Hartkopf A, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer E, Müller V, Janni W, Schneeweiss A, Fehm T
BREAST CANCER RES TR. 2013;137(2):503-510.

Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers
Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schütze D, Rausch A, Jänicke F, Milde-Langosch K, Müller V
J CANCER RES CLIN. 2013;139(5):809-16.

Management of patients with vulvar cancer: a perspective review according to tumour stage
Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jänicke F, Mahner S
THER ADV MED ONCOL. 2013;5(3):183-92.

Secondary sentinel node biopsy after previous excision of the primary tumor in squamous cell carcinoma of the vulva.
Wölber L, Grimm D, Vettorazzi E, Wisotzki C, Trillsch F, Jänicke F, Schwarz J, Choschzick M, Mahner S
ANN SURG ONCOL. 2013;20(5):1701-1706.

Progression and Death as Competing Risks in Ovarian Cancer
zu Eulenburg C, Mahner S, Wölber L, Wegscheider K
Int J Stat Med Res. 2013.

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium
Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R, Pils D
MOL CANCER. 2012;11:69.

Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome
Avril S, Hahn E, Specht K, Hauptmann S, Höss C, Kiechle M, Höfler H, Schmalfeldt B
GYNECOL ONCOL. 2012;127(3):516-24.

A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity.
Becker A, Graeser M, Landwehr C, Hilger T, Baus W, Wappenschmidt B, Meindl A, Weber R, Schmutzler R
BREAST CANCER RES TR. 2012;135(1):167-175.

A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women.
Black K, Lotke P, Bühling K, Zite N, Group I
EUR J CONTRACEP REPR. 2012;17(5):340-350.

Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation
Bondong S, Kiefel H, Hielscher T, Zeimet A, Zeillinger R, Pils D, Schuster E, Castillo-Tong D, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P
ANN ONCOL. 2012;23(7):1795-802.

Relationship between sonographically estimated fetal subcutaneous adipose tissue measurements and neonatal skinfold measurements.
Bühling K, Doll I, Siebert G, Catalano P
ULTRASOUND OBST GYN. 2012;39(5):558-562.

Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries.
Bühling K, Eydeler U, Borregaard S, Schlegelmilch R, Suesskind M
ARZNEIMITTEL-FORSCH. 2012;62(8):378-383.

Use of hormone therapy by female gynecologists and female partners of male gynecologists in Germany 8 years after the Women's Health Initiative study: results of a survey.
Bühling K, Studnitz v, Friederike S, Zu Eulenburg C, Eulenburg C, Mueck A
MENOPAUSE. 2012;19(10):1088-1091.

Attitude of German gynecologists towards prescribing HRT before and after the WHI study.
Bühling K, von Studnitz F, Jantke A, Zu Eulenburg C, Mueck A
CLIMACTERIC. 2012;15(4):326-331.

Role of cyclin D1 amplification and expression in vulvar carcinomas.
Choschzick M, Hess S, Tennstedt P, Holst F, Bohlken H, Gieseking F, Mahner S, Wölber L, Simon R, Sauter G
HUM PATHOL. 2012;43(9):1386-1393.

BIRC2 amplification in squamous cell carcinomas of the uterine cervix.
Choschzick M, Tabibzada A, Gieseking F, Wölber L, Jänicke F, Sauter G, Simon R
VIRCHOWS ARCH. 2012;461(2):123-128.

Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma.
Ditsch N, Mayr D, Lenhard M, Strauss C, Vodermaier A, Gallwas J, Stoeckl D, Graeser M, Weissenbacher T, Friese K, Jeschke U
ONCOL LETT. 2012;4(4):665-671.

Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood--a meta-analysis.
Doege K, Grajecki D, Zyriax B, Detinkina E, Zu Eulenburg C, Bühling K
BRIT J NUTR. 2012;107(1):1-6.

Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature.
Doll I, Doll R, Bühling K
ARCH GYNECOL OBSTET. 2012;285(3):689-697.

Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP).
Duesing N, Schwarz J, Choschzick M, Jänicke F, Gieseking F, Issa R, Mahner S, Wölber L
ARCH GYNECOL OBSTET. 2012;286(6):1549-1554.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S
ANN ONCOL. 2012;23(5):1185-9.

The effect of micronutrient supplements on female fertility: a systematic review.
Grajecki D, Zyriax B, Bühling K
ARCH GYNECOL OBSTET. 2012;285(5):1463-1471.

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob T, Heilenkötter U, Geist S, Paluchowski P, Wilke C, Jänicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A
BREAST CANCER RES TR. 2012;134(2):561-567.

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.
Henningsen M, Kress K, Kersten J, Kilic E, Choschzick M, Zander H, Müller V, Mahner S, Jänicke F, Wölber L, Milde-Langosch K
BMC CANCER. 2012;12:140.

Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion.
Jackisch C, Lück H, Untch M, Bischoff J, Müller V, Schmidt M, Thill M, Kiechle M
BREAST CARE. 2012;7(2):137-143.

Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3)
Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss M, Lindhofer H
CANCER RES. 2012;72(1):24-32.

Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.
Joosse S, Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, Pantel K
CLIN CANCER RES. 2012;18(4):993-1003.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes K, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M
EUR J CANCER. 2012;48(1):12-23.

Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review.
Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling K
GYNECOL ENDOCRINOL. 2012;28(9):703-709.

Treatment of breast cancer during pregnancy: an observational study.
Loibl S, Han S, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Kristel V, Linn S, Schlehe B, Gziri M, Westenend P, Müller V, Heyns L, Rack B, Ben V, Harbeck N, Lenhard M, Halaska M, Kaufmann M, Nekljudova V, Amant F
LANCET ONCOL. 2012;13(9):887-896.

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
Mahner S, Oskay-Özcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kölbl H, Markmann S, Sehouli J
J CANCER RES CLIN. 2012;138(8):1413-9.

Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer
Marmé F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong D, Sehouli J, Braicu I, Vergote I, Isabella C, Mahner S, Ferschke I, Rom J, Sohn C, Schneeweiss A, Altevogt P
INT J CANCER. 2012;131(4):E586-91.

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
Meier W, du Bois A, Rau J, Gropp-Meier M, Baumann K, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schröder W, Belau A, Stähle A, Burges A, Sehouli J
GYNECOL ONCOL. 2012;126(2):236-40.

High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers.
Minner S, Lübke A, Kluth M, Bokemeyer C, Jänicke F, Izbicki J, Schlomm T, Sauter G, Wilczak W
HISTOPATHOLOGY. 2012;61(3):445-453.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Group O
BREAST CANCER RES. 2012;14(4):118.

Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium
Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R
CANCER SCI. 2012;103(7):1334-41.

Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, Wölber L, Cadron I, Toon V, Zeillinger R, Castillo-Tong D, Sehouli J
INT J GYNECOL CANCER. 2012;22(3):380-385.

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.
Rhiem K, Engel C, Graeser M, Zachariae S, Kast K, Kiechle M, Ditsch N, Janni W, Mundhenke C, Golatta M, Varga D, Preisler-Adams S, Heinrich T, Bick U, Gadzicki D, Briest S, Meindl A, Schmutzler R
BREAST CANCER RES. 2012;14(6):156.

Aktuelles zum Ovarialkarzinom 2011
Schmalfeldt B, Seck K, Schmalzried H
2012. Tumorzentrum München Jahrbuch 2012. Jauch K, Nüssler V (Hrsg.). München: Agileum Verlag und Gesundheitsakademie GmbH, .

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.
Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart J, Solbach C, Holmberg L, Edlund K, Kultima H, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr H, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler J
CLIN CANCER RES. 2012;18(9):2695-2703.

Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.
Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K
BREAST CANCER RES TR. 2012;134(3):933-941.

Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients
Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov N, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, Diamandis E, Langer R, Sweep F, Schmitt M, Magdolen V
BIOL CHEM. 2012;393(5):391-401.

Effect of platinum-containing chemotherapy on olfactory, gustatory, and hearing function in ovarian cancer patients
Steinbach S, Hundt W, Schmalfeldt B, Böhner C, Berktold S, Wolf P, Harbeck N
ARCH GYNECOL OBSTET. 2012;286(2):473-80.

Lost in effusion
Trillsch F, Aberle J, Regier M, Choschzick M, Mahner S
LANCET. 2012;380(9841):620.

Relevance of PTEN loss in brain metastasis formation in breast cancer patients.
Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Müller V, Westphal M, Pantel K
BREAST CANCER RES. 2012;14(2):49.

Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel I, Milde-Langosch K, Sauter G, Westphal M, Lamszus K, Pantel K
PLOS ONE. 2012;7(10):47537.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
Wimberger P, Gilet H, Gonschior A, Heiss M, Moehler M, Oskay-Oezcelik G, Al-Batran S, Schmalfeldt B, Schmittel A, Schulze E, Parsons S
ANN ONCOL. 2012;23(8):1979-85.

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.
Witzel I, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Fasching P, Mau C, Schem C, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Müller V
BRIT J CANCER. 2012;107(6):956-960.

Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.
Witzel I, Schröder C, Müller V, Zander H, Tachezy M, Henningsen M, Jänicke F, Milde-Langosch K
ONCOLOGY-BASEL. 2012;82(6):305-312.

EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome.
Wölber L, Hess S, Bohlken H, Tennstedt P, Zu Eulenburg C, Simon R, Gieseking F, Jänicke F, Mahner S, Choschzick M
J CLIN PATHOL. 2012;65(2):133-139.

Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment
Wölber L, Zu Eulenburg C, Choschzick M, Krüll A, Petersen C, Gieseking F, Jänicke F, Mahner S
INT J GYNECOL CANCER. 2012;22(3):503-508.

Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg C, Rack B, Schneeweiss A, Fehm T
GYNECOL ONCOL. 2011;122(2):356-360.

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück H, Wagner U
GYNECOL ONCOL. 2011;123(1):27-32.

Das Ovarialkarzinom - Diagnose und Behandlung
Burges A, Schmalfeldt B
DTSCH ARZTEBL INT. 2011;108(38):635-41.

Ovarian cancer: diagnosis and treatment
Burges A, Schmalfeldt B
DTSCH ARZTEBL INT. 2011;108(38):635-41.

Role of TP53 mutations in vulvar carcinomas.
Choschzick M, Hantaredja W, Tennstedt P, Gieseking F, Wölber L, Simon R
INT J GYNECOL PATHOL. 2011;30(5):497-504.

Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Choschzick M, Oosterwijk E, Müller V, Wölber L, Simon R, Moch H, Tennstedt P
VIRCHOWS ARCH. 2011;459(2):193-200.

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer
Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M
ANN ONCOL. 2011;22(4):877-83.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer C, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber K, Feder I, Hennig G, Kronenwett R, Gehrmann M, Gnant M, Investigators E
CLIN CANCER RES. 2011;17(18):6012-6020.

Malignant transformation of a serous borderline tumor and early metastasis of associated low-grade serous carcinoma detected on screening mammography.
Grimm D, Trillsch F, Regier M, Choschzick M, Kommoss F, Hermsteiner M, Töllner T, Mattner U, Jänicke F, Mahner S
J CLIN ONCOL. 2011;29(30):763-765.

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry K, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A
INT J GYNECOL CANCER. 2011;21(2):289-95.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Henningsen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K
BREAST CANCER RES TR. 2011;129(2):347-360.

Surgery for recurrent ovarian cancer
Heitz F, du Bois A, Kurzeder C, Pfisterer J, Barinoff J, Grabowski J, Hilpert F, Mahner S, Harter P
Womens Health (Lond Engl). 2011;7(5):529-35.

Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin
Henningsen M, Kilic E, Koehler N, Löning T, Witzel I, Hagel C, Höller S, Kersten J, Müller V, Jänicke F, Milde-Langosch K
J CLIN PATHOL. 2011;64(2):146-152.

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu E, Mahner S, Speiser P, Marth C, Zeimet A, Ulmer H, Zeillinger R, Concin N
BRIT J CANCER. 2011;105(10):1593-9.

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang C, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A
PLOS ONE. 2011;6(12):28403.

Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A
BREAST CANCER RES TR. 2011;130(2):409-420.

Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Kock L, Mahner S, Choschzick M, Zu Eulenburg C, Milde-Langosch K, Schwarz J, Jänicke F, Müller V, Wölber L
INT J GYNECOL CANCER. 2011;21(1):141-148.

mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer
Kotzsch M, Dorn J, Doetzer K, Schmalfeldt B, Krol J, Baretton G, Kiechle M, Schmitt M, Magdolen V
BIOL CHEM. 2011;392(11):1047-51.

Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
Lee C, Friedlander M, Brown C, Gebski V, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza M, Sauthier P, Pujade-Lauraine E, Lord S, Simes R
JNCI-J NATL CANCER I. 2011;103(17):1338-42.

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Loibl S, Müller V, von Minckwitz G, Conrad B, Koehne C, Kremers S, Forstbauer H, Linder M, Nekljudova V, Moebus V
SUPPORT CARE CANCER. 2011;19(11):1789-1795.

Ovarialkarzinom
Mahner S, Greiner R, Jänicke F
2011. Interdisziplinäre Entscheidungswege in der Onkologie: Diagnose- und Therapiealgorithmen mit Erläuterungen. Deutscher Ärzte-Verlag: 110-113.

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, Fehm T, Group D
BREAST CANCER RES. 2011;13(4):71.

A phase 3 trial of bevacizumab in ovarian cancer
Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G, Carey M, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza M, Leminen A, Plante M, Stark D, Qian W, Parmar M, Oza A
NEW ENGL J MED. 2011;365(26):2484-96.

A clinically relevant gene signature in triple negative and basal-like breast cancer.
Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M
BREAST CANCER RES. 2011;13(5):97.

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.
Roth C, Pantel K, Müller V, Rack B, Kasimir-Bauer S, Janni W, Schwarzenbach H
BMC CANCER. 2011;11:4.

Circulating microRNAs: promising breast cancer biomarkers - author´s response
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H
BREAST CANCER RES. 2011;13(1):403.

Diagnostik und Therapie maligner Ovarialtumoren
Schmalfeldt B
2011. Tumorzentrum München Jahrbuch 2011. Jauch K, Nüssler V (Hrsg.). München: Agileum Verlag und Gesundheitsakademie GmbH, .

Mammakarzinom und Schwangerschaft
Schmalfeldt B, Bauerfeind I, Anthuber C, Niemeyer B, Oberlechner E, Raab A, Wolf C
2011. Manual Mammakarzinom. Empfehlungen zu Diagnostik, Therapie und Nachsorge.. Janni W (Hrsg.). München Wien New York : W. Zuckschwerdt Verlag, .

Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.
Schröder C, Witzel I, Müller V, Krenkel S, Wirtz R, Jänicke F, Schumacher U, Milde-Langosch K
J CANCER RES CLIN. 2011;137(8):1193-1201.

Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Schütze D, Wölber L, Jung S, Zu Eulenburg C, Choschzick M, Witzel I, Schwarz J, Jänicke F, Mahner S
J CANCER RES CLIN. 2011;137(7):1131-1137.

Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.
Schwarzenbach H, Müller V, Milde-Langosch K, Steinbach B, Pantel K
MOL BIOSYST. 2011;7(10):2848-2854.

Health-related quality of life and patient-defined benefit of clobetasol 0.05% in women with chronic lichen sclerosus of the vulva.
Schwegler J, Schwarz J, Zu Eulenburg C, Blome C, Henningsen M, Mahner S, Jänicke F, Augustin M, Wölber L
DERMATOLOGY. 2011;223(2):152-160.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl H, Schroeder W, Lichtenegger W, Oskay-Oezcelik G
J CLIN ONCOL. 2011;29(2):242-248.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M, Fasching P, Konecny G, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, Andreas D, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta K, von Minckwitz G, Loibl S
J CLIN ONCOL. 2011;29(25):3351-3357.

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Untch M, Fasching P, Konecny G, von Koch F, Conrad U, Fett W, Kurzeder C, Lück H, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G, Investigators A
ANN ONCOL. 2011;22(9):1988-1998.

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
Untch M, von Minckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück H, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching P, Investigators A
ANN ONCOL. 2011;22(9):1999-2006.

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Mehta K, Hilfrich J, Jackisch C, Gerber B, Andreas D, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P
BREAST CANCER RES TR. 2011;125(1):145-156.

Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.
Witzel I, Kantelhardt E, Milde-Langosch K, Henningsen M, Zeitz J, Harbeck N, Jänicke F, Müller V
ONKOLOGIE. 2011;34(6):304-308.

Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva.
Wölber L, Choschzick M, Zu Eulenburg C, Hager M, Jänicke F, Gieseking F, Kock L, Henningsen M, Petersen C, Schwarz J, Mahner S
ANN SURG ONCOL. 2011;18(13):3811-3818.

Clinical management of primary vulvar cancer.
Wölber L, Kock L, Gieseking F, Petersen C, Trillsch F, Choschzick M, Jänicke F, Mahner S
EUR J CANCER. 2011;47(15):2315-2321.

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer.
Wölber L, Kress K, Kersten J, Choschzick M, Kilic E, Herwig U, Lindner C, Schwarz J, Jänicke F, Mahner S, Milde-Langosch K, Müller V, Henningsen M
BMC CANCER. 2011;11:12.

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy
Abbas S, Beckmann L, Chang-Claude J, Hein R, Kropp S, Parthimos M, Dünnebier T, Hamann U, Brors B, Eils R, Zapatka M, Brauch H, Justenhoven C, Flesch-Janys D, Braendle L, Brüning T, Pesch B, Spickenheuer A, Baisch C, Ko Y, Dahmen N
INT J CANCER. 2010;126(12):2935-2946.

Advantages and challenges of oestrogen-free hormonal contraception.
Ahrendt H, Adolf D, Bühling K
CURR MED RES OPIN. 2010;26(8):1947-1955.

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women
Chang-Claude J, Beckmann L, Corson C, Hein R, Kropp S, Parthimos M, Dünnebier T, Hamann U, Brors B, Eils R, Brauch H, Justenhoven C, Flesch-Janys D, Braendle L, Brüning T, Pesch B, Spickenheuer A, Krankenhaus J, Ko Y, Baisch C, Dahmen N, Zapatka M
BREAST CANCER RES TR. 2010;119(2):463-474.

Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome.
Choschzick M, Lassen P, Lebeau A, Marx A, Terracciano L, Heilenkötter U, Jänicke F, Bokemeyer C, Izbicki J, Sauter G, Simon R
MODERN PATHOL. 2010;23(4):603-610.

Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Choschzick M, Wölber L, Hess S, Zu Eulenburg C, Schwarz J, Simon R, Mahner S, Jänicke F, Müller V
VIRCHOWS ARCH. 2010;456(5):483-490.

Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal A, Brüchmann M, Zustin J, Isbarn H, Hellwinkel O, Köllermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brümmendorf T, Izbicki J, Yekebas E, Fisch M, Huland H, Graefen M, Schlomm T
CLIN CANCER RES. 2010;16(1):56-64.

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg C, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K
BREAST CANCER RES TR. 2010;124(2):403-412.

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.
Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, Andreas D
EXPERT REV ANTICANC. 2010;10(1):81-88.

Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.
Henningsen M, Köhler N, Kersten J, Milde-Langosch K, Beck K, Höller S, Müller V, Witzel I, Jänicke F, Kilic E
DIS MARKERS. 2010;28(2):71-78.

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.
Henningsen M, Wirtz R, Kalogeras K, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki A, Papadimitriou C, Jänicke F, Briassoulis E, Pectasides D, Rody A, Fountzilas G, Müller V
BRIT J CANCER. 2010;103(7):1048-1056.

Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients
Hipp S, Berg D, Ergin B, Schuster T, Hapfelmeier A, Walch A, Avril S, Schmalfeldt B, Höfler H, Becker K
VIRCHOWS ARCH. 2010;457(6):705-13.

Das Mammakarzinom beim Mann: Eine Herausforderung für den Urologen
Hofer C, Schmalfeldt B, Gschwend J, Herkommer K
UROLOGE. 2010;49(9):1142, 1144-8.

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny G, Pauletti G, Untch M, Wang H, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon D
BREAST CANCER RES TR. 2010;120(2):481-489.

Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt W, Grob T, Burkhardt L, Hölzel D, Jackisch C, Thomssen C, Müller V, Untch M
J CLIN ONCOL. 2010;28(20):3264-3270.

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Mahner S, Wölber L, Zu Eulenburg C, Schwarz J, Carney W, Jänicke F, Milde-Langosch K, Müller V
BMC CANCER. 2010;10:139.

Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies.
Müller V, Alix-Panabières C, Pantel K
EUR J CANCER. 2010;46(7):1189-1197.

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Müller V, Thomssen C, Schmidt M, Glados M, Jackisch C, Heilmann V, Hinke A, Lehnert A, Borowicz H, Möbus V
BMC CANCER. 2010;10:430.

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K
CLIN CANCER RES. 2010;16(9):2634-2645.

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H
BREAST CANCER RES. 2010;12(6):90.

Besondere Lebenssituationen (Senium, Schwangerschaftsassoziiertes Mammakarzinom)
Schmalfeldt B
2010. Therapie des Mammakarzinoms. Harbeck N. Unimed Verlag, .

Veränderungen und Tumoren der Tuben / Veränderungen und Tumoren des Ovars
Schmalfeldt B
2010. Gynäkologie und Geburtshilfe. Kiechle M (Hrsg.). 2. Aufl. Urban & Fischer, .

The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells.
Schröder C, Schumacher U, Müller V, Wirtz R, Streichert T, Richter U, Wicklein D, Milde-Langosch K
EUR J CANCER. 2010;46(9):1650-1660.

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C, Schwaiger M, Jänicke F, Untch M, Avril N
BRIT J CANCER. 2010;102(1):35-41.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jänicke F, Oskay-Oezcelik G
CANCER CHEMOTH PHARM. 2010;66(5):861-868.

Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Bühling K, Richter R, El Khalfaoui K, Oskay-Ozcelik G
ANN ONCOL. 2010;21(11):2201-2205.

Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients.
Sehouli J, Richter R, Braicu E, Bühling K, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C
J SURG ONCOL. 2010;102(6):656-662.

Gustatory and olfactory function in breast cancer patients
Steinbach S, Hundt W, Zahnert T, Berktold S, Böhner C, Gottschalk N, Hamann M, Kriner M, Heinrich P, Schmalfeldt B, Harbeck N
SUPPORT CARE CANCER. 2010;18(6):707-13.

Clinical management of borderline ovarian tumors.
Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jänicke F, Du Bois A
EXPERT REV ANTICANC. 2010;10(7):1115-1124.

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl H, Lichinitser M, Manikhas A, Coumbos A, Kreienberg R, Andreas D, Harbeck N, Jackisch C, Müller V, Pauschinger M, Thomssen C, Lehle M, Catalani O, Lück H
J CLIN ONCOL. 2010;28(9):1473-1480.

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A
ANN SURG ONCOL. 2010;17(6):1642-8.

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Zu Eulenburg C, Roller M, Untch M, Müller V
BREAST CANCER RES TR. 2010;123(2):437-445.

Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
Witzel I, Milde-Langosch K, Wirtz R, Roth C, Henningsen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V
J CANCER RES CLIN. 2010;136(11):1709-1718.

Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.
Wölber L, Jung S, Zu Eulenburg C, Müller V, Schwarz J, Jänicke F, Mahner S
EJSO-EUR J SURG ONC. 2010;36(6):583-588.

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
Wölber L, Müller V, Zu Eulenburg C, Schwarz J, Carney W, Jänicke F, Milde-Langosch K, Mahner S
GYNECOL ONCOL. 2010;117(2):183-188.

Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L, Grob T, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A
BREAST CANCER RES TR. 2009.

Prognostic Value of Serum and Ascites Levels of Estradiol, FSH, LH and Prolactin in Ovarian Cancer.
Chen F, Oskay-Ozcelik G, Bühling K, Köpstein U, Mentze M, Lichtenegger W, Sehouli J
ANTICANCER RES. 2009;29(5):1575-1578.

Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.
Choschzick M, Lebeau A, Marx A, Tharun L, Terracciano L, Heilenkötter U, Jänicke F, Bokemeyer C, Simon R, Sauter G, Schwarz J
HUM PATHOL. 2009.

Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
Harter P, Hahmann M, Lueck H, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A
ANN SURG ONCOL. 2009;16(5):1324-30.

Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Andreas D
EXPERT REV ANTICANC. 2009;9(7):917-922.

Prognostic factors for complete debulking in first- and second-line ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Pfisterer J, Andreas D
INT J GYNECOL CANCER. 2009;19(2):14-17.

Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.
Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K
ONCOL REP. 2009;22(1):177-183.

Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up
Hölscher G, Anthuber C, Bastert G, Burges A, Mayr D, Oberlechner E, Schubert-Fritschle G, Sinz S, Sommer H, Schmalfeldt B, Engel J
ACTA OBSTET GYN SCAN. 2009;88(4):440-8.

Expression and prognostic value of activating transcription factor 2 (ATF2) and its phosphorylated form in mammary carcinomas.
Knippen S, Löning T, Müller V, Schröder C, Jänicke F, Milde-Langosch K
ANTICANCER RES. 2009;29(1):183-189.

A pilot study of gene expression-based categorization of pancreas transplant biopsies
Luan F, Trillsch F, Henger A, Eichinger F, Norman S, Appelman H, Kretzler M
TRANSPLANTATION. 2009;87(2):222-6.

Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction.
Mahner S, Wölber L, Jung S, Zu Eulenburg C, Henningsen M, Schwarz J, Sehouli J, Jänicke F
ANTICANCER RES. 2009;29(7):2817-2821.

Use of dydrogesterone in hormone replacement therapy.
Mueck A, Seeger H, Bühling K
MATURITAS. 2009.

Why use of dienogest for the first contraceptive pill with estradiol?
Mueck A, Seeger H, Bühling K
GYNECOL ENDOCRINOL. 2009;1-5.

Clinical Relevance of Disseminated Tumor Cells in Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients
Müller V, Fehm T, Janni W, Gebauer G, Solomayer E, Pantel K
BREAST CARE. 2009;4(5):333-338.

Adjuvante Chemotherapie und Antikörpertherapie
Müller V, Stickeler E
2009. Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome. Zuckerschwerdt Verlag: 23-40.

Longitudinal analysis of changes in energy intake and macronutrient composition during pregnancy and 6 weeks post-partum.
Neda T, Ritterath C, Siegmund T, Wascher C, Siebert G, Henrich W, Bühling K
ARCH GYNECOL OBSTET. 2009.

Subcutaneous mastectomy with conservation of the nipple-areola Skin: broadening the indications
Paepke S, Schmid R, Fleckner S, Paepke D, Niemeyer M, Schmalfeldt B, Jacobs V, Kiechle M
ANN SURG. 2009;250(2):288-92.

Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Pfisterer J, Du Bois A, Bentz E, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F
INT J GYNECOL CANCER. 2009;19(1):109-15.

Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).
Pölcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach G, Höss C, Leutner C, Braun M, Möbus V, Karbe I, Stimmler P, Rudlowski C, Schwarz J, Kuhn W
ONCOL REP. 2009;22(3):605-613.

Das Ovarialkarzinom aus Sicht des Viszeralchirurgen.
Pölcher M, Schmalfeldt B, Florack G, Kalff J, Kuhn W
2009. Viszeralchirurgie. Siewert J, Harder F, Rothmund M (Hrsg.). Berlin, Heidelberg, New York: Springer, .

Minimal Residual Cancer and its Clinical Relevance
Rack B, Müller V, Kasimir-Bauer S, Schindlbeck C, Janni W
CURR BREAST CANCER R. 2009;1:198-206.

Detection and Characterization of Disseminated Tumor Cells present in Bone Marrow of Cancer Patients
Riethdorf S, Müller V, Alix-Panabières C, Pantel K
2009. Bone and Cancer. Springer London: 103-117.

Adiponectin during pregnancy: correlation with fat metabolism, but not with carbohydrate metabolism.
Ritterath C, Rad N, Siegmund T, Heinze T, Siebert G, Bühling K
ARCH GYNECOL OBSTET. 2009.

Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis.
Rody A, Karn T, Ruckhäberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M
EUR J CANCER. 2009;45(3):405-413.

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M
BREAST CANCER RES TR. 2009;113(3):457-466.

Prognostic impact of thymidine phosphorylase expression in breast cancer - Comparison of microarray and immunohistochemical data.
Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A
EUR J CANCER. 2009.

Diagnostik und Therapie maligner Ovarialtumoren
Schmalfeldt B
2009. Tumorzentrum München Jahrbuch 2009. München: Agileum Verlag und Gesundheitsakademie GmbH, .

Operative Therapie
Schmalfeldt B
2009. Management des Ovarialkarzinoms. Kreienberg R (Hrsg.). Springer, .

Mammakarzinom und Schwangerschaft
Schmalfeldt B, Bauerfeind I, Anthuber C, Imhoff K, Oberlechner E, Raab A, Strauss A, wOLF C
2009. Manual Mammakarzinom. Empfehlungen zu Diagnostik, Therapie und Nachsorge.. Janni W (Hrsg.). W. Zuckschwerdt Verlag, .

Expression and prognostic value of L1-CAM in breast cancer.
Schröder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz R, Altevogt P, Krenkel S, Jänicke F, Milde-Langosch K
ONCOL REP. 2009;22(5):1109-1117.

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jänicke F, Avril N
J CLIN ONCOL. 2009;27(4):535-541.

Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G
CANCER CHEMOTH PHARM. 2009;64(3):585-591.

Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies
Steinbach S, Hummel T, Böhner C, Berktold S, Hundt W, Kriner M, Heinrich P, Sommer H, Hanusch C, Prechtl A, Schmidt B, Bauerfeind I, Seck K, Jacobs V, Schmalfeldt B, Harbeck N
J CLIN ONCOL. 2009;27(11):1899-905.

Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years.
Thoem I, Rogers C, Andritzky B, Witzel I, Schuch G, Hossfeld D, Bokemeyer C, Laack E
ONKOLOGIE. 2009;32(12):741-746.

Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.
Thomssen C, Harbeck N, Dittmer J, Abraha-Spaeth S, Papendick N, Paradiso A, Lisboa B, Jänicke F, Schmitt M, Vetter M
JNCI-J NATL CANCER I. 2009;101(14):1028-1029.

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Untch M, Möbus V, Kuhn W, Muck B, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry K, Wallwiener D, Kreienberg R, Albert U, Lück H, Hinke A, Jänicke F, Konecny G
J CLIN ONCOL. 2009;27(18):2938-2945.

Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer.
Wölber L, Mahner S, Voelker K, Zu Eulenburg C, Gieseking F, Choschzick M, Jänicke F, Schwarz J
ANTICANCER RES. 2009;29(2):545-552.

HER-2/neu analysis in breast cancer bone metastases.
Zustin J, Boddin K, Tsourlakis M, Burandt E, Mirlacher M, Jänicke F, Izbicki J, Rüther W, Rueger J, Bokemeyer C, Simon R, Sauter G
J CLIN PATHOL. 2009;62(6):542-546.

Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.
Barthell E, Wölber L, Hellner K, Camerer B, Gieseking F, Hauschild M, Mylonas I, Friese K, Sings H, Railkar R, Gause C, Barr E
ARCH GYNECOL OBSTET. 2008.

[Recommendations for hormone treatment with estrogen and progesterone in the climacteric and postmenopausal periods. 37th Workshop of the Zurich Discussion Group , September 2006]
Birkhauser M, Braendle L, Kiesel L, Kuhl H, Neulen J, Thaler C
Gynakol Geburtshilfliche Rundsch. 2008;48(1):38-46.

The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients
Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Höfler H, Becker K
BRIT J CANCER. 2008;98(2):489-95.

[Lipid disorders in pregnancy--a complication scarcely considered]
Bühling K
DEUT MED WOCHENSCHR. 2008;133(42):2177.

Nachweis von Metastasen bei Patientinnen mit Mamma - karzinom Vergleich von FDG-PET mit Röntgen-Thorax, Oberbauchsonographie und Skelett szintigraphie
Dose-Schwarz J, Mahner S, Schirrmacher S, Jenicke L, Müller V, Habermann C, Brenner W
NUKLEARMED-NUCL MED. 2008;47(3):97-103.

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
Fehm T, Müller V, Alix-Panabières C, Pantel K
BREAST CANCER RES. 2008;10(1):1.

Tumor cell dormancy: implications for the biology and treatment of breast cancer.
Fehm T, Müller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, Becker S
APMIS. 2008;116(7-8):742-753.

Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.
Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi-Osius N, Vettorazzi E, Braendle L, Bastert G, Hentschel S, Berger J, Chang-Claude J
INT J CANCER. 2008;123(4):933-941.

Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
Fotopoulou C, duBois A, Karavas A, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, Sehouli J
J CLIN ONCOL. 2008;26(16):2683-9.

Lymphatic phenotype of tumour vessels in malignant gliomas
Grau S, Trillsch F, von Lüttichau I, Nelson P, Herms J, Tonn J, Goldbrunner R
NEUROPATH APPL NEURO. 2008;34(6):675-9.

[Vaginal prolapse and rectal obstruction. Treated with a vaginal vault mesh colpo suspension and laparoscopic resection rectopexy]
Grebe M, Thiel B, Bley K, Schwarz N
CHIRURG. 2008;79(11):1072-1076.

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N, Nimmrich I, Hartmann A, Ross J, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R
J CLIN ONCOL. 2008;26(31):5036-5042.

Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Henningsen M, Müller V, Wirtz R, Schröder C, Krenkel S, Witzel I, Lisboa B, Jänicke F, Milde-Langosch K
BREAST CANCER RES TR. 2008;112(3):419-427.

The similarities of aromatase inhibitors outweigh the differences.
Jänicke F
ANTI-CANCER DRUG. 2008;19(2):7-9.

[Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]
Kilic E, Milde-Langosch K, Müller V, Wirtz R, Henningsen M
PATHOLOGE. 2008;29(2):347-352.

Expression des "activated leukocyte cell adhesion molecule" im Mammakarzinom. Prädiktivität für das Ansprechen auf eine taxanfreie Chemotherapie
Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M
PATHOLOGE. 2008;29 Suppl 2:347-52.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Krainick-Strobel U, Lichtenegger W, Wallwiener D, Tulusan A, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S
BMC CANCER. 2008;8:62.

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.
Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde-Langosch K
BRIT J CANCER. 2008;99(8):1269-1275.

Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
Mahner S, Schirrmacher S, Brenner W, Jenicke L, Habermann C, Avril N, Dose-Schwarz J
ANN ONCOL. 2008;19(7):1249-1254.

Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.
Milde-Langosch K, Janke S, Wagner I, Schröder C, Streichert T, Bamberger A, Jänicke F, Löning T
BREAST CANCER RES TR. 2008;107(3):337-347.

HER2 as marker for the detection of circulating tumor cells.
Müller V, Pantel K
BREAST CANCER RES TR. 2008.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO
Oskay-Oezcelik G, Koensgen D, Hindenburg H, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran S, Neumann U, Sehouli J
ANTICANCER RES. 2008;28(2B):1329-34.

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
BRIT J CANCER. 2008;99(6):930-938.

Present and future developments in the diagnosis and treatment of ovarian cancer.
Schmalfeldt B
GEBURTSH FRAUENHEILK. 2008;68(4):382-88.

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Schrohl A, Müller V, Christensen I, Pantel K, Thomssen C, Bruenner N
TUMOR BIOL. 2008;29(3):181-187.

Longitudinal changes in the continuous glucose profile measured by the CGMS in healthy pregnant women and determination of cut-off values.
Siegmund T, Rad N, Ritterath C, Siebert G, Henrich W, Bühling K
EUR J OBSTET GYN R B. 2008;139(1):46-52.

Trastuzumab in pregnancy associated with poor fetal outcome.
Witzel I, Müller V, Harps E, Jänicke F, De Wit M
ANN ONCOL. 2008;19(1):191-192.

Current status in human breast cancer micrometastasis.
Alix-Panabières C, Müller V, Pantel K
CURR OPIN ONCOL. 2007;19(6):558-563.

Detection and characterization of putative metastatic precursor cells in cancer patients.
Alix-Panabières C, Vendrell J, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K
CLIN CHEM. 2007;53(3):537-539.

[Recommendations for estrogen and progesterone substitution in climacteric and postmenopause]
Birkhauser M, Braendle L, Keller P, Kiesel L, Kuhl H, Neulen J
Gynakol Geburtshilfliche Rundsch. 2007;47(1):45-48.

[Recommendations for hormonal contraception. 36th Professional Meeting of the "Zurich Discussion Group", April 2006]
Birkhäuser M, Braendle L, Keller P, Kiesel L, Kuhl H, Neulen J
Gynakol Geburtshilfliche Rundsch. 2007;47(2):94-98.

Ulex europeus agglutinin-I binding as a potential prognostic marker in ovarian cancer.
Blonski K, Milde-Langosch K, Bamberger A, Osterholz T, Utler C, Berger J, Löning T, Schumacher U
ANTICANCER RES. 2007;27(4):2785-2790.

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study
Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein M, Heiss M, Gottwald T, Lindhofer H, Kimmig R
CLIN CANCER RES. 2007;13(13):3899-905.

Quality of life among breast cancer patients undergoing autologous breast reconstruction versus breast conserving therapy.
Dian D, Schwenn K, Mylonas I, Janni W, Friese K, Jänicke F
J CANCER RES CLIN. 2007;133(4):247-252.

Aesthetic result among breast cancer patients undergoing autologous breast reconstruction versus breast conserving therapy.
Dian D, Schwenn K, Mylonas I, Janni W, Jänicke F, Friese K
ARCH GYNECOL OBSTET. 2007;275(6):445-450.

Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients
Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, Diamandis E, Harbeck N
CLIN CANCER RES. 2007;13(6):1742-8.

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Müller V, Wallwiener D, Lane N, Solomayer E, Uhr J
BREAST CANCER RES. 2007;9(5):74.

Expression of VEGFR3 in glioma endothelium correlates with tumor grade
Grau S, Trillsch F, Herms J, Thon N, Nelson P, Tonn J, Goldbrunner R
J NEURO-ONCOL. 2007;82(2):141-50.

Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature.
Henningsen M, Mahner S, Jänicke F, Schwarz J
INT J GYNECOL CANCER. 2007;17(5):957-963.

Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
Holst F, Stahl P, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R
NAT GENET. 2007;39(5):655-660.

Continuing with letrozole offers greater benefits.
Jänicke F
J CANCER RES CLIN. 2007;133(7):445-453.

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann A, Nieland J, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle R, Meissner H, Müller R, Pawlita M, Petry K, Pilch H, Walek E, Schneider A
INT J CANCER. 2007;121(12):2794-2800.

Good agreement between physician and self-reported hormone therapy data in a case-control study.
Kropp S, Terboven T, Hedicke J, Mutschelknauss E, Slanger T, Braendle L, Berger J, Chang-Claude J, Flesch-Janys D
J CLIN EPIDEMIOL. 2007;60(12):1280-1287.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Müller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens J, Foekens J, Schmitt M, Harbeck N
EUR J CANCER. 2007;43(11):1679-1686.

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.
Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K
CLIN CANCER RES. 2007;13(3):920-928.

Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients
Röper B, Astner S, Heydemann-Obradovic A, Thamm R, Jacob V, Hölzel D, Schmalfeldt B, Kiechle-Bahat M, Höss C, Molls M
GYNECOL ONCOL. 2007;107(3):541-8.

Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer
Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J
HUM PATHOL. 2007;38(6):926-34.

Diagnostik und Therapie maligner Ovarialtumoren
Schmalfeldt B
Frauenarzt. 2007;48(11):1054-57.

Operative treatment of ovarian cancer.
Schmalfeldt B
GEBURTSH FRAUENHEILK. 2007;67(6):14-19.

Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren.
Schmalfeldt B, Pfisterer J
2007. Manual Mammakarzinom. . Janni W (Hrsg.). 11. Aufl. München Wien New York : W. Zuckschwerdt Verlag, .

Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells.
Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen H, Kantelhardt E, Krenkel S, Müller V, Sweep F, Thomssen C, Dittmer J
CANCER RES. 2007;67(22):10694-10702.

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
Schwarzenbach H, Müller V, Beeger C, Gottberg M, Stahmann N, Pantel K
BREAST CANCER RES. 2007;9(5):66.

Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy.
Slanger T, Mutschelknauss E, Kropp S, Braendle L, Flesch-Janys D, Chang-Claude J
ANN EPIDEMIOL. 2007;17(12):993-998.

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück H, Sehouli J, Gropp M, Stähle A, Schmalfeldt B, Meier W, Jackisch C
GYNECOL ONCOL. 2007;105(1):132-7.

Actual management of patients with familial ascending aortic aneurysms and type-A aortic dissections.
Weigang E, Chang X, Munk-Schulenburg S, Richter H, von Samson P, Goebel H, Frydrychowicz A, Geibel A, Ammann S, Schwering L, Brunner T, Severin T, Czerny M, Beyersdorf F
THORAC CARDIOV SURG. 2007;55(1):19-23.

[Recommendations for estrogen and progesterone replacement in climacteric and postmenopause. 33. Workshop of the "Zurich Discussion Circle", October 2004]
Birkhäuser M, Braendle L, Keller P, Kiesel L, Kuhl H, Neulen J
Gynakol Geburtshilfliche Rundsch. 2006;46(1-2):53-57.

[Recommendations for hormonal contraception. 34. Workshop of the "Zurich Discussion Circle", April 2005]
Birkhäuser M, Braendle L, Keller P, Kiesel L, Kuhl H, Neulen J
Gynakol Geburtshilfliche Rundsch. 2006;46(1-2):58-63.

Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer
Borgoño C, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis E
CLIN CANCER RES. 2006;12(5):1487-93.

Rate of dyspareunia after delivery in primiparae according to mode of delivery.
Bühling K, Schmidt S, Robinson J, Klapp C, Siebert G, Dudenhausen J
EUR J OBSTET GYN R B. 2006;124(1):42-46.

Management of skin-sparing mastectomy: results of a survey of German hospitals.
Dian D, Hemminger G, Janni W, Friese K, Jänicke F
ONKOLOGIE. 2006;29(6):267-270.

Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma
Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, Diamandis E, Schmitt M
BIOL CHEM. 2006;387(8):1121-8.

Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic Tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G
ANN ONCOL. 2006;17(1):93-6.

Ovarialkarzinom -- ist die intraperitoneale Therapie wirklich neuer Standard?
du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J
Zentralblatt für Gynäkologie. 2006;128(4):202-6.

Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?
du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J
INT J GYNECOL CANCER. 2006;16(5):1756-60.

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
Fehm T, Braun S, Müller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E
CANCER-AM CANCER SOC. 2006;107(5):885-892.

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl H, Breitbach G, Tanner B, Sehouli J
ANN SURG ONCOL. 2006;13(12):1702-10.

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander A, Löning T
CLIN CANCER RES. 2006;12(1):159-168.

Indications for primary and secondary exenterations in patients with cervical cancer.
Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K, Schneider A
GYNECOL ONCOL. 2006;103(3):1023-1030.

Recent translational research: circulating tumor cells in breast cancer patients.
Müller V, Hayes D, Pantel K
BREAST CANCER RES. 2006;8(5):110.

Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V, Witzel I, Pantel K, Krenkel S, Lück H, Neumann R, Keller T, Dittmer J, Jänicke F, Thomssen C
ANTICANCER RES. 2006;26(2):1479-1487.

BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.
Nakuci E, Mahner S, Direnzo J, ElShamy W
EXP CELL RES. 2006;312(16):3120-3131.

Akute Ovarialvenenthrombose im dritten Trimenon
Rattenhuber J, Schmalfeldt B, Fischer T, Schneider K
Zentralblatt für Gynäkologie. 2006;128(6):366-8.

Accuracy and influence of ascorbic acid on glucose-test with urine dip sticks in prenatal care.
Ritterath C, Siegmund T, Rad N, Stein U, Bühling K
J PERINAT MED. 2006;34(4):285-288.

Diagnostik und Therapie maligner Ovarialtumoren 2005: Die Empfehlungen der Kommission Ovar der AGO
Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg A, Jäger W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Lück H, Meier W, Münstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schröder W, Sehouli J, Tanner B, Wagner U, Weis J
Zentralblatt für Gynäkologie. 2006;128(1):11-7.

The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity.
Schrepfer S, Deuse T, Münzel T, Schäfer H, Braendle L, Reichenspurner H
MENOPAUSE. 2006;13(3):489-499.

[Continuous glucose monitoring using the glucose sensor CGMS in metabolically normal pregnant women during betamethasone therapy for fetal respiratory distress syndrome]
Schumacher A, Sidor J, Bühling K
Z GEBURTSH NEONATOL. 2006;210(5):184-190.

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer:results of a multicenter phase-II trial
Sehouli J, Oskay-Ozcelik G, Kühne J, Stengel D, Hindenburg H, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W
ANN ONCOL. 2006;17(6):957-61.

Evaluation of three different measurement methods for dural ectasia in Marfan syndrome.
Weigang E, Ghanem N, Chang X, Richter H, Frydrychowicz A, Szabó G, Dudeck O, Knirsch W, von Samson P, Langer M, Beyersdorf F
CLIN RADIOL. 2006;61(11):971-978.

Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
Witzel I, Thomssen C, Krenkel S, Wilczak W, Bubenheim M, Pantel K, Neumann R, Jänicke F, Müller V
INT J BIOL MARKER. 2006;21(3):131-140.

Disseminated tumor cells in breast cancer: detection, characterization and clinical relevance.
Wölfle U, Müller V, Pantel K
FUTURE ONCOL. 2006;2(4):553-561.

Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber W, Werner M, Graeff H, Schwaiger M, Kuhn W
J CLIN ONCOL. 2005;23(30):7445-53.

Independent association between leptin and blood pressure during third trimester in normal and gestational diabetic pregnancies.
Bühling K, Harder T, Sehouli J, Nanz J, Plagemann A, Dudenhausen J
EUR J OBSTET GYN R B. 2005;119(2):180-184.

Optimal timing for postprandial glucose measurement in pregnant women with diabetes and a non-diabetic pregnant population evaluated by the Continuous Glucose Monitoring System (CGMS).
Bühling K, Winkel T, Wolf C, Kurzidim B, Mandana M, Wohlfarth K, Wäscher C, Schink T, Dudenhausen J
J PERINAT MED. 2005;33(2):125-131.

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck H, Schroeder W, Burges A, Olbricht S, Elser G
GYNECOL ONCOL. 2005;96(2):444-51.

Effect of pregnancy on long-term kidney function in renal transplant recipients treated with cyclosporine and with azathioprine
Fischer T, Neumayer H, Fischer R, Barenbrock M, Schobel H, Lattrell B, Jacobs V, Paepke S, von Steinburg S, Schmalfeldt B, Schneider K, Budde K
AM J TRANSPLANT. 2005;5(11):2732-9.

Non-enrolment of ovarian cancer patients in clinical Trials: reasons and background
Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J
ANN ONCOL. 2005;16(11):1801-5.

Ultrasound finding and operative management of a uterine rupture during vaginal delivery after Cesarean section.
Henrich W, Tutschek B, Bühling K, Fuchs I, Dudenhausen J
ULTRASOUND OBST GYN. 2005;25(2):203-205.

Myoepitheliale Tumoren der Kopfspeicheldrüsen: Myoepithelial tumors of salivary glands
Hungermann D, Roeser K, Buerger H, Jäkel T, Löning T, Herbst H
PATHOLOGE. 2005;26(5):339-44.

Speichelgangkarzinome: Salivary duct carcinoma
Hungermann D, Roeser K, Buerger H, Jäkel T, Löning T, Herbst H
PATHOLOGE. 2005;26(5):353-8.

Development of a thinner and more flexible type of minihysteroscope with a controlled 90-degree bendable tip for vision-guided endometrium biopsy
Jacobs V, Paepke S, Schwarz-Boeger U, Fischer T, Pildner von Steinburg S, Plattner B, Schmalfeldt B, Schaaf H, Kiechle M
J MINIM INVAS GYN. 2005;12(5):426-31.

[Diagnosis and therapy of gestational diabetes--comparison of two surveys of established gynecologists in Berlin and Saxonia-Anhalt ]
Lüke C, Kemper I, Henschen S, Bühling K
Z GEBURTSH NEONATOL. 2005;209(6):219-222.

The Fos family of transcription factors and their role in tumourigenesis
Milde-Langosch K
EUR J CANCER. 2005;41(16):2449-61.

Vitamin B6 modulates glucocorticoid-dependent gene transcription in a promoter- and cell type-specific manner
Bamberger C, Else T, Ellebrecht I, Milde-Langosch K, Pankoke D, Beil F, Bamberger A
EXP CLIN ENDOCR DIAB. 2004;112(10):595-600.

No influence of high- and low-carbohydrate diet on the oral glucose tolerance test in pregnancy.
Bühling K, Elsner E, Wolf C, Harder T, Engel B, Wascher C, Siebert G, Dudenhausen J
CLIN BIOCHEM. 2004;37(4):323-327.

The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes.
Bühling K, Elze L, Henrich W, Starr E, Stein U, Siebert G, Dudenhausen J
EUR J OBSTET GYN R B. 2004;113(2):145-148.

Introductory experience with the continuous glucose monitoring system (CGMS; Medtronic Minimed) in detecting hyperglycemia by comparing the self-monitoring of blood glucose (SMBG) in non-pregnant women and in pregnant women with impaired glucose tolerance and gestational diabetes.
Bühling K, Kurzidim B, Wolf C, Wohlfarth K, Mahmoudi M, Wäscher C, Siebert G, Dudenhausen J
EXP CLIN ENDOCR DIAB. 2004;112(10):556-560.

[Association between amniotic fluid insulin in the second trimester, maternal glucose tolerance and fetal malformations]
Bühling K, Mönnich J, Henrich W, Brauer M, Heinze T, Siebert G, Dudenhausen J
Z GEBURTSH NEONATOL. 2004;208(6):226-231.

Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis
Diamandis E, Borgoño C, Scorilas A, Yousef G, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M
TUMOR BIOL. 2004;24(6):299-309.

Prognostische und prädiktive Faktoren bei Patientinnen mit Mammakarzinom: Management des Mammakarzinoms
Müller V, Jänicke F
2004. Management des Mammakarzinoms. Kreienberg R (Hrsg.). Heidelberg, New York: Springer, xx.

Sentinel Lymph Node Dissection and Micrometastasis Detection in Bone Marrow and Lymph Nodes: Molecular Oncology of Breast Cancer
Müller V, Kasimir-Bauer S, Pantel K
2004. Molecular Oncology of Breast Cancer. Ross J, Hortobagyi G (Hrsg.). Jones and Bartlett, 117-127.

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V, Witzel I, Lück H, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C
BREAST CANCER RES TR. 2004;86(1):9-18.

Wild-type p53 protein is up-regulated upon cyclic adenosine monophosphate-induced differentiation of human endometrial stromal cells
Pohnke Y, Schneider-Merck T, Fahnenstich J, Kempf R, Christian M, Milde-Langosch K, Brosens J, Gellersen B
J CLIN ENDOCR METAB. 2004;89(10):5233-44.

A randomized trial evaluating a predominantly fetal growth-based strategy to guide management of gestational diabetes in Caucasian women.
Schaefer-Graf U, Kjos S, Fauzan O, Bühling K, Siebert G, Bührer C, Ladendorf B, Dudenhausen J, Vetter K
DIABETES CARE. 2004;27(2):297-302.

Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer
Schwarzenbach H, Müller V, Stahmann N, Pantel K
ANN NY ACAD SCI. 2004;1022:25-32.

Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker
Scorilas A, Borgoño C, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis E
J CLIN ONCOL. 2004;22(4):678-85.

Detection and characterisation of occult metastatic cells in bone marrow of breast cancer patients: Micrometastasis
Braun S, Müller V, Pantel K
2003. Micrometastasis. Pantel K (Hrsg.). Kluwer Academic Press, 47-66.

Erkennung des Gestationsdiabetes
Bühling K, Dudenhausen J
Zentralblatt für Gynäkologie. 2003;125(3-4):123-8.

Comparison of point-of-care-testing glucose meters with standard laboratory measurement of the 50g-glucose-challenge test (GCT) during pregnancy
Buhling K, Henrich W, Kjos S, Siebert G, Starr E, Dreweck C, Stein U, Dudenhausen J
CLIN BIOCHEM. 2003;36(5):333-7.

Risk for gestational diabetes and hypertension for women with twin pregnancy compared to singleton pregnancy
Buhling K, Henrich W, Starr E, Lubke M, Bertram S, Siebert G, Dudenhausen J
ARCH GYNECOL OBSTET. 2003;269(1):33-6.

Jodversorgung in der Schwangerschaft--eine aktuelle Bestandsaufnahme in Berlin
Bühling K, Schaff J, Bertram H, Hansen R, Müller C, Wäscher C, Heinze T, Dudenhausen J
Z GEBURTSH NEONATOL. 2003;207(1):12-6.

Promyelocytic leukaemia zinc finger protein (PLZF) is a glucocorticoid- and progesterone-induced transcription factor in human endometrial stromal cells and myometrial smooth muscle cells
Fahnenstich J, Nandy A, Milde-Langosch K, Schneider-Merck T, Walther N, Gellersen B
MOL HUM REPROD. 2003;9(10):611-23.

Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients
Hantke B, Harbeck N, Schmalfeldt B, Claes I, Hiller O, Luther M, Welk A, Kuhn W, Schmitt M, Tschesche H, Muehlenweg B
BIOL CHEM. 2003;384(8):1247-51.

Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells
Hemsen A, Riethdorf L, Brünner N, Berger J, Ebel S, Thomssen C, Jänicke F, Pantel K
INT J CANCER. 2003;107(6):903-9.

Immunoexpression of the relaxin receptor LGR7 in breast and uterine tissues of humans and primates
Ivell R, Balvers M, Pohnke Y, Telgmann R, Bartsch O, Milde-Langosch K, Bamberger A, Einspanier A
REPROD BIOL ENDOCRIN. 2003;1:114.

Human kallikrein 8, a novel biomarker for ovarian carcinoma
Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis E
CANCER RES. 2003;63(11):2771-4.

Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue
Knappe U, Hagel C, Lisboa B, Wilczak W, Lüdecke D, Saeger W
ACTA NEUROPATHOL. 2003;106(5):471-8.

Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors
Muller V, Pantel K
AM J CANCER. 2003;2(2):77-86.

Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene
Nandy A, Jenatschke S, Hartung B, Milde-Langosch K, Bamberger A, Gellersen B
J MOL ENDOCRINOL. 2003;31(1):105-21.

Correlation on serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors
Witzel I, Thomssen C, Pantel K, Neumann R, Carney W, Loening T, Jaenicke F, Müller V
BREAST CANCER RES TR. 2003;82, Suppl. 1:S 143.

Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer
Yousef G, Polymeris M, Grass L, Soosaipillai A, Chan P, Scorilas A, Borgoño C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis E
CANCER RES. 2003;63(14):3958-65.

Teststreifenanalyse und Harnsediment
Bühling K, Dudenhausen J
DEUT MED WOCHENSCHR. 2002;127(33):1718, author reply 1718.

Transvaginal and transabdominal extended field-of-view (EFOV) and power doppler EFOV sonography in gynecology: advantages and applications
Henrich W, Fuchs I, Schmider A, Bühling K, Dudenhausen J
J ULTRAS MED. 2002;21(10):1137-44.

Prenatal sonographic findings of thalamic cavernous angioma
Henrich W, Stupin J, Bühling K, Bührer C, Bassir C, Dudenhausen J
ULTRASOUND OBST GYN. 2002;19(5):518-22.

Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine
Rost D, Mahner S, Sugiyama Y, Stremmel W
AM J PHYSIOL-GASTR L. 2002;282(4):G720-6.

Assoziation von niedrigem 50-g-Glukose-Screeningtest in der Schwangerschaft und fetaler Retardierung
Bühling K, Henrich W, Lübke M, Starr E, Dudenhausen J
Z GEBURTSH NEONATOL. 2001;205(2):39-42.

Photocycloaddition reactions of 2-acylcyclohex-2-enones
Ferrer L, Margaretha P
CHEM COMMUN. 2001;481-482.

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma
Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H
CANCER-AM CANCER SOC. 2001;92(10):2585-91.

Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer
Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W
GYNECOL ONCOL. 2001;82(2):291-8.

Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status.
Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger A, Löning T
BRIT J CANCER. 2001;85(4):546-551.

Synthesis of Nonenolizing 2-Acylcyclohex-2-enones
Oliveira-Ferrer L, Schmidt K, Margaretha P
HELV CHIM ACTA. 2001;84(12):3818-3821.

Tamoxifen sensitivity-testing of glioblastomas: comparison of in vitro and in vivo results.
Puchner M, Giese A, Zapf S, Grebe M, Westphal M
ACTA NEUROCHIR. 2001;143(6):563-573.

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer
Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E
CLIN CANCER RES. 2001;7(8):2396-404.

Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members.
Milde-Langosch K, Bamberger A, Methner C, Rieck G, Löning T
INT J CANCER. 2000;87(4):468-472.

Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications.
Milde-Langosch K, Riethdorf S, Löning T
VIRCHOWS ARCH. 2000;437(3):227-233.

Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential
Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H, Höfler H
VIRCHOWS ARCH. 2000;437(6):618-24.

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H
BRIT J CANCER. 1999;79(11-12):1746-51.

Natürlicher Verlauf der HPV-Infektion. Nutzen der HPV-Analytik in der Zervixdiagnostik
Milde-Langosch K, Riethdorf S, Park T
PATHOLOGE. 1999;20(1):15-24.

Synthesis and Photoreactivity of a 2-Pivaloylcyclohex-2-enone
Oliveira Ferrer L, Margaretha P
J CHEM RES-S. 1999;3:204-205.

Disease-adapted relapse therapy for ovarian cancer: results of a prospective study
Kuhn W, Schmalfeldt B, Pache L, Späthe K, Ulm K, Renziehausen K, Nöschel H, Canzler E, Richter B, Kroner M, Tilch G, Janicke F, Graeff H
INT J ONCOL. 1998;13(1):57-63.

Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer
Türkmen B, Schmitt M, Schmalfeldt B, Trommler P, Hell W, Creutzburg S, Graeff H, Magdolen V
ELECTROPHORESIS. 1997;18(5):686-9.

Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas
Hagel C, Laking G, Laas R, Scheil S, Jung R, Milde-Langosch K, Stavrou D
EUR J CANCER. 1996;32A(13):2242-2248.

Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs. Ergebnisse einer prospektiven randomisierlen Studie
Kuhn W, Schmalfeldt B, Dose J, Pache L, Ulm K, Freitag K, Jänicke F, Graeff H
GEBURTSH FRAUENHEILK. 1996;56(2):105-10.

HPV DNA and p53 alterations in oropharyngeal carcinomas
Barten M, Ostwald C, Milde-Langosch K, Müller P, Wukasch Y, Löning T
VIRCHOWS ARCH. 1995;427(2):153-7.

Die septische Ovarialvenenthrombose (POVT). Konservatives Management mit CT-geführter Verlaufskontrolle
Kuhn W, Schmalfeldt B, Lenz M, Loos W
GEBURTSH FRAUENHEILK. 1995;55(5):287-9.

The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists
Montano M, Müller V, Trobaugh A, Katzenellenbogen B
MOL ENDOCRINOL. 1995;9:814-825.

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2
Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H
CANCER RES. 1995;55(18):3958-63.

p53 Alterationen und HPV Status in oralen Plattenepithelkarzinomen
Barten M, Ostwald C, Müller P, Löning T, Milde-Langosch K, Wukasch Y
Verh Dtsch Ges Pathol. 1994;78:255-9.

Polymerase chain reaction-assisted papillomavirus detection in cervicovaginal smears: stratification by clinical risk and cytology reports.
Kühler-Obbarius C, Milde-Langosch K, Löning T, Helling-Giese G, Salfelder A, Peimann C
VIRCHOWS ARCH. 1994;425(2):157-163.

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy
Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H
GYNECOL ONCOL. 1994;55(3 Pt 1):401-9.

Blutbedarf in der operativen Gynäkologie. Strategien zur Vermeidung von Fremdblut
Loos W, Kuhn W, Prechtl A, Schmalfeldt B, Hipp R, Kycia J
Fortschr Med. 1994;112(29):405-9.

Human papillomavirus DNA in oral squamous cell carcinomas and normal mucosa
Ostwald C, Müller P, Barten M, Rutsatz K, Sonnenburg M, Milde-Langosch K, Löning T
J ORAL PATHOL MED. 1994;23(5):220-5.

Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III
Kuhn W, Jänicke F, Pache L, Hölscher M, Schattenmann G, Schmalfeldt B, Anderl H, Schüle G, Dettmar P, Siewert J
GEBURTSH FRAUENHEILK. 1993;53(5):293-302.

A simple and rapid technique to process formalin-fixed, paraffin-embedded tissues for the detection of viruses by the polymerase chain reaction
Kiene P, Milde-Langosch K, Runkel M, Schulz K, Löning T
VIRCHOWS ARCH. 1992;420(3):269-73.

Nachweis und biologische Bedeutung von Viren und Onkogenen bei Uteruskarzinomen
Milde-Langosch K, Wilckens C, Brack T, Löning T
Verh Dtsch Ges Pathol. 1991;75:363-365.

Immunogold-Silber-Technik zum Nachweis zellulärer Nukleinsäuren und Antigene in Plattenepithelkarzinomen
Henke R, Claviez A, Löning T, Rutter G, Milde-Langosch K
Acta Histochem Suppl. 1989;37:73-8.

HPV-Infektionen in Tumoren des oberen Atmungs- und Verdauungstrakts. In-situ-Hybridisierung und Dot-blot-Hybridisierung mit biotinylierten DNA-Proben
Milde-Langosch K, Löning T, Meichsner M, Henke R
Acta Histochem Suppl. 1989;37:103-8.

Human papillomavirus type 13 and focal epithelial hyperplasia of the oral mucosa: DNA hybridization on paraffin-embedded specimens.
Henke R, Milde-Langosch K, Löning T, Koppang H
VIRCHOWS ARCH. 1987;411(2):193-198.

Nachweis von Neuroblastomzellen im Knochenmark durch "Southern-Blot" und "In situ-Hybridisierung" mit Hilfe einer NMYC-DNS-Probe
Kabisch H, Heinsohn S, Milde-Langosch K, Löning T, Bartl S, Erttmann R, Landbeck G
MONATSSCHR KINDERH. 1987;135(4):210-213.

Zur Typisierung von Schleimhautpapillomen und -carcinomen
Löning T, Hoepfner I, Milde-Langosch K
PATHOLOGE. 1986;7(4):187-91.

Virale Tumormarker
Löning T, Milde-Langosch K
Verh Dtsch Ges Pathol. 1986;70:104-15.

Cell cycle parameters of Proteus mirabilis: interdependence of the biosynthetic cell cycle and the interdivision cycle
Gmeiner J, Sarnow E, Milde-Langosch K
J BACTERIOL. 1985;164(2):741-8.

Letzte Aktualisierung aus dem FIS: 22.12.2024 - 23:32 Uhr